

January 2014

Volume 2 Number 0

Editors: Kaye Wilson,

Donna Jennings & Sarah Le Leu

email: schedule@pharmac.govt.nz

Telephone +64 4 460 4990

Facsimile +64 4 460 4995

Level 9, 40 Mercer Street

PO Box 10 254 Wellington 6143

Freephone Information Line**0800 66 00 50** (9am – 5pm weekdays)**Circulation**

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

ProductionTypeset automatically from XML and T_EX.

XML version of the Schedule available from www.pharmac.govt.nz/pub/schedule/archive/

Programmers

Anrik Drenth & John Geering

email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3708 pdf

ISSN 1172-9694 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Part I General Rules 4**Part II** Alimentary Tract and Metabolism 12

Blood and Blood Forming Organs 25

Cardiovascular System 35

Dermatologicals 47

Genito-Urinary System 53

Hormone Preparations 57

Infections 62

Musculoskeletal System 85

Nervous System 95

Oncology Agents and Immunosuppressants 121

Respiratory System and Allergies 155

Sensory Organs 161

Various 167

Extemporaneous Compounds (ECPs) 175

Special Foods 178

Vaccines 192

Part III Optional Pharmaceuticals 197

Index 199

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. More information on the Board can be found at www.pharmac.govt.nz. The functions of PHARMAC are set out in section 48 of the Act. PHARMAC is required to perform these functions within the amount of funding provided to it and in accordance with its statement of intent and any directions given by the Minister (Section 103 of the Crown Entities Act). The Government has agreed that PHARMAC will assume responsibility for the assessment, prioritisation and procurement of medical devices on behalf of DHBs. Medical devices come within the definition of Pharmaceuticals in the Act. PHARMAC is assuming responsibility for procurement of some medical devices categories immediately, as a first step to full PHARMAC management of these categories within the Pharmaceutical Schedule.

Decision Criteria

PHARMAC takes into account the following criteria when considering amendments to the Schedule:

- a) the health needs of all eligible people within New Zealand;
- b) the particular health needs of Māori and Pacific peoples;
- c) the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- d) the clinical benefits and risks of pharmaceuticals;
- e) the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- f) the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Schedule;
- g) the direct cost to health service users;
- h) the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- i) such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

Contact PTAC C-/PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON 6143, Email: PTAC@pharmac.govt.nz

PTAC Subcommittees

PTAC has subcommittees from which it can seek specialist advice in relation to funding applications. PTAC may seek advice from one or more subcommittees in relation to a funding application, or may make recommendations to PHARMAC without seeking the advice of a subcommittee:

Analgesic Subcommittee	Haematology Subcommittee	Reproductive and Sexual Health Subcommittee
Anti-Infective Subcommittee	Hospital Pharmaceuticals Subcommittee	Respiratory Subcommittee
Cancer Treatments Subcommittee	Immunisation Subcommittee	Rheumatology Subcommittee
Cardiovascular Subcommittee	Mental Health Subcommittee	Special Foods Subcommittee
Dermatology Subcommittee	Neurological Subcommittee	Transplant Immunosuppressants Subcommittee
Diabetes Subcommittee	Ophthalmology Subcommittee	
Endocrinology Subcommittee	Pulmonary Arterial Hypertension Subcommittee	
Gastrointestinal Subcommittee		

PTAC also has a Tender Medical Evaluation Subcommittee to provide advice on clinical matters relating to PHARMAC's annual multi-product tender and other purchasing strategies. Current membership of PTAC's subcommittees can be found on PHARMAC's website: <http://www.pharmac.health.nz/about/committees/ptac>

Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at <http://www.pharmac.health.nz/tools- resources/forms/named-patient-pharmaceutical-assessment-nppa-forms>, or call the Panel Coordinators at (04) 9167553 or (04) 9167521.

The Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical or other Pharmaceuticals, including Medical Devices, used in DHB Hospitals, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, or other Pharmaceuticals, including Medical Devices, used in DHB Hospitals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in Section H

Section H lists Pharmaceuticals that can be used in DHB Hospitals, and is split into the following parts:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB Hospitals.
- Part II lists Hospital Pharmaceuticals that are funded for use in DHB Hospitals. These are classified based on the Anatomical Therapeutic Chemical (ATC) system used for Community Pharmaceuticals. It also provides information on any National Contracts that exist, and an indication of which products have Hospital Supply Status (HSS).
- Part III lists Optional Pharmaceuticals for which National Contracts exist, and DHB Hospitals may choose to fund. These are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance Limit (DV Limit).

The index located at the back of the Section H can be used to find page numbers for generic chemical entities and product brand names, for Hospital Pharmaceuticals. The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification

Glossary

Units of Measure

gram	microgram.....	millimole.....
kilogram	milligram	unit.....
international unit	millilitre.....	

Abbreviations

application	enteric coated.....	ointment.....
capsule	granules	solution.....
cream.....	injection	suppository.....
dispersible	linctus	tablet.....
effervescent.....	liquid	tincture.....
emulsion	lotion.....	

HSS Hospital Supply Status (Refer to Rule 20)

INTRODUCTION

Section H contains general rules that apply, and other information relating, to Hospital Pharmaceuticals and Optional Pharmaceuticals.

Where relevant, Section H shows the Price at which a Pharmaceutical can be purchased directly from the Pharmaceutical supplier by DHBs, providers of logistics services, wholesalers or other such distributors, or Contract Manufacturers.

The Price is determined via contractual arrangements between PHARMAC and the relevant Pharmaceutical supplier. Where a Pharmaceutical is listed in Part II of Section H, but no Price and/or brand of Pharmaceutical is indicated, each DHB may purchase any brand and/or pay the price that the DHB negotiates with the relevant Pharmaceutical supplier.

As required by section 23(7) of the Act, in performing any of its functions in relation to the supply of Pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule.

INTERPRETATION AND DEFINITIONS

1 Interpretation and Definitions

1.1 In this Schedule, unless the context otherwise requires:

“**Act**”, means the New Zealand Public Health and Disability Act 2000.

“**Combined Pharmaceutical Budget**”, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

“**Community**”, means any setting outside of a DHB Hospital.

“**Community Pharmaceutical**”, means a Pharmaceutical listed in Sections A to G or I of the Pharmaceutical Schedule that is subsidised by the Funder from the Combined Pharmaceutical Budget and, for the purposes of this Section H, includes Pharmaceutical Cancer Treatments (PCTs).

“**Contract Manufacturer**”, means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital.

“**Designated Delivery Point**”, means at a DHB Hospital's discretion:

- a) a delivery point agreed between a Pharmaceutical supplier and the relevant DHB Hospital, to which delivery point that Pharmaceutical supplier must supply a National Contract Pharmaceutical directly at the Price; and/or
- b) any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30 km of the relevant Pharmaceutical supplier's national distribution centre.

“**DHB**”, means an organisation established as a District Health Board by or under Section 19 of the Act.

“**DHB Hospital**”, means a hospital (including community trust hospitals) and/or an associated health service that is funded by a DHB including (but not limited to) district nursing services and child dental services.

“**DV Limit**”, means, for a particular National Contract Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“**DV Pharmaceutical**”, means a discretionary variance Pharmaceutical that does not have HSS but is used in place of one that does. Usually this means it is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant National Contract Pharmaceutical with HSS. Where this is not the case, a note will be included with the listing of the relevant Hospital Pharmaceutical.

“**Extemporaneously Compounded Product**”, means a Pharmaceutical that is compounded from two or more Pharmaceuticals, for the purposes of reconstitution, dilution or otherwise.

“**First Transition Period**”, means the period of time after notification that a Pharmaceutical has been awarded HSS and before HSS is implemented.

“**Funder**”, means the body or bodies responsible, pursuant to the Act, for the funding of Pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“**Give**”, means to administer, provide or dispense (or, in the case of a Medical Device, use) a Pharmaceutical, or to arrange for the administration, provision or dispensing (or, in the case of a Medical Device, use) of a Pharmaceutical, and “**Given**” has a corresponding meaning.

“**Hospital Pharmaceuticals**”, means the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals.

“**HSS**”, stands for hospital supply status, which means the status of being the brand of the relevant National Contract Pharmaceutical that DHBs are obliged to purchase, subject to any DV Limit, for the period of hospital supply,

as awarded under an agreement between PHARMAC and the relevant Pharmaceutical supplier. Pharmaceuticals with HSS are listed in Section H in bold text.

“Indication Restriction”, means a limitation placed by PHARMAC on the funding of a Hospital Pharmaceutical which restricts funding to treatment of particular clinical circumstances.

“Individual DV Limit”, means, for a particular National Contract Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital’s Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“Local Restriction”, means a restriction on the use of a Pharmaceutical in specific DHB Hospitals on the basis of prescriber type that is implemented by the relevant DHB in accordance with rule 7.

“Medical Device”, has the meaning set out in the Medicines Act 1981.

“Named Patient Pharmaceutical Assessment Advisory Panel”, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising PHARMAC, in accordance with its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and any Exceptional Circumstances renewal applications submitted after 1 March 2012.

“National Contract”, means a contractual arrangement between PHARMAC and a Pharmaceutical supplier which sets out the basis on which any Pharmaceutical may be purchased for use in a DHB Hospital, including an agreement as to a national price.

“National Contract Pharmaceutical”, means a brand of Pharmaceutical listed in Section H, where PHARMAC has entered into contractual arrangements with the relevant Pharmaceutical supplier that specify the terms and conditions of listing, including the Price. Such Pharmaceuticals are recognisable in Section H because the relevant listing identifies the brand and Price.

“National DV Limit”, means, for a particular National Contract Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“Optional Pharmaceuticals”, means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule.

“PHARMAC”, means the Pharmaceutical Management Agency established by Section 46 of the Act.

“Pharmacode”, means the six or seven digit identifier assigned to a Pharmaceutical by the Pharmacy Guild following application from a Pharmaceutical supplier.

“Pharmaceutical”, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

“Pharmaceutical Cancer Treatment”, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund for use in their DHB hospitals, and/or in association with outpatient services provided by their DHB Hospitals, in relation to the treatment of cancers.

“Prescriber Restriction”, means a restriction placed by PHARMAC on the funding of a Pharmaceutical on the basis of prescriber type (and where relevant in these rules, includes a Local Restriction).

“Price”, means the standard national price for a National Contract Pharmaceutical, and, unless agreed otherwise between PHARMAC and the Pharmaceutical supplier, includes any costs associated with the supply of the National Contract Pharmaceutical to, at a DHB Hospital’s discretion, any Designated Delivery Point, or to a Contract Manufacturer (expressly for the purpose of compounding), but does not include the effect of any rebates which may have been negotiated between PHARMAC and the Pharmaceutical supplier.

“Restriction”, means a limitation, put in place by PHARMAC or a DHB, restricting the funding of a Pharmaceutical and includes Indication Restrictions, Local Restrictions and Prescriber Restrictions (as defined in this Part I of Section H).

“Schedule”, means this Pharmaceutical Schedule and all its sections and appendices.

“Special Authority Approval”, means an approval for funding of a Community Pharmaceutical that is marked in Sections B-G of the Schedule as being subject to a Special Authority restriction.

“Total Market Volume”, means, for a particular Hospital Pharmaceutical with HSS in any given period, in accordance with the data available to PHARMAC, the sum of:

- a) the total number of Units of the relevant Hospital Pharmaceutical with HSS purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit; and
- b) the total number of Units of all the relevant DV Pharmaceuticals purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit.

“**Unapproved Indication**”, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Clinicians prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in rule 23.

“**Unit**”, means an individual unit of a Pharmaceutical (e.g. a tablet, 1 ml of an oral liquid, an ampoule or a syringe).

“**Unlisted Pharmaceutical**”, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II.

1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:

- a) the singular includes the plural; and
- b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under, that legislation.

HOSPITAL SUPPLY OF PHARMACEUTICALS

2 Hospital Pharmaceuticals

2.1 Section H Part II contains the list of Hospital Pharmaceuticals that must be funded by DHB Hospitals. Section H Part II does not currently encompass the following categories of pharmaceuticals:

- a) Medical Devices;
- b) whole or fractionated blood products;
- c) diagnostic products which have an ex vivo use, such as pregnancy tests and reagents;
- d) disinfectants and sterilising products, except those that are to be used in or on a patient;
- e) foods and probiotics;
- f) radioactive materials;
- g) medical gases; and
- h) parenteral nutrition.

Subject to rule 2.2, the funding of pharmaceuticals identified in a)–h) above is a decision for individual DHB Hospitals.

2.2 Section H Part III lists Optional Pharmaceuticals that PHARMAC and the relevant Pharmaceutical supplier have entered into contractual arrangements for the purchase of, including an agreement on a national price and other obligations such as HSS. DHB Hospitals may choose whether or not to fund the Optional Pharmaceuticals listed in Part III of Section H, but if they do, they must comply with any National Contract requirements.

2.3 Section H Part II does not encompass the provision of pharmaceutical treatments for DHB Hospital staff as part of an occupational health and safety programme. DHB Hospitals may choose whether or not to fund pharmaceutical treatments for such use, but if they do, they must comply with any National Contract requirements.

3 DHB Supply Obligations

3.1 In accordance with section 23(7) of the Act, in performing any of its functions in relation to the supply of pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule, which includes these General Rules.

3.2 DHB Hospitals are not required to hold stock of every Hospital Pharmaceutical listed in Section H Part II, but they must Give it within a reasonable time if it is prescribed.

3.3 DHB Hospitals are able to hold stock of an Unlisted Pharmaceutical if doing so is considered necessary for the DHB Hospital to be able to Give the Unlisted Pharmaceutical in a timely manner under rules 11–17 inclusive.

3.4 Except where permitted in accordance with rule 11, DHBs must not Give:

- a) an Unlisted Pharmaceutical; or
- b) a Hospital Pharmaceutical outside of any relevant Restrictions.

4 Funding

4.1 The purchase costs of Hospital Pharmaceuticals or Optional Pharmaceuticals administered, provided or dispensed by DHB Hospitals must be funded by the relevant DHB Hospital from its own budget, with the exception of:

- a) Pharmaceutical Cancer Treatments;
- b) Community Pharmaceuticals that have been brought to the DHB hospital by the patient who is being treated by outpatient Services or who is admitted as an inpatient;
- c) Community Pharmaceuticals that have been dispensed to a mental health day clinic under a Practitioner's Supply Order; and

d) Unlisted Pharmaceutical that have been brought to the DHB Hospital by the patient who is admitted as an inpatient.

4.2 For the avoidance of doubt, Pharmaceutical Cancer Treatments and Community Pharmaceuticals are funded through the Combined Pharmaceutical Budget, and Unlisted Pharmaceuticals are funded by the patient.

LIMITS ON SUPPLY

5 Prescriber Restrictions

- 5.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has a Prescriber Restriction if it is prescribed:
- by a clinician of the type specified in the restriction for that Pharmaceutical or, subject to rule 5.2, pursuant to a recommendation from such a clinician;
 - in accordance with a protocol or guideline that has been endorsed by the DHB Hospital; or
 - in an emergency situation, provided that the prescriber has made reasonable attempts to comply with rule 5.1(a) above. If on-going treatment is required (i.e. beyond 24 hours) subsequent prescribing must comply with rule 5.1(a).
- 5.2 Where a Hospital Pharmaceutical is prescribed pursuant to a recommendation from a clinician of the type specified in the restriction for that Pharmaceutical:
- the prescriber must consult with a clinician of the type specified in the restriction for that Pharmaceutical; and
 - the consultation must relate to the patient for whom the prescription is written; and
 - the consultation may be in person, by telephone, letter, facsimile or email; and
 - appropriate records are kept of the consultation, including recording the name of the advising clinician on the prescription/chart.
- 5.3 Where a clinician is working under supervision of a consultant who is of the type specified in the restriction for that Pharmaceutical, the requirements of rule 5.2 can be deemed to have been met.

6 Indication Restrictions

- 6.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has an Indication Restriction, if it is prescribed for treatment of a patient with the particular clinical circumstances set out in the Indication Restriction.
- 6.2 If a patient has a current Special Authority Approval for the Hospital Pharmaceutical that the DHB Hospital wishes to Give, then the Indication Restriction is deemed to have been met.
- 6.3 If a Hospital Pharmaceutical has an Indication Restriction that is “for continuation only” then the DHB Hospital should only Give the Hospital Pharmaceutical where:
- the patient has been treated with the Pharmaceutical in the Community; or
 - the patient is unable to be treated with an alternative Hospital Pharmaceutical, and the prescriber has explained to the patient that the Pharmaceutical is not fully subsidised in the Community.

7 Local Restrictions

- 7.1 A DHB Hospital may implement a Local Restriction, provided that:
- in doing so, it ensures that the Local Restriction does not unreasonably limit funded access to the Hospital Pharmaceutical or undermine PHARMAC’s decision that the Hospital Pharmaceutical must be funded;
 - it provides PHARMAC with details of each Local Restriction that it implements; and
- 7.2 PHARMAC may, when it considers that a Local Restriction does not conform to rule 7.1 above, require a DHB to amend or remove that Local Restriction.

8 Community use of Hospital Pharmaceuticals

- 8.1 Except where otherwise specified in Section H, DHB Hospitals can Give any Hospital Pharmaceutical to a patient for use in the Community, provided that:
- the quantity does not exceed that sufficient for up to 30 days’ treatment, unless:
 - it would be inappropriate to provide less than the amount in an original pack; or
 - the relevant DHB Hospital has a Dispensing for Discharge Policy and the quantity dispensed is in accordance with that policy; and
 - the Hospital Pharmaceutical is supplied consistent with any applicable Restrictions.

9 Community use of Medical Devices

- 9.1 Subject to rules 9.2 and 9.3, DHB Hospitals may Give a Medical Device for patients for use in the Community.
- 9.2 Where a Medical Device (or a similar Medical Device) is a Community Pharmaceutical, the DHB Hospital must supply:
- the brand of Medical Device that is listed in Sections A-G of the Schedule; and

- b) only to patients who meet the funding eligibility criteria set out in Sections A-G of the Schedule.
- 9.3 Where a DHB Hospital has supplied a Medical Device to a patient; and
 - a) that Medical Device (or a similar Medical Device) is subsequently listed in Sections A-G of the Schedule; and
 - b) the patient would not meet any funding eligibility criteria for the Medical Device set out in Sections A-G of the Schedule; and
 - c) the Medical Device has consumable components that need to be replaced throughout its usable life; then DHB Hospitals may continue to fund consumable products for that patient until the end of the usable life of the Medical Device. At the end of the usable life of the device, funding for a replacement device must be consistent with the Pharmaceutical Schedule and/or in accordance with the Named Patient Pharmaceutical Assessment policy.
- 9.4 DHB Hospitals may also continue to fund consumable products, as in rule 9.3 above, in situations where the DHB has been funding consumable products but where the Medical Device was funded by the patient.
- 10 **Extemporaneous Compounding**
 - 10.1 A DHB Hospital may Give any Extemporaneously Compounded Product for a patient in its care, provided that:
 - a) all of the component Pharmaceuticals of the Extemporaneously Compounded Product are Hospital Pharmaceuticals; and
 - b) the Extemporaneously Compounded Product is supplied consistent with any applicable rules or Restrictions for its component Hospital Pharmaceuticals.
 - 10.2 For the avoidance of doubt, this rule 10.1 applies to any Extemporaneously Compounded Product, whether it is manufactured by the DHB Hospital or by a Contract Manufacturer.

EXCEPTIONS

- 11 **Named Patient Pharmaceutical Assessment**
 - 11.1 A DHB Hospitals may only Give:
 - a) an Unlisted Pharmaceutical; or
 - b) a Hospital Pharmaceutical outside of any relevant Restrictions,in accordance with the Named Patient Pharmaceutical Assessment Policy or rules 12–17 inclusive.
- 12 **Continuation**
 - 12.1 Where a patient's clinical circumstances have been stabilised via treatment in the Community with a pharmaceutical that has not been funded by the Funder, and that patient is admitted to hospital as an inpatient, a DHB Hospital may fund that pharmaceutical for the duration of the patient's stay, where:
 - a) the patient has not brought (or cannot arrange to bring) the pharmaceuticals to the DHB Hospital, or pharmacy staff consider that the pharmaceuticals brought to the DHB Hospital by the patient cannot be used; and
 - b) interrupted or delayed treatment would have significant adverse clinical consequences; and
 - c) it is not considered appropriate to switch treatment to a Hospital Pharmaceutical.
- 13 **Pre-Existing Use**
 - 13.1 Subject to 13.2, where a DHB Hospital has Given a pharmaceutical for a patient prior to 1 July 2013, and the pharmaceutical:
 - a) is an Unlisted Pharmaceutical; or
 - b) treatment of the patient would not comply with any relevant Restrictions;the DHB Hospital may continue to Give that pharmaceutical if it is considered that there would be significant adverse clinical consequences from ceasing or switching treatment.
 - 13.2 Each DHB Hospital must, by no later than 1 October 2013, provide PHARMAC with a report on pharmaceuticals it has Given in accordance with this rule 13 where treatment has continued beyond 1 August 2013.
- 14 **Clinical Trials and Free Stock**
 - 14.1 DHB Hospitals may Give any pharmaceutical that is funded by a third party and is being used:
 - 14.1.1 as part of a clinical trial that has Ethics Committee approval; or
 - 14.1.2 for on-going treatment of patients following the end of such a clinical trial.
 - 14.2 DHB Hospitals may Give any pharmaceutical that is provided free of charge by a supplier, provided that the pharmaceutical is provided as part of a programme of which the DHB, or supplier, has notified PHARMAC.
- 15 **Pharmaceutical Cancer Treatments in Paediatrics**

DHB Hospitals may Give any pharmaceutical for use within a paediatric oncology/haematology service for the treatment of cancer.

16 Other Government Funding

DHB Hospitals may Give any pharmaceutical where funding for that pharmaceutical has been specifically provided by a Government entity other than PHARMAC or a DHB.

17 Other Exceptions

- 17.1 PHARMAC may also approve the funding of a pharmaceutical within a single DHB Hospital for information gathering purposes or otherwise related to PHARMAC's decision-making process for considering additions to or amendments to the Pharmaceutical Schedule.
- 17.2 Funding approvals granted under rule 17.1 will be subject to specific limitations on use as determined appropriate by PHARMAC in each circumstance, in consultation with the relevant DHB Hospital and/or DHB.

NATIONAL CONTRACTING**18 Hospital Pharmaceutical Contracts**

- 18.1 A DHB Hospital may enter into a contract for the purchase of any Pharmaceutical, including any Medical Device, that it is entitled to fund in accordance with this Schedule H and that is not a National Contract Pharmaceutical, provided that such a contract:
 - a) does not oblige the relevant DHB Hospital to purchase a volume of that Pharmaceutical, if that Pharmaceutical is a DV Pharmaceutical, that is greater than the relevant DV Limit;
 - b) enables PHARMAC to access and use future price and volume data in respect of that Pharmaceutical; and
 - c) enables the relevant DHB Hospital to terminate the contract or relevant parts of the contract in order to give full effect to the National Contract on no more than 3 months' written notice to the Pharmaceutical supplier.
- 18.2 From 1 July 2013, where a DHB Hospital has a pre-existing supply contract for a particular brand of chemical entity for which there is a National Contract Pharmaceutical, the DHB may continue purchasing the chemical entity in accordance with its pre-existing supply contract however:
 - a) from the day its pre-existing supply contract expires, that DHB Hospital is to purchase the relevant National Contract Pharmaceutical listed in Section H at the Price, and is to comply with any DV Limits for the National Contract Pharmaceutical where it has HSS;
 - b) if purchase of the relevant National Contract Pharmaceutical listed in Section H at the Price, where it has HSS, would not cause the relevant DHB Hospital to be in breach of its pre-existing supply contract for a particular brand of chemical entity; the DHB Hospital must purchase the National Contract Pharmaceutical.
- 18.3 Following written notification from PHARMAC that a Pharmaceutical is a National Contract Pharmaceutical, either through Section H updates or otherwise, DHB Hospitals must, unless PHARMAC expressly notifies otherwise:
 - a) take any steps available to them to terminate pre-existing contracts or relevant parts of such a contract, and
 - b) not enter any new contracts or extend the period of any current contracts, for the supply of that National Contract Pharmaceutical or the relevant chemical entity or Medical Device.

19 National Contract Pharmaceuticals

- 19.1 DHB Hospitals must take all necessary steps to enable any contracts between PHARMAC and a Pharmaceutical supplier in relation to National Contract Pharmaceuticals to be given full effect.
- 19.2 The contractual arrangement between PHARMAC and the relevant supplier of a National Contract Pharmaceutical requires it to be made available for purchase at the relevant Price by any or all of the following:
 - a) DHB Hospitals at Designated Delivery Points; and/or
 - b) Contract Manufacturers (expressly for the purpose of compounding).

In the case of Medical Devices, a National Contract may require the Medical Device to be purchased by, and/or supplied to, a third party logistics provider.

20 Hospital Supply Status (HSS)

- 20.1 The DV Limit for any National Contract Pharmaceutical which has HSS is set out in the listing of the relevant National Contract Pharmaceutical in Section H, and may be amended from time to time.
- 20.2 If a National Contract Pharmaceutical is listed in Section H as having HSS, DHB Hospitals:
 - a) are expected to use up any existing stocks of DV Pharmaceuticals during the First Transition Period;
 - b) must not purchase DV Pharmaceuticals in volumes exceeding their usual requirements, or in volumes exceeding those which they reasonably expect to use, within the First Transition Period;
 - c) must ensure that Contract Manufacturers, when manufacturing an Extemporaneously Compounded Product on their behalf, use the National Contract Pharmaceutical with HSS; and
 - d) must purchase the National Contract Pharmaceutical with HSS except:

- i) to the extent that the DHB Hospital may use its discretion to purchase a DV Pharmaceutical within the DV Limit, provided that (subject to rule 20.2(d)(iii) below) the DV Limit has not been exceeded nationally;
 - ii) if the Pharmaceutical supplier fails to supply that National Contract Pharmaceutical, in which case the relevant DHB Hospital does not have to comply with the DV Limit for that National Contract Pharmaceutical during that period of non-supply (and any such month(s) included in a period of non-supply will be excluded in any review of the DV Limit in accordance with rule 20.3 below);
 - iii) that where the DV Limit has been exceeded nationally, the DHB Hospital may negotiate with the Pharmaceutical supplier that supplies the National Contract Pharmaceutical with HSS for written permission to vary the application of that DHB Hospital's Individual DV Limit for any patient whose exceptional needs require a DV Pharmaceutical.
- 20.3 PHARMAC may, in its discretion, for any period or part period:
 - a) review usage by DHB Hospitals of the National Contract Pharmaceutical and DV Pharmaceuticals to determine whether the DV Limit has been exceeded; and
 - b) audit compliance by DHB Hospitals with the DV Limits and related requirements.
- 20.4 PHARMAC will address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit by:
 - a) obtaining the relevant DHB or DHB Hospital's assurance that it will comply with the DV Limit for that National Contract Pharmaceutical with HSS in the remainder of the applicable period and any subsequent periods; and
 - b) informing the relevant supplier of the HSS Pharmaceutical of any individual DHB or DHB Hospital's non-compliance with the DV Limit for that HSS Pharmaceutical.
- 20.5 In addition to the steps taken by PHARMAC under rule 20.4 above to address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit, the relevant Pharmaceutical supplier may require, in its discretion, financial compensation from the relevant DHB or DHB Hospital:
 - a) an amount representing that DHB or DHB Hospital's contribution towards exceeding the DV Limit (where PHARMAC is able to quantify this based on the information available to it); or
 - b) the sum of \$1,000 or \$5,000 (depending on the terms of the applicable national contract applying to the HSS Pharmaceutical),whichever is the greater as between sub-paragraphs (a) and (b) within the number of business days specified in the notice from the Pharmaceutical supplier requiring such payment to be made.
- 21 **Collection of rebates and payment of financial compensation**
 - 21.1 Following the receipt of any rebates from a Pharmaceutical supplier in respect of a particular National Contract Pharmaceutical, PHARMAC will notify each relevant DHB and DHB Hospital of the amount of the rebate owing to it, being a portion of the total rebate determined by PHARMAC on the basis of that DHB Hospital's usage of that National Contract Pharmaceutical, where this is able to be determined. Where data to determine individual DHB Hospitals' usage is not available, PHARMAC will apportion rebates on the basis of an alternative method agreed between the relevant DHBs and PHARMAC.
 - 21.2 PHARMAC will pay each DHB Hospital the rebate amounts (if any) owing to it, no less frequently than once each calendar quarter in respect of rebates received quarterly (or more often).
- 22 **Price and Volume Data**
 - 22.1 DHB Hospitals must provide to PHARMAC, on a monthly basis in accordance with PHARMAC's requirements, any volume data and, unless it would result in a breach of a pre-existing contract, price data held by those DHB Hospitals in respect of any Pharmaceutical (including any Medical Device) listed in Section H.
 - 22.2 All price and volume data provided to PHARMAC under rule 22.1 above should identify the relevant Hospital Pharmaceutical by using a Pharmacode or some other unique numerical identifier, and the date (month and year) on which the DHB Hospital incurred a cost for the purchase of that Hospital Pharmaceutical. Volume is to be measured in units (that being the smallest possible whole Unit – e.g. a capsule, a vial, a millilitre etc).

MISCELLANEOUS PROVISIONS

- 23 **Unapproved Pharmaceuticals**

Prescribers should, where possible, prescribe Hospital Pharmaceuticals that are approved under the Medicines Act 1981. However, the funding criteria (including Restrictions) under which a Hospital Pharmaceutical is listed in Section H of the Schedule may:

23.1 in some cases, explicitly permit a DHB to fund a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or

23.2 not explicitly prohibit a DHB from funding a Pharmaceutical for use for an Unapproved Indication;

Accordingly, if clinicians are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, they should:

23.1 be aware of and comply with their obligations under sections 25 and/or 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;

23.2 be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that clinicians obtain written consent); and

23.3 exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Clinicians should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule, PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Antacids and Antiflatulents

Antacids and Reflux Barrier Agents

ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE

Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg *e.g. Mylanta*

Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml *e.g. Mylanta*

Oral liq 400 mg with magnesium hydroxide 400 mg and simethicone 30 mg per 5 ml *e.g. Mylanta Double Strength*

SIMETHICONE

Oral drops 100 mg per ml

SODIUM ALGINATE WITH MAGNESIUM ALGINATE

Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet *e.g. Gaviscon Infant*

SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE

Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg *e.g. Gaviscon Double Strength*

Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml 4.95 500 ml Acidex

SODIUM CITRATE

Oral liq 8.8% (300 mmol/l)

Phosphate Binding Agents

ALUMINIUM HYDROXIDE

Tab 600 mg

CALCIUM CARBONATE – **Restricted** see terms below

☞ Oral liq 250 mg per ml (100 mg elemental per ml) 39.00 500 ml Roxane

☞ **Restricted**

Only for use in children under 12 years of age for use as a phosphate binding agent

Antidiarrhoeals and Intestinal Anti-Inflammatory Agents

Antipropulsives

DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE

Tab 2.5 mg with atropine sulphate 25 mcg

LOPERAMIDE HYDROCHLORIDE

Tab 2 mg

Cap 2 mg 8.95 400 Diamide Relief

Rectal and Colonic Anti-Inflammatories

BUDESONIDE – **Restricted** see terms on the next page

☞ Cap 3 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔ Restricted			
Crohn's disease			
Both:			
1	Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and		
2	Any of the following:		
2.1	Diabetes; or		
2.2	Cushingoid habitus; or		
2.3	Osteoporosis where there is significant risk of fracture; or		
2.4	Severe acne following treatment with conventional corticosteroid therapy; or		
2.5	History of severe psychiatric problems associated with corticosteroid treatment; or		
2.6	History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or		
2.7	Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).		
Collagenous and lymphocytic colitis (microscopic colitis)			
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies			
Gut Graft versus Host disease			
Patient has a gut Graft versus Host disease following allogeneic bone marrow transplantation			
HYDROCORTISONE ACETATE			
Rectal foam 10% (14 applications) – 1% DV Jan-13 to 2015	25.30	21.1 g	Colifoam
MESALAZINE			
Tab EC 400 mg	49.50	100	Asacol
Tab EC 500 mg	49.50	100	Asamax
Tab long-acting 500 mg	59.05	100	Pentasa
Modified release granules 1 g	141.72	120 g	Pentasa
Suppos 500 mg – 1% DV Sep-11 to 2014	22.80	20	Asacol
Suppos 1 g	50.96	28	Pentasa
Enema 1 g per 100 ml – 1% DV Sep-12 to 2015	54.60	30	Pentasa
Enema 1 g per 100 ml – 1% DV Sep-12 to 2015	44.12	7	Pentasa
OLSALAZINE			
Tab 500 mg			
Cap 250 mg			
SODIUM CROMOGLYCATE			
Cap 100 mg			
SULPHASALAZINE			
Tab 500 mg – 1% DV Oct-13 to 2016	11.68	100	Salazopyrin
Tab EC 500 mg – 1% DV Oct-13 to 2016	12.89	100	Salazopyrin EN
Local Preparations for Anal and Rectal Disorders			
Antihæmorrhoidal Preparations			
CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE			
Oint 5 mg with hydrocortisone 5 mg per g	15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g	9.90	12	Proctosedyl
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE			
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g	6.35	30 g	Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg	2.66	12	Ultraproct

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Management of Anal Fissures			
GLYCERYL TRINITRATE			
Oint 0.2%	22.00	30 g	Rectogesic
Rectal Sclerosants			
OILY PHENOL [PHENOL OILY]			
Inj 5%, 5 ml vial			
Antispasmodics and Other Agents Altering Gut Motility			
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – 1% DV Oct-13 to 2016.....	28.56	10	Max Health
HYOSCINE BUTYLBROMIDE			
Tab 10 mg – 1% DV Sep-11 to 2014	1.48	20	Gastrosoothe
Inj 20 mg, 1 ml ampoule – 1% DV Nov-11 to 2014.....	9.57	5	Buscopan
MEBEVERINE HYDROCHLORIDE			
Tab 135 mg – 1% DV Sep-11 to 2014	18.00	90	Colofac
Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL			
Tab 200 mcg			
H2 Antagonists			
CIMETIDINE			
Tab 200 mg			
Tab 400 mg			
RANITIDINE			
Tab 150 mg – 1% DV Sep-11 to 2014	6.79	250	Arrow-Ranitidine
Tab 300 mg – 1% DV Sep-11 to 2014	9.34	250	Arrow-Ranitidine
Oral liq 150 mg per 10 ml – 1% DV Sep-11 to 2014.....	5.92	300 ml	Peptisoothe
Inj 25 mg per ml, 2 ml ampoule	8.75	5	Zantac
Proton Pump Inhibitors			
LANSOPRAZOLE			
Cap 15 mg – 1% DV Jan-13 to 2015	2.00	28	Solox
Cap 30 mg – 1% DV Jan-13 to 2015	2.32	28	Solox
OMEPRAZOLE			
⚡ Tab dispersible 20 mg			
➡ Restricted			
Only for use in tube-fed patients			
Cap 10 mg – 1% DV Oct-11 to 2014	2.91	90	Omezol Relief
Cap 20 mg – 1% DV Oct-11 to 2014	3.78	90	Omezol Relief
Cap 40 mg – 1% DV Oct-11 to 2014	5.57	90	Omezol Relief
Powder for oral liq – 1% DV Sep-11 to 2014.....	42.50	5 g	Midwest
Inj 40 mg ampoule – 1% DV Sep-11 to 2014.....	19.00	5	Dr Reddy's Omeprazole
Inj 40 mg ampoule with diluent – 1% DV Sep-11 to 2014.....	28.65	5	Dr Reddy's Omeprazole

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PANTOPRAZOLE			
Tab 20 mg	1.23	28	Dr Reddy's Pantoprazole
Tab 40 mg	1.54	28	Dr Reddy's Pantoprazole
Inj 40 mg vial			

Site Protective Agents

BISMUTH TRIOXIDE			
Tab 120 mg	32.50	112	De-Nol
SUCRALFATE			
Tab 1 g			

Bile and Liver Therapy

L-ORNITHINE L-ASPARTATE – **Restricted** see terms below

⚡ Grans for oral liquid 3 g

↪ **Restricted**

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

Diabetes

Alpha Glucosidase Inhibitors

ACARBOSE			
Tab 50 mg – 1% DV Dec-12 to 2015	9.82	90	Accarb
Tab 100 mg – 1% DV Dec-12 to 2015	15.83	90	Accarb

Hyperglycaemic Agents

DIAZOXIDE – **Restricted** see terms below

⚡ Cap 25 mg 110.00 100 Proglidem

⚡ Cap 100 mg 280.00 100 Proglidem

↪ **Restricted**

For patients with confirmed hypoglycaemia caused by hyperinsulinism.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit 32.00 1 Glucagen Hypokit

GLUCOSE

Tab 1.5 g

Tab 3.1 g

Gel 40%

GLUCOSE WITH SUCROSE AND FRUCTOSE

Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

Insulin - Intermediate-Acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml,
3 ml prefilled pen 52.15 5 NovoMix 30 FlexPen

INSULIN ISOPHANE

Inj insulin human 100 u per ml, 10 ml vial

Inj insulin human 100 u per ml, 3 ml cartridge

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge	42.66	5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge	42.66	5	Humalog Mix 50
INSULIN NEUTRAL WITH INSULIN ISOPHANE			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge			
Insulin - Long-Acting Preparations			
INSULIN GLARGINE			
Inj 100 u per ml, 3 ml disposable pen	94.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge	94.50	5	Lantus
Inj 100 u per ml, 10 ml vial	63.00	1	Lantus
Insulin - Rapid-Acting Preparations			
INSULIN ASPART			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
INSULIN GLULISINE			
Inj 100 u per ml, 10 ml vial	27.03	1	Apidra
Inj 100 u per ml, 3 ml cartridge	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen	46.07	5	Apidra Solostar
INSULIN LISPRO			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Insulin - Short-Acting Preparations			
INSULIN NEUTRAL			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE			
Tab 5 mg			
GLICLAZIDE			
Tab 80 mg – 1% DV Sep-11 to 2014	17.60	500	Apo-Gliclazide
GLIPIZIDE			
Tab 5 mg – 1% DV Dec-12 to 2015	3.00	100	Minidiab

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)
e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METFORMIN			
Tab immediate-release 500 mg – 1% DV Oct-12 to 2015.....	12.30	1,000	Apotex
Tab immediate-release 850 mg – 1% DV Oct-12 to 2015.....	10.10	500	Apotex
PIOGLITAZONE			
Tab 15 mg – 1% DV Sep-12 to 2015	1.50	28	Pizaccord
Tab 30 mg – 1% DV Sep-12 to 2015	2.50	28	Pizaccord
Tab 45 mg – 1% DV Sep-12 to 2015	3.50	28	Pizaccord

Digestives Including Enzymes

PANCREATIC ENZYME

- Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease
- Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease
- Cap EC 25,000 BP u lipase, 22,500 BP u amylase and 1,250 BP u protease
- Powder 25,000 u lipase with 30,000 u amylase and 1,400 u protease per g

URSODEOXYCHOLIC ACID – **Restricted** see terms below

- Cap 250 mg – 1% DV May-12 to 2014 71.50 100 **Ursosan**

↪ **Restricted**

Alagille syndrome or progressive familial intrahepatic cholestasis

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Cirrhosis

Either:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 µmol/l; decompensated cirrhosis).

Pregnancy

Patient diagnosed with cholestasis of pregnancy.

Haematological transplant

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Laxatives			
Bowel-Cleansing Preparations			
CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE			
Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet			<i>e.g. PicoPrep</i>
MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet			<i>e.g. Glycoprep-C</i>
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet			<i>e.g. Glycoprep-C</i>
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE			
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet	14.31	4	Klean Prep
Bulk-Forming Agents			
ISPAGHULA (PSYLLIUM) HUSK			
Powder for oral soln – 1% DV Sep-13 to 2016	5.51	500 g	Konsyl-D
STERCULIA WITH FRANGULA – Restricted: For continuation only			
➔ Powder for oral soln			
Faecal Softeners			
DOCUSATE SODIUM			
Cap 50 mg – 1% DV Sep-11 to 2014	2.57	100	Laxofast 50
Cap 120 mg – 1% DV Sep-11 to 2014	3.48	100	Laxofast 120
DOCUSATE SODIUM WITH SENNOSIDES			
Tab 50 mg with sennosides 8 mg	6.38	200	Laxsol
PARAFFIN			
Oral liquid 1 mg per ml			
Enema 133 ml			
POLOXAMER			
Oral drops 10% – 1% DV Sep-11 to 2014	3.78	30 ml	Coloxyl
Osmotic Laxatives			
GLYCEROL			
Suppos 1.27 g			
Suppos 2.55 g			
Suppos 3.6 g – 1% DV Jan-13 to 2015	6.50	20	PSM
LACTULOSE			
Oral liq 10 g per 15 ml – 1% DV May-14 to 2014	3.84	500 ml	Laevolac
	7.68	1,000 ml	Laevolac
<i>(Laevolac Oral liq 10 g per 15 ml to be delisted 1 May 2014)</i>			

↑ Item restricted (see ➔ above); ↓ Item restricted (see ➔ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE – Restricted see terms below			
⚡ Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg			
⚡ Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Nov-13 to 2014	10.00	30	Lax-Sachets

➔ **Restricted**

Either:

- 1 The patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; or
- 2 For short-term use for faecal disimpaction.

SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Sep-13 to 2016	19.95	50	Micolette
--	-------	----	------------------

SODIUM PHOSPHATE WITH PHOSPHORIC ACID

Oral liq 16.4% with phosphoric acid 25.14%			
Enema 10% with phosphoric acid 6.58%	2.50	1	Fleet Phosphate Enema

Stimulant Laxatives

BISACODYL

Tab 5 mg	4.99	200	Lax-Tabs
Suppos 5 mg	3.00	6	Dulcolax
Suppos 10 mg	3.00	6	Dulcolax

DANTHRON WITH POLOXAMER – Restricted see terms below

⚡ Oral liq 25 mg with poloxamer 200 mg per 5 ml	21.30	300 ml	Pinorax
⚡ Oral liq 75 mg with poloxamer 1 g per 5 ml	43.60	300 ml	Pinorax Forte

➔ **Restricted**

Only for the prevention or treatment of constipation in the terminally ill

SENNOSIDES

Tab 7.5 mg

Metabolic Disorder Agents

ARGININE

Powder
Inj 600 mg per ml, 25 ml vial

BETAINE – Restricted see terms below

⚡ Powder

➔ **Restricted**

Metabolic disorders physician or metabolic disorders dietitian

BIOTIN – Restricted see terms below

⚡ Cap 50 mg
⚡ Cap 100 mg
⚡ Inj 10 mg per ml, 5 ml vial

➔ **Restricted**

Metabolic disorders physician or metabolic disorders dietitian.

HAEM ARGINATE

Inj 25 mg per ml, 10 ml ampoule

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
IMIGLUCERASE – Restricted see terms below			
‡ Inj 40 iu per ml, 5 ml vial			
‡ Inj 40 iu per ml, 10 ml vial			
➔ Restricted			
Only for use in patients with approval by the Gaucher's Treatment Panel			
LEVOCARNITINE – Restricted see terms below			
‡ Cap 500 mg			
‡ Oral soln 500 mg per 15 ml			
‡ Inj 200 mg per ml, 5 ml vial			
➔ Restricted			
Metabolic disorders physician, metabolic disorders dietitian or neurologist			
PYRIDOXAL-5-PHOSPHATE – Restricted see terms below			
‡ Tab 50 mg			
➔ Restricted			
Metabolic disorders physician, metabolic disorders dietician or neurologist			
SODIUM BENZOATE			
Cap 500 mg			
Powder			
Soln 100 mg per ml			
Inj 20%, 10 ml ampoule			
SODIUM PHENYLBUTYRATE			
Tab 500 mg			
Oral liq 250 mg per ml			
Inj 200 mg per ml, 10 ml ampoule			
TRIENTINE DIHYDROCHLORIDE			
Cap 300 mg			

Minerals

Calcium

CALCIUM CARBONATE			
Tab 1.25 g (500 mg elemental) – 1% DV Feb-12 to 2014	6.38	250	Arrow-Calcium
Tab 1.5 g (600 mg elemental)			
Tab eff 1.75 g (1 g elemental) – 1% DV Nov-11 to 2014	6.21	30	Calsource

Fluoride

SODIUM FLUORIDE			
Tab 1.1 mg (0.5 mg elemental)			

Iodine

POTASSIUM IODATE			
Tab 256 mcg (150 mcg elemental iodine)			
POTASSIUM IODATE WITH IODINE			
Oral liq 10% with iodine 5%			

Iron

FERROUS FUMARATE			
Tab 200 mg (65 mg elemental)	4.35	100	Ferro-tab

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
FERROUS FUMARATE WITH FOLIC ACID			
Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID			
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULPHATE			
Tab long-acting 325 mg (105 mg elemental)			
Oral liq 30 mg (6 mg elemental) per ml	10.30	500 ml	Ferodan
FERROUS SULPHATE WITH ASCORBIC ACID			
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
FERROUS SULPHATE WITH FOLIC ACID			
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg			
IRON POLYMALTOSE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-11 to 2014	19.90	5	Ferrum H
IRON SUCROSE			
Inj 20 mg per ml, 5 ml ampoule	100.00	5	Venofer

Magnesium

MAGNESIUM HYDROXIDE			
Tab 311 mg (130 mg elemental)			
MAGNESIUM OXIDE			
Cap 663 mg (400 mg elemental)			
MAGNESIUM SULPHATE			
Inj 0.4 mmol per ml, 250 ml bag			
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Feb-13 to 2014	18.35	10	Martindale

Zinc

ZINC			
Oral liq 5 mg per 5 drops			
ZINC CHLORIDE			
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule			
ZINC SULPHATE			
Cap 137.4 mg (50 mg elemental) – 1% DV Nov-11 to 2014.....	11.00	100	Zincaps

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE			
Soln 0.15%			
Spray 0.15%			
BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE			
Lozenge 3 mg with cetylpyridinium chloride			
CARBOXYMETHYLCELLULOSE			
Oral spray			
CHLORHEXIDINE GLUCONATE			
Mouthwash 0.2% – 1% DV Dec-12 to 2015.....	2.68	200 ml	healthE

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE Adhesive gel 8.7% with cetalkonium chloride 0.01%			
DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL Lozenge 1.2 mg with amylmetacresol 0.6 mg			
SODIUM CARBOXYMETHYLCELLULOSE WITH PECTIN AND GELATINE Paste Powder			
TRIAMCINOLONE ACETONIDE Paste 0.1% – 1% DV Sep-11 to 2014	4.34	5 g	Oracort

Oropharyngeal Anti-Infectives

AMPHOTERICIN B Lozenge 10 mg	5.86	20	Fungilin
MICONAZOLE Oral gel 20 mg per g – 1% DV Feb-13 to 2015	4.95	40 g	Decozol
NYSTATIN Oral liquid 100,000 u per ml – 1% DV Sep-11 to 2014	3.19	24 ml	Nilstat

Other Oral Agents

SODIUM HYALURONATE – **Restricted** see terms below

⚡ Inj 20 mg per ml, 1 ml syringe

➡ **Restricted**

Otolaryngologist

THYMOL GLYCERIN

Compound, BPC

Vitamins

Multivitamin Preparations

MULTIVITAMINS

Tab (BPC cap strength)

e.g. Mvite

⚡ Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg

e.g. Vitabdeck

➡ **Restricted**

Either:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome.

⚡ Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg

e.g. Paediatric Seravit

➡ **Restricted**

Patient has inborn errors of metabolism.

⬆️ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)			<i>e.g. Pabrinex IM</i>
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
VITAMIN A WITH VITAMINS D AND C			
Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops			<i>e.g. Vitadol C</i>

Vitamin A

RETINOL

Tab 10,000 iu
Cap 25,000 iu
Oral liq 150,000 iu per ml

Vitamin B

HYDROXOCOBALAMIN ACETATE

Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-12 to 2015 5.10 3 **ABM**
Hydroxocobalamin

PYRIDOXINE HYDROCHLORIDE

Tab 25 mg – 1% DV Sep-11 to 2014 2.20 90 **PyridoxADE**
Tab 50 mg – 1% DV Sep-11 to 2014 12.16 500 **Apo-Pyridoxine**
Inj 100 mg per ml, 1 ml ampoule

THIAMINE HYDROCHLORIDE

Tab 50 mg
Tab 100 mg
Inj 100 mg per ml, 2 ml vial

VITAMIN B COMPLEX

Tab strong, BPC

Vitamin C

ASCORBIC ACID

Tab 100 mg – 1% DV Nov-13 to 2016 7.00 500 **Cvite**
Tab chewable 250 mg

Vitamin D

ALFACALCIDOL

Cap 0.25 mcg 26.32 100 One-Alpha
Cap 1 mcg 87.98 100 One-Alpha
Oral drops 2 mcg per ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CALCITRIOL			
Cap 0.25 mcg	3.03	30	Airflow
	10.10	100	Calcitriol-AFT
Cap 0.5 mcg	5.62	30	Airflow
	18.73	100	Calcitriol-AFT
Oral liq 1 mcg per ml			
Inj 1 mcg per ml, 1 ml ampoule			
CHOLECALCIFEROL			
Tab 1.25 mg (50,000 iu)	7.76	12	Cal-d-Forte

Vitamin E

ALPHA TOCOPHERYL ACETATE – **Restricted** see terms below

- ⚡ Cap 100 u
- ⚡ Cap 500 u
- ⚡ Oral liq 156 u per ml

↪ **Restricted**

Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Osteoradionecrosis

For the treatment of osteoradionecrosis

Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

ERYTHROPOIETIN ALPHA – **Restricted** see terms below

⚡ Inj 1,000 iu in 0.5 ml syringe	48.68	6	Eprex
⚡ Inj 2,000 iu in 0.5 ml syringe	120.18	6	Eprex
⚡ Inj 3,000 iu in 0.3 ml syringe	166.87	6	Eprex
⚡ Inj 4,000 iu in 0.4 ml syringe	193.13	6	Eprex
⚡ Inj 5,000 iu in 0.5 ml syringe	243.26	6	Eprex
⚡ Inj 6,000 iu in 0.6 ml syringe	291.92	6	Eprex
⚡ Inj 10,000 iu in 1 ml syringe	395.18	6	Eprex

➔ **Restricted**

Both:

- 1 Both:
 - 1.1 Patient in chronic renal failure; and
 - 1.2 Haemoglobin ≤ 100g/L; and
- 2 Any of the following:
 - 2.1 Both:
 - 2.1.1 Patient is not diabetic; and
 - 2.1.2 Glomerular filtration rate ≤ 30ml/min; or
 - 2.2 Both:
 - 2.2.1 Patient is diabetic; and
 - 2.2.2 Glomerular filtration rate ≤ 45ml/min; or
 - 2.3 Patient is on haemodialysis or peritoneal dialysis.

ERYTHROPOIETIN BETA – **Restricted** see terms below

⚡ Inj 2,000 iu in 0.3 ml syringe	120.18	6	NeoRecormon
⚡ Inj 3,000 iu in 0.3 ml syringe	166.87	6	NeoRecormon
⚡ Inj 4,000 iu in 0.3 ml syringe	193.13	6	NeoRecormon
⚡ Inj 5,000 iu in 0.3 ml syringe	243.26	6	NeoRecormon
⚡ Inj 6,000 iu in 0.3 ml syringe	291.92	6	NeoRecormon
⚡ Inj 10,000 iu in 0.6 ml syringe	395.18	6	NeoRecormon

➔ **Restricted**

Both:

- 1 Both:
 - 1.1 Patient in chronic renal failure; and
 - 1.2 Haemoglobin ≤ 100g/L; and
- 2 Any of the following:
 - 2.1 Both:
 - 2.1.1 Patient is not diabetic; and
 - 2.1.2 Glomerular filtration rate ≤ 30ml/min; or
 - 2.2 Both:
 - 2.2.1 Patient is diabetic; and
 - 2.2.2 Glomerular filtration rate ≤ 45ml/min; or
 - 2.3 Patient is on haemodialysis or peritoneal dialysis.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Megaloblastic			
FOLIC ACID			
Tab 0.8 mg			
Tab 5 mg			
Oral liq 50 mcg per ml	24.00	25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			

Antifibrinolytics, Haemostatics and Local Sclerosants

APROTININ – **Restricted** see terms below

⚡ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial

➡ **Restricted**

Cardiac anaesthetist

Either:

- 1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
- 2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – **Restricted** see terms below

⚡ Tab 25 mg 1,771.00 28 Revolade

⚡ Tab 50 mg 3,542.00 28 Revolade

➡ **Restricted**

Haematologist

Initiation (idiopathic thrombocytopenic purpura - post-splenectomy)

Re-assessment required after 6 weeks

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has a platelet count of $\leq 20,000$ platelets per microlitre and has evidence of active bleeding; or
 - 3.2 Patient has a platelet count of $\leq 10,000$ platelets per microlitre.

Initiation - (idiopathic thrombocytopenic purpura - preparation for splenectomy)

Re-assessment required after 6 weeks

The patient requires eltrombopag treatment as preparation for splenectomy.

Continuation - (idiopathic thrombocytopenic purpura - post-splenectomy)

Re-assessment required after 12 months

The patient has obtained a response (see note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of $> 30,000$ platelets per microlitre.

FERRIC SUBSULFATE

Gel 25.9%

Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE

Inj 3%, 2 ml ampoule

THROMBIN

Powder

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRANEXAMIC ACID			
Tab 500 mg	32.92	100	Cyklokapron
Inj 100 mg per ml, 5 ml ampoule	124.73	10	Cyklokapron

Blood Factors

EPTACOG ALFA [RECOMBINANT FACTOR VIIIA] – **Restricted** see terms below

⚡ Inj 1 mg syringe	1,163.75	1	NovoSeven RT
⚡ Inj 2 mg syringe	2,327.50	1	NovoSeven RT
⚡ Inj 5 mg syringe	5,818.75	1	NovoSeven RT
⚡ Inj 8 mg syringe	9,310.00	1	NovoSeven RT

↳ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group..

FACTOR EIGHT INHIBITORS BYPASSING AGENT – **Restricted** see terms below

⚡ Inj 500 U	1,640.00	1	FEIBA
⚡ Inj 1,000 U	3,280.00	1	FEIBA

↳ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group..

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms below

⚡ Inj 250 iu vial	225.00	1	Xyntha
⚡ Inj 500 iu vial	450.00	1	Xyntha
⚡ Inj 1,000 iu vial	900.00	1	Xyntha
⚡ Inj 2,000 iu vial	1,800.00	1	Xyntha
⚡ Inj 3,000 iu vial	2,700.00	1	Xyntha

↳ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group..

NONACOG ALFA [RECOMBINANT FACTOR IX] – **Restricted** see terms below

⚡ Inj 250 iu vial	310.00	1	BeneFIX
⚡ Inj 500 iu vial	620.00	1	BeneFIX
⚡ Inj 1,000 iu vial	1,240.00	1	BeneFIX
⚡ Inj 2,000 iu vial	2,480.00	1	BeneFIX

↳ **Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group..

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms on the next page

⚡ Inj 250 iu vial	237.50	1	Advate
	250.00		Kogenate FS
⚡ Inj 500 iu vial	475.00	1	Advate
	500.00		Kogenate FS
⚡ Inj 1,000 iu vial	950.00	1	Advate
	1,000.00		Kogenate FS
⚡ Inj 1,500 iu vial	1,425.00	1	Advate
⚡ Inj 2,000 iu vial	1,900.00	1	Advate
	2,000.00		Kogenate FS
⚡ Inj 3,000 iu vial	2,850.00	1	Advate
	3,000.00		Kogenate FS

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Vitamin K

PHYTOMENADIONE

Inj 2 mg in 0.2 ml ampoule	8.00	5	Konakion MM
Inj 10 mg per ml, 1 ml ampoule	9.21	5	Konakion MM

Anti-thrombotics

Anticoagulants

BIVALIRUDIN – **Restricted** see terms below

⚡ Inj 250 mg vial

➔Restricted

Either:

- 1 For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance; or
- 2 For use in patients undergoing endovascular procedures.

DABIGATRAN

Cap 75 mg	148.00	60	Pradaxa
Cap 110 mg	148.00	60	Pradaxa
Cap 150 mg	148.00	60	Pradaxa

DALTEPARIN

Inj 2,500 iu in 0.2 ml syringe	19.97	10	Fragmin
Inj 5,000 iu in 0.2 ml syringe	39.94	10	Fragmin
Inj 7,500 iu in 0.75 ml syringe	60.03	10	Fragmin
Inj 10,000 iu in 1 ml syringe	77.55	10	Fragmin
Inj 12,500 iu in 0.5 ml syringe	99.96	10	Fragmin
Inj 15,000 iu in 0.6 ml syringe	120.05	10	Fragmin
Inj 18,000 iu in 0.72 ml syringe	158.47	10	Fragmin

DANAPAROID – **Restricted** see terms below

⚡ Inj 750 u in 0.6 ml ampoule

➔Restricted

For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

DEFIBROTIDE – **Restricted** see terms below

⚡ Inj 80 mg per ml, 2.5 ml ampoule

➔Restricted

Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities

DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml,
100 ml bag

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENOXAPARIN			
Inj 20 mg in 0.2 ml syringe – 1% DV Sep-12 to 2015	37.24	10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe – 1% DV Sep-12 to 2015	49.69	10	Clexane
Inj 60 mg in 0.6 ml syringe – 1% DV Sep-12 to 2015	74.91	10	Clexane
Inj 80 mg in 0.8 ml syringe – 1% DV Sep-12 to 2015	99.86	10	Clexane
Inj 100 mg in 1 ml syringe – 1% DV Sep-12 to 2015	125.06	10	Clexane
Inj 120 mg in 0.8 ml syringe – 1% DV Sep-12 to 2015	155.40	10	Clexane
Inj 150 mg in 1 ml syringe – 1% DV Sep-12 to 2015	177.60	10	Clexane
FONDAPARINUX SODIUM – Restricted see terms below			
☒ Inj 2.5 mg in 0.5 ml syringe			
☒ Inj 7.5 mg in 0.6 ml syringe			
☛ Restricted			
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance			
HEPARIN SODIUM			
Inj 100 iu per ml, 250 ml bag			
Inj 1,000 iu per ml, 1 ml ampoule	66.80	50	Mayne
Inj 1,000 iu per ml, 35 ml ampoule			
Inj 1,000 iu per ml, 5 ml ampoule	11.44	10	Pfizer
	46.30	50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule			
Inj 5,000 iu per ml, 1 ml ampoule	14.20	5	Mayne
Inj 5,000 iu per ml, 5 ml ampoule	182.00	50	Pfizer
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml ampoule	32.50	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
PHENINDIONE			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
PROTAMINE SULPHATE			
Inj 10 mg per ml, 5 ml ampoule			
RIVAROXABAN – Restricted see terms below			
☒ Tab 10 mg	153.00	15	Xarelto
☛ Restricted			
Either:			
1 Limited to five weeks' treatment for the prophylaxis of venous thromboembolism following a total hip replacement; or			
2 Limited to two weeks' treatment for the prophylaxis of venous thromboembolism following a total knee replacement.			
SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE			
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride			
74.6 mcg per ml, 5,000 ml bag			
TRISODIUM CITRATE			
Inj 4%, 5 ml ampoule			
Inj 46.7%, 5 ml ampoule			

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
WARFARIN SODIUM			
Tab 1 mg	6.86	100	Marevan
Tab 2 mg			
Tab 3 mg	9.70	100	Marevan
Tab 5 mg	11.75	100	Marevan
Antiplatelets			
ASPIRIN			
Tab 100 mg – 1% DV Mar-14 to 2016	1.60	90	Ethics Aspirin EC
	10.50	990	Ethics Aspirin EC
Suppos 300 mg			
CLOPIDOGREL			
Tab 75 mg – 1% DV Dec-13 to 2016	5.48	84	Arrow - Clopid
DIPYRIDAMOLE			
Tab 25 mg			
Tab long-acting 150 mg – 1% DV Oct-11 to 2014	11.52	60	Pytazen SR
Inj 5 mg per ml, 2 ml ampoule			
EPTIFIBATIDE – Restricted see terms below			
⚡ Inj 2 mg per ml, 10 ml vial	111.00	1	Integrilin
⚡ Inj 750 mcg per ml, 100 ml vial	324.00	1	Integrilin
➡ Restricted			
Either:			
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or			
2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.			
PRASUGREL – Restricted see terms below			
⚡ Tab 5 mg	108.00	28	Effient
⚡ Tab 10 mg	120.00	28	Effient
➡ Restricted			
Bare metal stents			
Limited to 6 months' treatment			
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.			
Drug-eluting stents			
Limited to 12 months' treatment			
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.			
Stent thrombosis			
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.			
Myocardial infarction			
Limited to 7 days' treatment			
For short term use while in hospital following ST-elevated myocardial infarction.			
Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.			
TICAGRELOR – Restricted see terms below			
⚡ Tab 90 mg	90.00	56	Brilliant
➡ Restricted			
Restricted to treatment of acute coronary syndromes specifically for patients who have recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.			
TICLOPIDINE			
Tab 250 mg			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Fibrinolytic Agents

ALTEPLASE

- Inj 10 mg vial
- Inj 50 mg vial

TENECTEPLASE

- Inj 50 mg vial

UROKINASE

- Inj 10,000 iu vial
- Inj 50,000 iu vial
- Inj 100,000 iu vial
- Inj 500,000 iu vial

Colony-Stimulating Factors

Granulocyte Colony-Stimulating Factors

FILGRASTIM – **Restricted** see terms below

⚡ Inj 300 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015	540.00	5	Zarzio
⚡ Inj 300 mcg in 1 ml vial	650.00	5	Neupogen
⚡ Inj 480 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015	864.00	5	Zarzio

→**Restricted**

Oncologist or haematologist

PEGFILGRASTIM – **Restricted** see terms below

⚡ Inj 6 mg per 0.6 ml syringe	1,080.00	1	Neulastim
-------------------------------	----------	---	-----------

→**Restricted**

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*).

*Febrile neutropenia risk ≥ 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE

- Inj 100 mg per ml, 10 ml vial

CALCIUM GLUCONATE

Inj 10%, 10 ml ampoule	21.40	10	Mayne
------------------------	-------	----	-------

COMPOUND ELECTROLYTES

Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag	5.00	500 ml	Baxter
	3.10	1,000 ml	Baxter

COMPOUND ELECTROLYTES WITH GLUCOSE

Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag	7.00	1,000 ml	Baxter
---	------	----------	--------

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l, bag	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
COMPOUND SODIUM LACTATE WITH GLUCOSE			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag	5.38	1,000 ml	Baxter
GLUCOSE			
Inj 5%, bag	2.87	50 ml	Baxter
	2.84	100 ml	Baxter
	3.87	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
Inj 10%, bag	3.70	500 ml	Baxter
	5.29	1,000 ml	Baxter
Inj 50%, bag	6.84	500 ml	Baxter
Inj 50%, 10 ml ampoule – 1% DV Sep-11 to 2014.....	19.50	5	Biomed
Inj 50%, 90 ml bottle – 1% DV Sep-11 to 2014.....	11.25	1	Biomed
Inj 70%, 1,000 ml bag			
Inj 70%, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE			
Inj 5% glucose with 20 mmol/l potassium chloride, bag	7.36	1,000 ml	Baxter
Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag			
Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag	3.45	500 ml	Baxter
	4.30	1,000 ml	Baxter
Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag	3.62	1,000 ml	Baxter
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
GLUCOSE WITH SODIUM CHLORIDE			
Inj glucose 2.5% with sodium chloride 0.45%, bag	4.95	500 ml	Baxter
Inj glucose 5% with sodium chloride 0.45%, bag	9.87	500 ml	Baxter
	5.80	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.9%, bag	4.54	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.2%, 500 ml bag			
POTASSIUM CHLORIDE			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
POTASSIUM CHLORIDE WITH SODIUM CHLORIDE			
Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag	3.85	1,000 ml	Baxter
Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag	2.59	1,000 ml	Baxter
Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag	6.62	1,000 ml	Baxter
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag			
Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, 100 ml bag			
POTASSIUM DIHYDROGEN PHOSPHATE			
Inj 1 mmol per ml, 10 ml ampoule			
RINGER'S SOLUTION			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag	5.13	1,000 ml	Baxter
SODIUM ACETATE			
Inj 4 mmol per ml, 20 ml ampoule			
SODIUM BICARBONATE			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial	19.95	1	Biomed
Inj 8.4%, 100 ml vial	20.50	1	Biomed
SODIUM CHLORIDE			
Inj 0.45%, bag	5.50	500 ml	Baxter
⚡ Inj 0.9%, 3 ml syringe			
➔ Restricted			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, bag	1.70	500 ml	Freeflex
	1.71	1,000 ml	Freeflex
	3.01	50 ml	Baxter
	2.28	100 ml	Baxter
	3.60	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
⚡ Inj 0.9%, 5 ml syringe			
➔ Restricted			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 10 ml syringe			
➔ Restricted			
For use in flushing of in-situ vascular access devices only.			
Inj 3%, bag	5.69	1,000 ml	Baxter
Inj 0.9%, 5 ml ampoule	10.85	50	Multichem
	15.50		Pfizer
Inj 0.9%, 10 ml ampoule	11.50	50	Multichem
	15.50		Pfizer
Inj 0.9%, 20 ml ampoule	8.41	20	Multichem
Inj 23.4% (4 mmol/ml), 20 ml – 1% DV Sep-13 to 2016	31.25	5	Biomed
Inj 1.8%, 500 ml bottle			
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]			
Inj 1 mmol per ml, 20 ml ampoule			

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
WATER			
Inj, bag	2.75	1,000 ml	Baxter
Inj 5 ml ampoule	10.25	50	Multichem
Inj 10 ml ampoule	11.25	50	Multichem
Inj 20 ml ampoule	6.50	20	Multichem
Inj 250 ml bag			
Inj 500 ml bag			

Oral Administration

CALCIUM POLYSTYRENE SULPHONATE			
Powder	169.85	300 g	Calcium Resonium
COMPOUND ELECTROLYTES			
Powder for oral soln			
COMPOUND ELECTROLYTES WITH GLUCOSE			
Soln with electrolytes			
PHOSPHORUS			
Tab eff 500 mg			
POTASSIUM CHLORIDE			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol) – 1% DV Oct-12 to 2015	7.42	200	Span-K
Oral liq 2 mmol per ml			
SODIUM BICARBONATE			
Cap 840 mg	8.52	100	Sodibic
SODIUM CHLORIDE			
Tab 600 mg			
Oral liq 2 mmol/ml			
SODIUM POLYSTYRENE SULPHONATE			
Powder			

Plasma Volume Expanders

GELATINE, SUCCINYLATED			
Inj 4%, 500 ml bag	92.50	10	Gelafusal
	108.00		Gelofusine
HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE			
Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag	198.00	20	Volulyte 6%
HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE			
Inj 6% with sodium chloride 0.9%, 500 ml bag	198.00	20	Voluven

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Agents Affecting the Renin-Angiotensin System

ACE Inhibitors

CAPTOPRIL

Tab 12.5 mg	2.00	100	m-Captopril
Tab 25 mg	2.40	100	m-Captopril
Tab 50 mg	3.50	100	m-Captopril
➔ Oral liq 5 mg per ml	94.99	95 ml	Capoten

➔ Restricted

Any of the following:

- 1 For use in children under 12 years of age; or
- 2 For use in tube-fed patients; or
- 3 For management of rebound transient hypertension following cardiac surgery.

CILAZAPRIL

Tab 0.5 mg – 1% DV Sep-13 to 2016	2.00	90	Zapril
Tab 2.5 mg – 1% DV Sep-13 to 2016	4.31	90	Zapril
Tab 5 mg – 1% DV Sep-13 to 2016	6.98	90	Zapril

ENALAPRIL MALEATE

Tab 5 mg	1.19	100	Ethics Enalapril
Tab 10 mg	1.47	100	Ethics Enalapril
Tab 20 mg	1.91	100	Ethics Enalapril

LISINOPRIL

Tab 5 mg – 1% DV Jan-13 to 2015	3.58	90	Arrow-Lisinopril
Tab 10 mg – 1% DV Jan-13 to 2015	4.08	90	Arrow-Lisinopril
Tab 20 mg – 1% DV Jan-13 to 2015	4.88	90	Arrow-Lisinopril

PERINDOPRIL

Tab 2 mg	3.75	30	Apo-Perindopril
Tab 4 mg	4.80	30	Apo-Perindopril

QUINAPRIL

Tab 5 mg – 1% DV Apr-13 to 2015	3.44	90	Arrow-Quinapril 5
Tab 10 mg – 1% DV Apr-13 to 2015	4.64	90	Arrow-Quinapril 10
Tab 20 mg – 1% DV Apr-13 to 2015	6.34	90	Arrow-Quinapril 20

TRANDOLAPRIL – Restricted: For continuation only

- ➔ Cap 1 mg
- ➔ Cap 2 mg

ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Mar-14 to 2016	6.30	28	Inhibace Plus
	10.72	100	Apo-Cilazapril/ Hydrochlorothiazide

(Inhibace Plus Tab 5 mg with hydrochlorothiazide 12.5 mg to be delisted 1 March 2014)

ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE – Restricted: For continuation only

- ➔ Tab 20 mg with hydrochlorothiazide 12.5 mg

QUINAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015	3.37	30	Accuretic 10
Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015	4.57	30	Accuretic 20

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL – Restricted see terms below			
⚡ Tab 4 mg – 1% DV Nov-12 to 2015	4.13	90	Candestar
⚡ Tab 8 mg – 1% DV Nov-12 to 2015	6.10	90	Candestar
⚡ Tab 16 mg – 1% DV Nov-12 to 2015	10.18	90	Candestar
⚡ Tab 32 mg – 1% DV Nov-12 to 2015	17.66	90	Candestar

➔Restricted
ACE inhibitor intolerance

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retriial (same or new ACE inhibitor);
or
- 2 Patient has a history of angioedema.

Unsatisfactory response to ACE inhibitor

Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

LOSARTAN POTASSIUM			
Tab 12.5 mg – 1% DV Dec-11 to 2014	2.88	90	Lostaar
Tab 25 mg – 1% DV Dec-11 to 2014	3.20	90	Lostaar
Tab 50 mg – 1% DV Dec-11 to 2014	5.22	90	Lostaar
Tab 100 mg – 1% DV Dec-11 to 2014	8.68	90	Lostaar

Angiotensin II Antagonists with Diuretics

LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-11 to 2014	4.89	30	Arrow-Losartan & Hydrochlorothiazide

Alpha-Adrenoceptor Blockers

DOXAZOSIN			
Tab 2 mg – 1% DV Jun-11 to 2014	8.23	500	Apo-Doxazosin
Tab 4 mg – 1% DV Jun-11 to 2014	12.40	500	Apo-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE			
Cap 10 mg			
Inj 50 mg per ml, 2 ml ampoule			
PHEHTOLAMINE MESYLATE			
Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN			
Tab 1 mg	5.53	100	Apo-Prazo
Tab 2 mg	7.00	100	Apo-Prazo
Tab 5 mg	11.70	100	Apo-Prazo
TERAZOSIN			
Tab 1 mg – 1% DV Sep-13 to 2016	0.50	28	Arrow
Tab 2 mg – 1% DV Sep-13 to 2016	0.45	28	Arrow
Tab 5 mg – 1% DV Sep-13 to 2016	0.68	28	Arrow

Antiarrhythmics

ADENOSINE			
Inj 3 mg per ml, 2 ml vial			
⚡ Inj 3 mg per ml, 10 ml vial			

⚡ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)
 e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
For use in cardiac catheterisation, electrophysiology and MRI.			
AJMALINE – Restricted see terms below			
⚡ Inj 5 mg per ml, 10 ml ampoule			
➔Restricted			
Cardiologist			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg			
Tab 200 mg			
Inj 50 mg per ml, 3 ml ampoule – 1% DV Aug-13 to 2016	22.80	6	Cordarone-X
ATROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule – 1% DV Jan-13 to 2015	71.00	50	AstraZeneca
DIGOXIN			
Tab 62.5 mcg			
Tab 250 mcg			
Oral liq 50 mcg per ml			
Inj 250 mcg per ml, 2 ml vial			
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			
Cap 150 mg			
FLECAINIDE ACETATE			
Tab 50 mg	45.82	60	Tambocor
Tab 100 mg	80.92	60	Tambocor
Cap long-acting 100 mg	45.82	30	Tambocor CR
Cap long-acting 200 mg	80.92	30	Tambocor CR
Inj 10 mg per ml, 15 ml ampoule	52.45	5	Tambocor
MEXILETINE HYDROCHLORIDE			
Cap 150 mg	65.00	100	Mexiletine Hydrochloride USP
Cap 250 mg	102.00	100	Mexiletine Hydrochloride USP
PROPAFENONE HYDROCHLORIDE			
Tab 150 mg			

Antihypotensives

MIDODRINE – **Restricted** see terms below

⚡ Tab 2.5 mg

⚡ Tab 5 mg

➔Restricted

All of the following:

- 1 Disabling orthostatic hypotension not due to drugs; and
- 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
- 3 Patient has tried non-pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Beta-Adrenoceptor Blockers			
ATENOLOL			
Tab 50 mg – 1% DV Oct-12 to 2015	5.56	500	Mylan Atenolol
Tab 100 mg – 1% DV Oct-12 to 2015	9.12	500	Mylan Atenolol
Oral liq 5 mg per ml	21.25	300 ml	Atenolol-AFT
BISOPROLOL			
Tab 2.5 mg	3.88	30	Bosvate
Tab 5 mg	4.74	30	Bosvate
Tab 10 mg	9.18	30	Bosvate
CARVEDILOL			
Tab 6.25 mg	21.00	30	Dilatrend
Tab 12.5 mg	27.00	30	Dilatrend
Tab 25 mg	33.75	30	Dilatrend
CELIPROLOL			
Tab 200 mg	19.00	180	Celol
ESMOLOL HYDROCHLORIDE			
Inj 10 mg per ml, 10 ml vial			
LABELALOL			
Tab 50 mg	8.23	100	Hybloc
Tab 100 mg	10.06	100	Hybloc
Tab 200 mg	17.55	100	Hybloc
Tab 400 mg			
Inj 5 mg per ml, 20 ml ampoule			
METOPROLOL SUCCINATE			
Tab long-acting 23.75 mg – 1% DV Sep-12 to 2015	0.96	30	Metoprolol - AFT CR
Tab long-acting 47.5 mg – 1% DV Sep-12 to 2015	1.41	30	Metoprolol - AFT CR
Tab long-acting 95 mg – 1% DV Sep-12 to 2015	2.42	30	Metoprolol - AFT CR
Tab long-acting 190 mg – 1% DV Sep-12 to 2015	4.66	30	Metoprolol - AFT CR
METOPROLOL TARTRATE			
Tab 50 mg – 1% DV Aug-12 to 2015	16.00	100	Lopresor
Tab 100 mg – 1% DV Aug-12 to 2015	21.00	60	Lopresor
Tab long-acting 200 mg – 1% DV Aug-12 to 2015	18.00	28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial – 1% DV Dec-12 to 2015	24.00	5	Lopresor
NADOLOL			
Tab 40 mg – 1% DV Apr-13 to 2015	15.57	100	Apo-Nadolol
Tab 80 mg – 1% DV Apr-13 to 2015	23.74	100	Apo-Nadolol
PINDOLOL			
Tab 5 mg – 1% DV Nov-13 to 2016	9.72	100	Apo-Pindolol
Tab 10 mg – 1% DV Nov-13 to 2016	15.62	100	Apo-Pindolol
Tab 15 mg – 1% DV Nov-13 to 2016	23.46	100	Apo-Pindolol
PROPRANOLOL			
Tab 10 mg	3.65	100	Apo-Propranolol
Tab 40 mg	4.65	100	Apo-Propranolol
Cap long-acting 160 mg	16.06	100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SOTALOL			
Tab 80 mg	27.50	500	Mylan
Tab 160 mg	10.50	100	Mylan
Inj 10 mg per ml, 4 ml ampoule	65.39	5	Sotacor
TIMOLOL MALEATE			
Tab 10 mg			

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE			
Tab 2.5 mg – 1% DV Mar-12 to 2014	2.45	100	Apo-Amlodipine
Tab 5 mg – 1% DV Oct-11 to 2014	2.65	100	Apo-Amlodipine
Tab 10 mg – 1% DV Oct-11 to 2014	4.15	100	Apo-Amlodipine
FELODIPINE			
Tab long-acting 2.5 mg – 1% DV Sep-12 to 2015	2.90	30	Plendil ER
Tab long-acting 5 mg – 1% DV Nov-12 to 2015	3.10	30	Plendil ER
Tab long-acting 10 mg – 1% DV Nov-12 to 2015	4.60	30	Plendil ER
ISRADIPINE			
Tab 2.5 mg			
Cap long-acting 2.5 mg			
Cap long-acting 5 mg			
NIFEDIPINE			
Tab long-acting 10 mg			
Tab long-acting 20 mg	9.59	100	Nyefax Retard
Tab long-acting 30 mg	8.56	30	Adefin XL
Tab long-acting 60 mg	12.28	30	Arrow-Nifedipine XR
Cap 5 mg			Adefin XL
			Arrow-Nifedipine XR
NIMODIPINE			
Tab 30 mg			
Inj 200 mcg per ml, 50 ml vial			

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE			
Tab 30 mg – 5% DV Sep-12 to 2015	4.60	100	Dilzem
Tab 60 mg – 5% DV Sep-12 to 2015	8.50	100	Dilzem
Cap long-acting 120 mg	1.91	30	Cardizem CD
	31.83	500	Apo-Diltiazem CD
Cap long-acting 180 mg – 5% DV Feb-13 to 2015	47.67	500	Apo-Diltiazem CD
Cap long-acting 240 mg – 5% DV Feb-13 to 2015	63.58	500	Apo-Diltiazem CD
Inj 5 mg per ml, 5 ml vial			
PERHEXILINE MALEATE – Restricted see terms on the next page			
⚡ Tab 100 mg	62.90	100	Pexsig

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔Restricted

- Both:
- 1 Patient has refractory angina; and
 - 2 Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long-acting nitrate.

VERAPAMIL HYDROCHLORIDE

Tab 40 mg – 1% DV Sep-11 to 2014	7.01	100	Isoptin
Tab 80 mg – 1% DV Sep-11 to 2014	11.74	100	Isoptin
Tab long-acting 120 mg	15.20	250	Verpamil SR
Tab long-acting 240 mg	25.00	250	Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule	7.54	5	Isoptin

Centrally-Acting Agents

CLONIDINE

Patch 2.5 mg, 100 mcg per day	23.30	4	Catapres-TTS-1
Patch 5 mg, 200 mcg per day	32.80	4	Catapres-TTS-2
Patch 7.5 mg, 300 mcg per day	41.20	4	Catapres-TTS-3

CLONIDINE HYDROCHLORIDE

Tab 25 mcg – 1% DV Jul-13 to 2015	15.09	112	Clonidine BNM
Tab 150 mcg – 1% DV Feb-13 to 2015	34.32	100	Catapres
Inj 150 mcg per ml, 1 ml ampoule – 1% DV Nov-12 to 2015	16.07	5	Catapres

METHYLDOPA

Tab 125 mg	14.25	100	Prodopa
Tab 250 mg	15.10	100	Prodopa
Tab 500 mg	23.15	100	Prodopa

Diuretics

Loop Diuretics

BUMETANIDE

Tab 1 mg	16.36	100	Burinex
Inj 500 mcg per ml, 4 ml vial			

FUROSEMIDE (FRUSEMIDE)

Tab 40 mg – 1% DV Sep-12 to 2015	10.25	1,000	Diurin 40
Tab 500 mg – 1% DV Feb-13 to 2015	25.00	50	Urex Forte
Oral liq 10 mg per ml			
Inj 10 mg per ml, 2 ml ampoule	1.30	5	Frusemide-Claris
Inj 10 mg per ml, 25 ml ampoule			

Osmotic Diuretics

MANNITOL

Inj 10%, 1,000 ml bag	14.21	1,000 ml	Baxter
Inj 15%, 500 ml bag	9.84	500 ml	Baxter
Inj 20%, 500 ml bag	10.80	500 ml	Baxter

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE

Tab 5 mg with furosemide 40 mg

AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE

Tab 5 mg with hydrochlorothiazide 50 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Potassium Spraying Diuretics			
AMILORIDE HYDROCHLORIDE			
Tab 5 mg	17.50	100	Apo-Amiloride
Oral liq 1 mg per ml	30.00	25 ml	Biomed
SPIRONOLACTONE			
Tab 25 mg – 1% DV Sep-13 to 2016	3.65	100	Spiractin Spirotone
Tab 100 mg – 1% DV Sep-13 to 2016	11.80	100	Spiractin Spirotone
Oral liq 5 mg per ml	30.00	25 ml	Biomed

Thiazide and Related Diuretics			
BENDROFLUMETHAZIDE [BENDROFLUAZIDE]			
Tab 2.5 mg – 1% DV Sep-11 to 2014	6.48	500	Arrow-Bendrofluazide
Tab 5 mg – 1% DV Sep-11 to 2014	9.95	500	Arrow-Bendrofluazide
CHLOROTHIAZIDE			
Oral liq 50 mg per ml	26.00	25 ml	Biomed
CHLORTALIDONE [CHLORThALIDONE]			
Tab 25 mg	8.00	50	Hygroton
INDAPAMIDE			
Tab 2.5 mg – 1% DV Oct-13 to 2016	2.25	90	Dapa-Tabs
METOLAZONE – Restricted see terms below			
↓ Tab 5 mg			
➔ Restricted			
Either:			
1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or			
2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions			

Lipid-Modifying Agents

Fibrates			
BEZAFIBRATE			
Tab 200 mg – 1% DV Mar-13 to 2015	9.70	90	Bezalip
Tab long-acting 400 mg – 1% DV Oct-12 to 2015	5.70	30	Bezalip Retard
GEMFIBROZIL			
Tab 600 mg – 1% DV Nov-13 to 2016	17.60	60	Lipazil

HMG CoA Reductase Inhibitors (Statins)

ATORVASTATIN			
Tab 10 mg – 1% DV Oct-12 to 2015	2.52	90	Zarator
Tab 20 mg – 1% DV Oct-12 to 2015	4.17	90	Zarator
Tab 40 mg – 1% DV Oct-12 to 2015	7.32	90	Zarator
Tab 80 mg – 1% DV Oct-12 to 2015	16.23	90	Zarator

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PRAVASTATIN			
Tab 10 mg			
Tab 20 mg – 1% DV Nov-11 to 2014	5.44	30	Cholvastin
Tab 40 mg – 1% DV Nov-11 to 2014	9.28	30	Cholvastin
SIMVASTATIN			
Tab 10 mg – 1% DV Sep-11 to 2014	1.40	90	Arrow-Simva
Tab 20 mg – 1% DV Sep-11 to 2014	1.95	90	Arrow-Simva
Tab 40 mg – 1% DV Sep-11 to 2014	3.18	90	Arrow-Simva
Tab 80 mg – 1% DV Sep-11 to 2014	9.31	90	Arrow-Simva

Resins

CHOLESTYRAMINE

Powder for oral liq 4 g

COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – **Restricted** see terms below

⚡ Tab 10 mg

➡ **Restricted**

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – **Restricted** see terms below

⚡ Tab 10 mg with simvastatin 10 mg

⚡ Tab 10 mg with simvastatin 20 mg

⚡ Tab 10 mg with simvastatin 40 mg

⚡ Tab 10 mg with simvastatin 80 mg

➡ **Restricted**

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

NICOTINIC ACID

Tab 50 mg

Tab 500 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Nitrates

GLYCERYL TRINITRATE

Tab 600 mcg – 1% DV Sep-11 to 2014.....	8.00	100	Lycinate
Inj 1 mg per ml, 5 ml ampoule – 1% DV Dec-12 to 2015.....	22.70	10	Nitronal
Inj 1 mg per ml, 50 ml vial – 1% DV Dec-12 to 2015.....	86.60	10	Nitronal
Inj 5 mg per ml, 10 ml ampoule	40.00	5	Mayne
Oral spray, 400 mcg per dose – 1% DV Mar-12 to 2014.....	4.45	250 dose	Glytrin
Patch 25 mg, 5 mg per day – 1% DV Sep-11 to 2014.....	16.56	30	Nitroderm TTS 5
Patch 50 mg, 10 mg per day – 1% DV Sep-11 to 2014.....	19.50	30	Nitroderm TTS 10

ISOSORBIDE MONONITRATE

Tab 20 mg – 1% DV Jun-11 to 2014.....	17.10	100	Ismo-20
Tab long-acting 40 mg – 1% DV Jun-11 to 2014.....	7.50	30	Corangin
Tab long-acting 60 mg	3.94	90	Duride

Other Cardiac Agents

LEVOSIMENDAN – **Restricted** see terms below

- ⚡ Inj 2.5 mg per ml, 5 ml vial
- ⚡ Inj 2.5 mg per ml, 10 ml vial

➔ **Restricted**

Heart transplant

Either:

- 1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
- 2 For the treatment of heart failure following heart transplant.

Heart failure - cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

Sympathomimetics

ADRENALINE

Inj 1 in 1,000, 1 ml ampoule	4.98	5	Aspen Adrenaline
	5.25		Mayne
Inj 1 in 1,000, 30 ml vial			
Inj 1 in 10,000, 10 ml ampoule	27.00	5	Mayne
	49.00	10	Aspen Adrenaline
Inj 1 in 10,000, 10 ml syringe			

DOBUTAMINE HYDROCHLORIDE

Inj 12.5 mg per ml, 20 ml vial

DOPAMINE HYDROCHLORIDE

Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-12 to 2015..... 69.77 10 **Martindale**

EPHEDRINE

Inj 3 mg per ml, 10 ml syringe

Inj 30 mg per ml, 1 ml ampoule – 1% DV Nov-12 to 2014..... 66.00 10 **Max Health**

ISOPRENALINE

Inj 200 mcg per ml, 1 ml ampoule

Inj 200 mcg per ml, 5 ml ampoule

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METARAMINOL			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule			
NORADRENALINE			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag			
Inj 1 mg per ml, 2 ml ampoule	42.00	6	Levophed
PHENYLEPHRINE HYDROCHLORIDE			
Inj 10 mg per ml, 1 ml vial	115.50	25	Neosynephrine HCL

Vasodilators

ALPROSTADIL HYDROCHLORIDE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-12 to 2015.....	1,417.50	5	Prostin VR
AMYL NITRITE			
Liq 98% in 3 ml capsule			
DIAZOXIDE			
Inj 15 mg per ml, 20 ml ampoule			
HYDRALAZINE HYDROCHLORIDE			
⚡ Tab 25 mg			
➡ Restricted			
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.			
Inj 20 mg ampoule	25.90	5	Apresoline Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule			
MINOXIDIL – Restricted see terms below			
⚡ Tab 10 mg	70.00	100	Loniten
➡ Restricted			
For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies.			
NICORANDIL – Restricted see terms below			
⚡ Tab 10 mg	27.95	60	Ikorel
⚡ Tab 20 mg	33.28	60	Ikorel
➡ Restricted			
Both:			
1 Patient has refractory angina; and			
2 Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long-acting nitrate.			

↑ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PAPAVERINE HYDROCHLORIDE			
Inj 30 mg per ml, 1 ml vial			
Inj 12 mg per ml, 10 ml ampoule	73.12	5	Mayne
PENTOXIFYLLINE [OXPENTIFYLLINE]			
Tab 400 mg			
SODIUM NITROPRUSSIDE			
Inj 50 mg vial			

Endothelin Receptor Antagonists

AMBRISENTAN – **Restricted** see terms below

⚡ Tab 5 mg	4,585.00	30	Volibris
⚡ Tab 10 mg	4,585.00	30	Volibris

→ **Restricted**

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisations in emergency situations.

BOSENTAN – **Restricted** see terms below

⚡ Tab 62.5 mg	1,500.00	60	pms-Bosentan Tracleer
	4,585.00		
⚡ Tab 125 mg	1,500.00	60	pms-Bosentan Tracleer
	4,585.00		

→ **Restricted**

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisation in emergency situations.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – **Restricted** see terms below

⚡ Tab 25 mg – 1% DV May-13 to 2014	1.85	4	Silagra
⚡ Tab 50 mg – 1% DV May-13 to 2014	1.85	4	Silagra
⚡ Tab 100 mg – 1% DV May-13 to 2014	7.45	4	Silagra

→ **Restricted**

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 For use in weaning patients from inhaled nitric oxide; or
- 4 For perioperative use in cardiac surgery patients; or
- 5 For use in intensive care as an alternative to nitric oxide; or
- 6 In-hospital stabilisation in emergency situations; or
- 7 All of the following:
 - 7.1 Patient has Raynaud’s phenomenon; and
 - 7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
 - 7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
 - 7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Prostacyclin Analogues			
ILOPROST			
Inj 50 mcg in 0.5 ml ampoule	925.00	5	Ilomedin
¶ Nebuliser soln 10 mcg per ml, 2 ml	1,185.00	30	Ventavis

➡Restricted

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In hospital stabilisation in emergency situations.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
FUSIDATE SODIUM [FUSIDIC ACID]			
Crm 2%	3.25	15 g	Foban
Oint 2% – 1% DV Sep-13 to 2016	3.45	15 g	Foban
HYDROGEN PEROXIDE			
Crm 1%	8.56	15 g	Crystaderm
Soln 3% (10 vol)			
MAFENIDE ACETATE – Restricted see terms below			
↓ Powder 50 g sachet			
➔ Restricted			
For the treatment of burns patients.			
MUPIROCIN			
Oint 2%			
SULPHADIAZINE SILVER			
Crm 1%	12.30	50 g	Flamazine

Antifungals

AMOROLFINE – Restricted : For continuation only			
➔ Nail soln 5%			
CLOTRIMAZOLE			
Crm 1% – 1% DV Nov-11 to 2014	0.54	20 g	Clomazol
➔ Soln 1% – Restricted : For continuation only			
ECONAZOLE NITRATE			
➔ Crm 1% – Restricted : For continuation only			
Foaming soln 1%			
KETOCONAZOLE			
Shampoo 2% – 1% DV Sep-11 to 2014	3.08	100 ml	Sebizole
METRONIDAZOLE			
Gel 0.75%			
MICONAZOLE NITRATE			
Crm 2% – 1% DV Nov-11 to 2014	0.46	15 g	Multichem
➔ Lotn 2% – Restricted : For continuation only			
Tinc 2%			
NYSTATIN			
Crm 100,000 u per g			
CICLOPIROX OLAMINE			
Nail soln 8%			
➔ Soln 1% – Restricted : For continuation only			

Antiparasitics

LINDANE [GAMMA BENZENE HEXACHLORIDE]			
Crm 1%			

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MALATHION [MALDISON] Lotn 0.5% Shampoo 1%			
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2% Note: Temporary listing to cover out-of-stock.			
PERMETHRIN Crm 5% – 1% DV Sep-11 to 2014	4.20	30 g	Lyderm
Lotn 5% – 1% DV Sep-11 to 2014	3.24	30 ml	A-Scabies

Antiacne Preparations

ADAPALENE Crm 0.1% Gel 0.1%			
BENZOYL PEROXIDE Soln 5%			
ISOTRETINOIN Cap 10 mg – 1% DV Jan-13 to 2015	18.71	120	Oratane
Cap 20 mg – 1% DV Jan-13 to 2015	28.91	120	Oratane
TRETINOIN Crm 0.05%			

Antipruritic Preparations

CALAMINE Crm, aqueous, BP – 1% DV Mar-13 to 2015	1.77	100 g	Pharmacy Health
Lotn, BP – 1% DV Nov-12 to 2015	13.45	2,000 ml	PSM
CROTAMITON Crm 10% – 1% DV Sep-12 to 2015	3.48	20 g	Itch-Soothe

Barrier Creams and Emollients

Barrier Creams

DIMETHICONE Crm 5%			
ZINC Crm			e.g. Zinc Cream (Orion); Zinc Cream (PSM)
Oint Paste			e.g. Zinc oxide (PSM)
ZINC AND CASTOR OIL Crm – 1% DV Apr-12 to 2014	1.63	20 g	Orion
Oint, BP			
ZINC WITH WOOL FAT Crm zinc 15.25% with wool fat 4%			e.g. Sudocrem

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)
e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Emollients			
AQUEOUS CREAM			
Crn 100 g – 1% DV Sep-11 to 2014	1.23	100 g	AFT
Note: DV limit applies to the pack sizes of 100 g or less.			
Crn 500 g – 1% DV Sep-11 to 2014	1.96	500 g	AFT
Note: DV limit applies to the pack sizes of greater than 100 g.			
CETOMACROGOL			
Crn BP, 500 g	3.50	500 g	Pharmacy Health
Crn BP, 100 g	1.65	1	healthE
CETOMACROGOL WITH GLYCEROL			
Crn 90% with glycerol 10%, tube	2.10	100 g	Pharmacy Health
	2.00		Pharmacy Health
	3.20		healthE
Crn 90% with glycerol 10%	4.50	500 ml	Pharmacy Health
			Sorbolene with Glycerin
	6.50	1,000 ml	Pharmacy Health
			Sorbolene with Glycerin
Crn 90% with glycerol 10%, 500 ml, 1 bottle	5.46	1	healthE
EMULSIFYING OINTMENT			
Oint BP – 1% DV Nov-11 to 2014	1.95	100 g	Jaychem
Oint BP, 500 g – 1% DV Sep-11 to 2014	3.04	500 g	AFT
Note: DV limit applies to pack sizes of greater than 100 g.			
GLYCEROL WITH PARAFFIN			
Crn glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			<i>e.g. QV cream</i>
OIL IN WATER EMULSION			
Crn – 1% DV Dec-12 to 2015	2.63	500 g	healthE Fatty Cream
Crn, 100 g	1.60	1	healthE Fatty Cream
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%	3.10	100 g	healthE
White soft – 1% DV Feb-13 to 2015	0.92	10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
Yellow soft			
PARAFFIN WITH WOOL FAT			
Lotn liquid paraffin 15.9% with wool fat 0.6%			<i>e.g. AlphaKeri;BK ;DP; Hydroderm Lotn</i>
Lotn liquid paraffin 91.7% with wool fat 3%			<i>e.g. Alpha Keri Bath Oil</i>
UREA			
Crn 10%			
WOOL FAT			
Crn			
Corticosteroids			
BETAMETHASONE DIPROPIONATE			
Crn 0.05%			
Oint 0.05%			

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BETAMETHASONE VALERATE			
Crm 0.1%			
Oint 0.1%			
Lotn 0.1%			
CLOBETASOL PROPIONATE			
Crm 0.05%	3.68	30 g	Dermol
Oint 0.05%	3.68	30 g	Dermol
CLOBETASONE BUTYRATE			
Crm 0.05%			
DIFLUCORTOLONE VALERATE – Restricted: For continuation only			
➔ Crm 0.1%			
➔ Fatty oint 0.1%			
HYDROCORTISONE			
Crm 1%, 100 g	3.75	100 g	Pharmacy Health
Crm 1%, 500 g – 1% DV Nov-11 to 2014	14.00	500 g	Pharmacy Health
Note: DV limit applies to the pack sizes of greater than 100 g.			
HYDROCORTISONE ACETATE			
Crm 1%	2.48	14.2 g	AFT
HYDROCORTISONE BUTYRATE			
Crm 0.1% – 1% DV Mar-13 to 2015	2.30	30 g	Locoid Lipocream
	6.85	100 g	Locoid Lipocream
Oint 0.1% – 1% DV Mar-13 to 2015	6.85	100 g	Locoid
Milky emul 0.1% – 1% DV Mar-13 to 2015	6.85	100 ml	Locoid Crelo
HYDROCORTISONE WITH PARAFFIN AND WOOL FAT			
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%			
METHYLPREDNISOLONE ACEPONATE			
Crm 0.1%	4.95	15 g	Advantan
Oint 0.1%	4.95	15 g	Advantan
MOMETASONE FUROATE			
Crm 0.1% – 1% DV Sep-12 to 2015	1.78	15 g	m-Mometasone
	3.42	45 g	m-Mometasone
Oint 0.1% – 1% DV Sep-12 to 2015	1.78	15 g	m-Mometasone
	3.42	45 g	m-Mometasone
Lotn 0.1%			
TRIAMCINOLONE ACETONIDE			
Crm 0.02% – 1% DV Sep-11 to 2014	6.63	100 g	Aristocort
Oint 0.02% – 1% DV Sep-11 to 2014	6.69	100 g	Aristocort

Corticosteroids with Anti-Infective Agents

BETAMETHASONE VALERATE WITH CLIOQUINOL – Restricted see terms below

⚡ Crm 0.1% with clioquinol 3%

⚡ Oint 0.1% with clioquinol 3%

➔ **Restricted**

Either:

- 1 For the treatment of intertrigo; or
- 2 For continuation use

BETAMETHASONE VALERATE WITH FUSIDIC ACID

Crm 0.1% with fusidic acid 2%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HYDROCORTISONE WITH MICONAZOLE			
Crn 1% with miconazole nitrate 2%	2.20	15 g	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN			
Crn 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g	Pimafucort
TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN			
Crn 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g			

Psoriasis and Eczema Preparations

ACITRETIN			
Cap 10 mg	35.95	100	Neotigason
	38.66	60	Novatretin
Cap 25 mg	83.11	60	Novatretin
	85.40	100	Neotigason
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL			
Gel 500 mcg with calcipotriol 50 mcg per g	26.12	30 g	Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g	26.12	30 g	Daivobet
CALCIPOTRIOL			
Crn 50 mcg per g	45.00	100 g	Daivonex
Oint 50 mcg per g	45.00	100 g	Daivonex
Soln 50 mcg per ml	16.00	30 ml	Daivonex
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Oint 12% with salicylic acid 2% and sulphur 4%			
COAL TAR WITH TRIETHANOLAMINE LARYL SULPHATE AND FLUORESCEIN			
Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium – 1% DV Nov-11 to 2014	3.05	500 ml	Pinetarsol
	5.82	1,000 ml	Pinetarsol
METHOXSALLEN [8-METHOXYPSORALEN]			
Cap 10 mg			
Lotn 1.2%			
POTASSIUM PERMANGANATE			
Tab 400 mg			
Crystals			

Scalp Preparations

BETAMETHASONE VALERATE			
Scalp app 0.1%	7.75	100 ml	Beta Scalp
CLOBETASOL PROPIONATE			
Scalp app 0.05%	6.96	30 ml	Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1% – 1% DV Mar-13 to 2015.....	3.65	100 ml	Locoid

Wart Preparations

IMIQUIMOD – Restricted see terms on the next page			
☛ Crn 5%, 250 mg sachet – 1% DV Nov-11 to 2014	62.00	12	Aldara

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔Restricted

Any of the following:

- 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
- 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
- 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.

Notes:

Superficial basal cell carcinoma

- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.
- Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.
- Every effort should be made to biopsy the lesion to confirm that it is a superficial basal cell carcinoma.

External anogenital warts

- Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

PODOPHYLLOTOXIN

Soln 0.5%	33.60	3.5 ml	Condyline
-----------------	-------	--------	-----------

SILVER NITRATE

Sticks with applicator

Other Skin Preparations

DIPHEMANIL METILSULFATE

Powder 2%

SUNSCREEN, PROPRIETARY

Crm

Lotn	2.55	100 g	Marine Blue Lotion SPF 30+
	5.10	200 g	Marine Blue Lotion SPF 30+

Antineoplastics

FLUOROURACIL SODIUM

Crm 5% – 1% DV Feb-13 to 2015	25.16	20 g	Efudix
-------------------------------------	-------	------	--------

METHYL AMINOLEVULINATE HYDROCHLORIDE – **Restricted** see terms below

⚡ Crm 16%

➔Restricted

Dermatologist or plastic surgeon

Wound Management Products

CALCIUM GLUCONATE

Gel 2.5%	21.00	1	healthE
----------------	-------	---	---------

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Anti-Infective Agents

ACETIC ACID

- Soln 3%
- Soln 5%

ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID

- Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

CHLORHEXIDINE

- Crn 1% – 1% DV Oct-12 to 2015 1.24 50 g **healthE**

CHLORHEXIDINE GLUCONATE

- Lotn 1%, 200 ml 6.75 1 healthE

CLOTRIMAZOLE

- Vaginal crm 1% with applicator – 1% DV Dec-13 to 2016 1.45 35 g **Clomazol**
- Vaginal crm 2% with applicator – 1% DV Dec-13 to 2016 2.20 20 g **Clomazol**

MICONAZOLE NITRATE

- Vaginal crm 2% with applicator

NYSTATIN

- Vaginal crm 100,000 u per 5 g with applicator(s)

Contraceptives

Antiandrogen Oral Contraceptives

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

- Tab 2 mg with ethinyloestradiol 35 mcg

Combined Oral Contraceptives

ETHINYLOESTRADIOL WITH DESOGESTREL

- Tab 20 mcg with desogestrel 150 mcg
- Tab 30 mcg with desogestrel 150 mcg

ETHINYLOESTRADIOL WITH LEVONORGESTREL

- Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets 2.65 84 Ava 20 ED
- Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets 2.30 84 Ava 30 ED
- Tab 20 mcg with levonorgestrel 100 mcg
- Tab 30 mcg with levonorgestrel 150 mcg
- Tab 50 mcg with levonorgestrel 125 mcg 9.45 84 Microgynon 50 ED

ETHINYLOESTRADIOL WITH NORETHISTERONE

- Tab 35 mcg with norethisterone 1 mg
- Tab 35 mcg with norethisterone 500 mcg

NORETHISTERONE WITH MESTRANOL

- Tab 1 mg with mestranol 50 mcg

Contraceptive Devices

INTRA-UTERINE DEVICE

- IUD

*e.g. Multiload Cu375,
Multiload Cu375 SL*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Emergency Contraception

LEVONORGESTREL Tab 1.5 mg – 1% DV Jul-13 to 2016	3.50	1	Postinor-1
---	------	---	-------------------

Progestogen-Only Contraceptives

LEVONORGESTREL Tab 30 mcg			
Implant 75 mg	133.65	1	Jadelle
⚡ Intra-uterine system, 20 mcg per day			<i>e.g. Mirena</i>

➡ Restricted

Initiation – heavy menstrual bleeding

Obstetrician or gynaecologist

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Any of the following:
 - 3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or
 - 3.2 Haemoglobin level < 120 g/l; or
 - 3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.

Continuation – heavy menstrual bleeding

Either:

- 1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
- 2 Previous insertion was removed or expelled within 3 months of insertion.

Initiation – endometriosis

The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.

Continuation – endometriosis

Either:

- 1 Patient demonstrated satisfactory management of endometriosis; or
- 2 Previous insertion was removed or expelled within 3 months of insertion.

Note: endometriosis is an unregistered indication.

MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe – 1% DV Sep-13 to 2016	7.00	1	Depo-Provera
---	------	---	---------------------

NORETHISTERONE Tab 350 mcg			
-------------------------------	--	--	--

Obstetric Preparations

Antiprogestogens

MIFEPRISTONE Tab 200 mg			
----------------------------	--	--	--

Oxytocics

CARBOPROST TROMETAMOL Inj 250 mcg per ml, 1 ml ampoule			
---	--	--	--

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DINOPROSTONE			
Pessaries 10 mg			
Gel 1 mg in 2.5 ml	52.65	1	Prostin E2
Gel 2 mg in 2.5 ml	64.60	1	Prostin E2
ERGOMETRINE MALEATE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-11 to 2014	31.00	5	DBL Ergometrine
OXYTOCIN			
Inj 5 iu per ml, 1 ml ampoule – 1% DV Feb-14 to 2015	4.75	5	Oxytocin BNM
	5.94		Syntocinon
Inj 10 iu per ml, 1 ml ampoule – 1% DV Feb-14 to 2015	5.98	5	Oxytocin BNM
	7.48		Syntocinon
<i>(Syntocinon Inj 5 iu per ml, 1 ml ampoule to be delisted 1 February 2014)</i>			
<i>(Syntocinon Inj 10 iu per ml, 1 ml ampoule to be delisted 1 February 2014)</i>			
OXYTOCIN WITH ERGOMETRINE MALEATE			
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Oct-12 to 2015	11.13	5	Syntometrine

Tocolytics

PROGESTERONE – **Restricted** see terms below

⚡ Cap 100 mg	16.50	30	Utrogestan
--------------------	-------	----	------------

➔ **Restricted**

Obstetrician or gynaecologist

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks) or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1).

TERBUTALINE – **Restricted** see terms below

⚡ Inj 500 mcg ampoule			
-----------------------	--	--	--

➔ **Restricted**

Obstetrician

Oestrogens

OESTRIOL

- Crms 1 mg per g with applicator
- Pessaries 500 mcg

Urologicals

5-Alpha Reductase Inhibitors

FINASTERIDE – **Restricted** see terms on the next page

⚡ Tab 5 mg – 1% DV Nov-11 to 2014	5.10	30	Rex Medical
---	------	----	--------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Alpha-1A Adrenoceptor Blockers

TAMSULOSIN – **Restricted** see terms below

⚡ Cap 400 mcg – 1% DV Dec-13 to 2016 13.51 100 **Tamsulosin-Rex**

➔ **Restricted**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Urinary Alkalisers

POTASSIUM CITRATE – **Restricted** see terms below

⚡ Oral liq 3 mmol per ml 30.00 200 ml Biomed

➔ **Restricted**

Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

SODIUM CITRO-TARTRATE

Grans eff 4 g sachets 3.93 28 Ural

Urinary Antispasmodics

OXYBUTYNIN

Tab 5 mg – 1% DV Jun-13 to 2016 11.20 500 **Apo-Oxybutynin**

Oral liq 5 mg per 5 ml – 1% DV Jun-13 to 2016 56.45 473 ml **Apo-Oxybutynin**

SOLIFENACIN SUCCINATE – **Restricted** see terms below

⚡ Tab 5 mg 56.50 30 Vesicare

⚡ Tab 10 mg 56.50 30 Vesicare

➔ **Restricted**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

TOLTERODINE TARTRATE – **Restricted** see terms below

⚡ Tab 1 mg 14.56 56 Arrow-Tolterodine

⚡ Tab 2 mg 14.56 56 Arrow-Tolterodine

➔ **Restricted**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anabolic Agents			
OXANDROLINE			
⚠ Tab 2.5 mg			
➔ Restricted			
For the treatment of burns patients.			
Androgen Agonists and Antagonists			
CYPROTERONE ACETATE			
Tab 50 mg – 1% DV Oct-12 to 2015	18.80	50	Siterone
Tab 100 mg – 1% DV Oct-12 to 2015	34.25	50	Siterone
TESTOSTERONE			
Patch 2.5 mg per day	80.00	60	Androderm
TESTOSTERONE CYPIONATE			
Inj 100 mg per ml, 10 ml vial – 1% DV Feb-12 to 2014	76.50	1	Depo-Testosterone
TESTOSTERONE ESTERS			
Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule			
TESTOSTERONE UNDECANOATE			
Cap 40 mg – 1% DV Oct-12 to 2015	31.17	60	Andriol Testocaps
Inj 250 mg per ml, 4 ml ampoule	86.00	1	Reandron 1000
Calcium Homeostasis			
CALCITONIN			
Inj 100 iu per ml, 1 ml ampoule – 1% DV Sep-11 to 2014	110.00	5	Miacalcic
ZOLEDRONIC ACID			
⚠ Inj 0.8 mg per ml, 5 ml vial	550.00	1	Zometa
➔ Restricted			
For hypercalcaemia of malignancy			
Corticosteroids			
BETAMETHASONE			
Tab 500 mcg			
Inj 4 mg per ml, 1 ml ampoule			
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE			
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule			
DEXAMETHASONE			
Tab 1 mg – 1% DV Aug-12 to 2015	5.87	100	Douglas
Tab 4 mg – 1% DV Aug-12 to 2015	8.16	100	Douglas
Oral liq 1 mg per ml	45.00	25 ml	Biomed
DEXAMETHASONE PHOSPHATE			
Inj 4 mg per ml, 1 ml ampoule	21.50	5	Hospira
Inj 4 mg per ml, 2 ml vial	31.00	5	Hospira
FLUDROCORTISONE ACETATE			
Tab 100 mcg	14.32	100	Florinef

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HYDROCORTISONE			
Tab 5 mg – 1% DV Nov-12 to 2015	8.10	100	Douglas
Tab 20 mg – 1% DV Nov-12 to 2015	20.32	100	Douglas
Inj 100 mg vial – 1% DV Oct-13 to 2016	4.99	1	Solu-Cortef
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)			
Tab 4 mg – 1% DV Oct-12 to 2015	60.00	100	Medrol
Tab 100 mg – 1% DV Oct-12 to 2015	166.52	20	Medrol
Inj 40 mg vial – 1% DV Oct-12 to 2015	7.50	1	Solu-Medrol
Inj 125 mg vial – 1% DV Oct-12 to 2015	18.50	1	Solu-Medrol
Inj 500 mg vial – 1% DV Oct-12 to 2015	18.00	1	Solu-Medrol
Inj 1 g vial – 1% DV Oct-12 to 2015	37.50	1	Solu-Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial – 1% DV Oct-12 to 2015	6.70	1	Depo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE			
Inj 40 mg with lignocaine 10 mg per ml, 1 ml vial – 1% DV Oct-12 to 2015	7.50	1	Depo-Medrol with Lidocaine
PREDNISOLONE			
Oral liq 5 mg per ml	10.45	30 ml	Redipred
Enema 200 mcg per ml, 100 ml			
PREDNISONE			
Tab 1 mg	2.13	100	Apo-Prednisone S29
	10.68	500	Apo-Prednisone
Tab 2.5 mg	12.09	500	Apo-Prednisone
Tab 5 mg	11.09	500	Apo-Prednisone
Tab 20 mg	29.03	500	Apo-Prednisone
TRIAMCINOLONE ACETONIDE			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Jun-12 to 2014	21.90	5	Kenacort-A
Inj 40 mg per ml, 1 ml ampoule – 1% DV Jun-12 to 2014	53.79	5	Kenacort-A40
TRIAMCINOLONE HEXACETONIDE			
Inj 20 mg per ml, 1 ml vial			

Hormone Replacement Therapy

Oestrogens

OESTRADIOL

- Tab 1 mg
- Tab 2 mg
- Patch 25 mcg per day
- Patch 50 mcg per day
- Patch 100 mcg per day

OESTRADIOL VALERATE

- Tab 1 mg
- Tab 2 mg

OESTROGENS (CONJUGATED EQUINE)

- Tab 300 mcg
- Tab 625 mcg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Progestogen and Oestrogen Combined Preparations

- OESTRADIOL WITH NORETHISTERONE ACETATE
 Tab 1 mg with 0.5 mg norethisterone acetate
 Tab 2 mg with 1 mg norethisterone acetate
 Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestra-
 diol (12) and tab 1 mg oestradiol (6)

- OESTROGENS WITH MEDROXYPROGESTERONE ACETATE
 Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone
 acetate
 Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone ac-
 etate

Progestogens

MEDROXYPROGESTERONE ACETATE			
Tab 2.5 mg – 1% DV Sep-13 to 2016	3.09	30	Provera
Tab 5 mg – 1% DV Sep-13 to 2016	13.06	100	Provera
Tab 10 mg – 1% DV Sep-13 to 2016	6.85	30	Provera

Other Endocrine Agents

CABERGOLINE – Restricted see terms below			
⚡ Tab 0.5 mg – 1% DV Sep-12 to 2015	6.25	2	Dostinex
	25.00	8	Dostinex

- ➡ **Restricted**
 Any of the following:
 1 Inhibition of lactation; or
 2 Patient has pathological hyperprolactinemia; or
 3 Patient has acromegaly.

CLOMIPHENE CITRATE			
Tab 50 mg – 1% DV Sep-13 to 2016	29.84	10	Serophene

DANAZOL			
Cap 100 mg	68.33	100	Azol
Cap 200 mg	97.83	100	Azol

GESTRINONE
 Cap 2.5 mg

METYRAPONE
 Cap 250 mg

PENTAGASTRIN
 Inj 250 mcg per ml, 2 ml ampoule

Other Oestrogen Preparations

ETHINYLOESTRADIOL
 Tab 10 mcg

OESTRADIOL
 Implant 50 mg

OESTRIOL
 Tab 2 mg

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Other Progestogen Preparations			
MEDROXYPROGESTERONE			
Tab 100 mg – 1% DV Sep-13 to 2016	96.50	100	Provera
Tab 200 mg	70.50	30	Provera
NORETHISTERONE			
Tab 5 mg – 1% DV Nov-11 to 2014	26.50	100	Primolut N

Pituitary and Hypothalamic Hormones and Analogues

CORTICOTRORELIN (OVINE)

Inj 100 mcg vial

THYROTROPIN ALFA

Inj 900 mcg vial

Adrenocorticotrophic Hormones

TETRACOSACTIDE [TETRACOSACTRIN]

Inj 250 mcg per ml, 1 ml ampoule – 1% DV Sep-11 to 2014..... 177.18

Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-11 to 2014..... 29.56

10

Synacthen

1

Synacthen Depot

GnRH Agonists and Antagonists

BUSERELIN

Inj 1 mg per ml, 5.5 ml vial

GONADORELIN

Inj 100 mcg vial

GOSERELIN

Implant 3.6 mg 166.20

Implant 10.8 mg 443.76

1

Zoladex

1

Zoladex

LEUPRORELIN ACETATE

Inj 3.75 mg syringe 221.60

Inj 7.5 mg syringe 166.20

Inj 11.25 mg syringe 591.68

Inj 22.5 mg syringe 443.76

Inj 30 mg syringe 1,109.40

Inj 30 mg vial 591.68

Inj 45 mg syringe 832.05

1

Lucrin Depot PDS

1

Eligard

1

Lucrin Depot PDS

1

Eligard

1

Lucrin Depot PDS

1

Eligard

1

Eligard

Gonadotrophins

CHORIOGONADOTROPIN ALFA

Inj 250 mcg in 0.5 ml syringe

Growth Hormone

SOMATROPIN – **Restricted** see terms below

⚡ Inj 16 iu (5.3 mg) vial

⚡ Inj 36 iu (12 mg) vial

➡ **Restricted**

Only for use in patients with approval by the New Zealand Growth Hormone Committee or the Adult Growth Hormone Panel

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Thyroid and Antithyroid Preparations

CARBIMAZOLE

Tab 5 mg

IODINE

Soln BP 50 mg per ml

LEVOTHYROXINE

Tab 25 mcg

Tab 50 mcg

Tab 100 mcg

LIOTHYRONINE SODIUM

⚡ Tab 20 mcg

➔ **Restricted**

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy

Inj 20 mcg vial

POTASSIUM IODATE

Tab 170 mg

POTASSIUM PERCHLORATE

Cap 200 mg

PROPYLTHIOURACIL – **Restricted** see terms below

⚡ Tab 50 mg 35.00 100 PTU

➔ **Restricted**

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

Vasopressin Agents

ARGIPRESSIN [VASOPRESSIN]

Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – **Some items restricted** see terms below

⚡ Tab 100 mcg 36.40 30 Minirin

⚡ Tab 200 mcg 93.60 30 Minirin

Nasal spray 10 mcg per dose – 1% DV Sep-11 to 2014..... 27.48 6 ml **Desmopressin-PH&T**

Inj 4 mcg per ml, 1 ml ampoule

Inj 15 mcg per ml, 1 ml ampoule

Nasal drops 100 mcg per ml

➔ **Restricted**

Nocturnal enuresis

Either:

- 1 The nasal forms of desmopressin are contraindicated; or
- 2 An enuresis alarm is contraindicated.

Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated

TERLIPRESSIN

Inj 1 mg vial 450.00 5 Glypressin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antibacterials			
Aminoglycosides			
AMIKACIN – Restricted see terms below			
‡ Inj 5 mg per ml, 10 ml syringe			
‡ Inj 5 mg per ml, 5 ml syringe – 1% DV Nov-12 to 2014	176.00	10	Biomed
‡ Inj 15 mg per ml, 5 ml syringe			
‡ Inj 250 mg per ml, 2 ml vial			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule	8.56	5	Mayne
Inj 10 mg per ml, 2 ml ampoule	175.10	25	APP Pharmaceuticals
Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-12 to 2015	6.50	10	Pfizer
PAROMOMYCIN – Restricted see terms below			
‡ Cap 250 mg	126.00	16	Humatin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
STREPTOMYCIN SULPHATE – Restricted see terms below			
‡ Inj 400 mg per ml, 2.5 ml ampoule			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
TOBRAMYCIN – Restricted see terms below			
‡ Inj 40 mg per ml, 2 ml vial – 1% DV Sep-11 to 2014	29.32	5	DBL Tobramycin
‡ Inj 100 mg per ml, 5 ml vial			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
Carbapenems			
ERTAPENEM – Restricted see terms below			
‡ Inj 1 g vial	70.00	1	Invanz
➔ Restricted			
Infectious disease physician or clinical microbiologist			
IMIPENEM WITH CILASTATIN – Restricted see terms below			
‡ Inj 500 mg with 500 mg cilastatin vial – 1% DV Dec-12 to 2014	18.37	1	Primaxin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
MEROPENEM – Restricted see terms below			
‡ Inj 500 mg vial – 1% DV Mar-12 to 2014	10.50	1	Penembact
‡ Inj 1 g vial – 1% DV Mar-12 to 2014	21.00	1	Penembact
➔ Restricted			
Infectious disease physician or clinical microbiologist			
Cephalosporins and Cephamycins - 1st Generation			
CEFALEXIN			
Cap 500 mg – 1% DV Oct-13 to 2016	5.70	20	Cephalexin ABM
Grans for oral liq 25 mg per ml – 1% DV Oct-13 to 2016	8.50	100 ml	Cefalexin Sandoz
Grans for oral liq 50 mg per ml – 1% DV Oct-13 to 2016	11.50	100 ml	Cefalexin Sandoz

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CEFAZOLIN			
Inj 500 mg vial – 1% DV Mar-12 to 2014	3.99	5	AFT
Inj 1 g vial – 1% DV Mar-12 to 2014	3.99	5	AFT

Cephalosporins and Cephamycins - 2nd Generation

CEFACLOR			
Cap 250 mg – 1% DV Dec-13 to 2016	26.00	100	Ranbaxy-Cefaclor
Grans for oral liq 25 mg per ml – 1% DV Dec-13 to 2016	3.53	100 ml	Ranbaxy-Cefaclor
CEFOXITIN			
Inj 1 g vial	55.00	5	Hospira
CEFUROXIME			
Tab 250 mg	29.40	50	Zinnat
Inj 750 mg vial – 1% DV Mar-12 to 2014	6.96	5	m-Cefuroxime
Inj 1.5 g vial – 1% DV Mar-12 to 2014	2.65	1	Mylan

Cephalosporins and Cephamycins - 3rd Generation

CEFOTAXIME			
Inj 500 mg vial – 1% DV Oct-11 to 2014	1.90	1	Cefotaxime Sandoz
Inj 1 g vial – 1% DV Nov-11 to 2014	15.58	10	DBL Cefotaxime
CEFTAZADIME – Restricted see terms below			
⚡ Inj 500 mg vial – 1% DV Oct-11 to 2014	2.37	1	Fortum
⚡ Inj 1 g vial	3.25	1	DBL Ceftazidime
⚡ Inj 2 g vial	6.49	1	DBL Ceftazidime
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
CEFTRIAZONE			
Inj 500 mg vial – 1% DV Mar-14 to 2016	1.50	1	Ceftriaxone-AFT
	2.70		Veracol
Inj 1 g vial – 1% DV Mar-14 to 2016	5.22	5	Ceftriaxone-AFT
	10.49		Aspen Ceftriaxone
Inj 2 g vial – 1% DV Mar-14 to 2016	2.75	1	Ceftriaxone-AFT
	5.20		Veracol

(Veracol Inj 500 mg vial to be delisted 1 March 2014)

(Aspen Ceftriaxone Inj 1 g vial to be delisted 1 March 2014)

(Veracol Inj 2 g vial to be delisted 1 March 2014)

Cephalosporins and Cephamycins - 4th Generation

CEFEPIME – Restricted see terms below			
⚡ Inj 1 g vial – 1% DV Oct-12 to 2015	8.80	1	DBL Cefepime
⚡ Inj 2 g vial – 1% DV Oct-12 to 2015	17.60	1	DBL Cefepime
➔ Restricted			
Infectious disease physician or clinical microbiologist			

Macrolides

AZITHROMYCIN – Restricted see terms on the next page			
⚡ Tab 250 mg	10.00	30	Apo-Azithromycin
⚡ Tab 500 mg – 1% DV Feb-13 to 2015	1.25	2	Apo-Azithromycin
⚡ Oral liq 40 mg per ml	6.60	15 ml	Zithromax

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Any of the following:			
1 Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or			
2 Patient has cystic fibrosis and has chronic infection with <i>Pseudomonas aeruginosa</i> or <i>Pseudomonas</i> related gram negative organisms; or			
3 For any other condition for five days' treatment, with review after five days.			
CLARITHROMYCIN – Restricted see terms below			
⚡ Tab 250 mg – 1% DV Jan-12 to 2014	4.19	14	Apo-Clarithromycin
⚡ Tab 500 mg – 1% DV Apr-12 to 2014	10.95	14	Apo-Clarithromycin
⚡ Grans for oral liq 25 mg per ml	23.12	70 ml	Klacid
⚡ Inj 500 mg vial – 1% DV Oct-11 to 2014	30.00	1	Klacid
➔Restricted			
Tab 250 mg and oral liquid			
Tab 250 mg and oral liquid			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.			
Tab 500 mg			
Helicobacter pylori eradication.			
Infusion			
Infusion			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or			
3 Community-acquired pneumonia (clarithromycin is not to be used as the first-line macrolide).			
ERYTHROMYCIN (AS ETHYLSUCCINATE)			
Tab 400 mg	16.95	100	E-Mycin
Grans for oral liq 200 mg per 5 ml	4.35	100 ml	E-Mycin
Grans for oral liq 400 mg per 5 ml	5.85	100 ml	E-Mycin
ERYTHROMYCIN (AS LACTOBIONATE)			
Inj 1 g vial	16.00	1	Erythrocin IV
ERYTHROMYCIN (AS STEARATE) – Restricted : For continuation only			
➔ Tab 250 mg			
➔ Tab 500 mg			
ROXITHROMYCIN			
Tab 150 mg – 1% DV Sep-12 to 2015	7.48	50	Arrow-Roxithromycin
Tab 300 mg – 1% DV Sep-12 to 2015	14.40	50	Arrow-Roxithromycin
Penicillins			
AMOXYCILLIN			
Cap 250 mg – 1% DV Mar-14 to 2016	16.18	500	Alphamox Apo-Amoxi
Cap 500 mg	26.50	500	Alphamox
Grans for oral liq 25 mg per ml	1.55	100 ml	Ospamox
Grans for oral liq 50 mg per ml	1.10	100 ml	Ospamox
Inj 250 mg vial – 1% DV Nov-11 to 2014	12.96	10	Ibiamox
Inj 500 mg vial – 1% DV Nov-11 to 2014	15.08	10	Ibiamox
Inj 1 g vial – 1% DV Nov-11 to 2014	21.94	10	Ibiamox
<i>(Alphamox Cap 250 mg to be delisted 1 March 2014)</i>			

↑ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
AMOXYCILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg – 1% DV Aug-12 to 2014	12.55	100	Curam Duo
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml – 1% DV Nov-12 to 2015	1.61	100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml – 1% DV Nov-12 to 2015	2.19	100 ml	Augmentin
Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Jan-13 to 2015	10.14	10	m-Amoxiclav
Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Jan-13 to 2015	14.03	10	m-Amoxiclav
BENZATHINE BENZYL PENICILLIN			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-12 to 2015	315.00	10	Bicillin LA
BENZYL PENICILLIN SODIUM [PENICILLIN G]			
Inj 600 mg (1 million units) vial – 1% DV Nov-11 to 2014	11.50	10	Sandoz
FLUCLOXACILLIN			
Cap 250 mg – 1% DV Oct-12 to 2015	22.00	250	Staphlex
Cap 500 mg – 1% DV Oct-12 to 2015	74.00	500	Staphlex
Grans for oral liq 25 mg per ml – 1% DV Sep-12 to 2015	2.49	100 ml	AFT
Grans for oral liq 50 mg per ml – 1% DV Sep-12 to 2015	3.25	100 ml	AFT
Inj 250 mg vial – 1% DV Nov-11 to 2014	10.86	10	Flucloxin
Inj 500 mg vial – 1% DV Nov-11 to 2014	11.32	10	Flucloxin
Inj 1 g vial – 1% DV Nov-11 to 2014	14.28	10	Flucloxin
PHENOXYMETHYL PENICILLIN [PENICILLIN V]			
Cap 250 mg	11.99	50	Cilicaine VK
Cap 500 mg	14.45	50	Cilicaine VK
Grans for oral liq 25 mg per ml	1.68	100 ml	AFT
Grans for oral liq 50 mg per ml	1.78	100 ml	AFT
PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below			
☒ Inj 4 g with tazobactam 0.5 g vial – 1% DV Oct-13 to 2016	5.84	1	Tazocin EF
☛ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PROCAINE PENICILLIN			
Inj 1.5 g in 3.4 ml syringe – 1% DV Nov-11 to 2014	123.50	5	Cilicaine
TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms below			
☒ Inj 3 g with clavulanic acid 0.1 mg vial			
☛ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
Quinolones			
CIPROFLOXACIN – Restricted see terms below			
☒ Tab 250 mg – 1% DV Dec-11 to 2014	2.20	28	Cipflox
☒ Tab 500 mg – 1% DV Dec-11 to 2014	3.00	28	Cipflox
☒ Tab 750 mg – 1% DV Dec-11 to 2014	5.15	28	Cipflox
☒ Oral liq 50 mg per ml			
☒ Oral liq 100 mg per ml			
☒ Inj 2 mg per ml, 100 ml bag	41.00	10	Aspen Ciprofloxacin
☛ Restricted			
Infectious disease physician or clinical microbiologist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MOXIFLOXACIN – Restricted see terms below			
☒ Tab 400 mg	52.00	5	Avelox
☒ Inj 1.6 mg per ml, 250 ml bag	70.00	1	Avelox IV 400

☛ **Restricted**

Mycobacterium infection

Infectious disease physician, clinical microbiologist or respiratory physician

- 1 Active tuberculosis, with any of the following:
 - 1.1 Documented resistance to one or more first-line medications; or
 - 1.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications.
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated

Pneumonia

Infectious disease physician or clinical microbiologist

- 1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
- 2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

Penetrating eye injury

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury

Mycoplasma genitalium

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and
- 2 Has tried and failed to clear infection using azithromycin; and
- 3 Treatment is only for 7 days.

NORFLOXACIN

Tab 400 mg – 1% DV Sep-11 to 2014	15.45	100	Arrow-Norfloxacin
---	-------	-----	--------------------------

Tetracyclines

DEMECLOCYCLINE HYDROCHLORIDE

Cap 150 mg

DOXYCYCLINE

☛ Tab 50 mg – **Restricted:** For continuation only

Tab 100 mg – 1% DV Sep-11 to 2014	7.95	250	Doxine
---	------	-----	---------------

Inj 5 mg per ml, 20 ml vial

MINOCYCLINE

Tab 50 mg

☛ Cap 100 mg – **Restricted:** For continuation only

TETRACYCLINE

Tab 250 mg

Cap 500 mg	46.00	30	Tetracyclin Wolff
------------------	-------	----	-------------------

TIGECYCLINE – Restricted see terms below

☒ Inj 50 mg vial

☛ **Restricted**

Infectious disease physician or clinical microbiologist

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Other Antibacterials			
AZTREONAM – Restricted see terms below			
⚡ Inj 1 g vial – 1% DV Sep-11 to 2014	131.00	5	Azactam
➔ Restricted			
Infectious disease physician or clinical microbiologist			
CHLORAMPHENICOL – Restricted see terms below			
⚡ Inj 1 g vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
CLINDAMYCIN – Restricted see terms below			
⚡ Cap 150 mg – 1% DV Oct-13 to 2016	5.80	16	Clindamycin ABM
⚡ Oral liq 15 mg per ml			
⚡ Inj 150 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016	100.00	10	Dalacin C
➔ Restricted			
Infectious disease physician or clinical microbiologist			
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – Restricted see terms below			
⚡ Inj 150 mg per ml, 1 ml vial	65.00	1	Colistin-Link
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
DAPTOMYCIN – Restricted see terms below			
⚡ Inj 350 mg vial			
⚡ Inj 500 mg vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
FOSFOMYCIN – Restricted see terms below			
⚡ Powder for oral solution, 3 g sachet			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
FUSIDIC ACID – Restricted see terms below			
⚡ Tab 250 mg	34.50	12	Fucidin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
HEXAMINE HIPPURATE			
Tab 1 g			
LINCOMYCIN – Restricted see terms below			
⚡ Inj 300 mg per ml, 2 ml vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
LINEZOLID – Restricted see terms below			
⚡ Tab 600 mg			
⚡ Oral liq 20 mg per ml			
⚡ Inj 2 mg per ml, 300 ml bag			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
NITROFURANTOIN			
Tab 50 mg			
Tab 100 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PIVMECILLINAM – Restricted see terms below			
☒ Tab 200 mg			
☛ Restricted			
Infectious disease physician or clinical microbiologist			
SULPHADIAZINE – Restricted see terms below			
☒ Tab 500 mg			
☛ Restricted			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
TEICOPLANIN – Restricted see terms below			
☒ Inj 400 mg vial			
☛ Restricted			
Infectious disease physician or clinical microbiologist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg	9.28	50	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]			
Tab 80 mg with sulphamethoxazole 400 mg			
Oral liq 8 mg with sulphamethoxazole 40 mg per ml	2.15	100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – Restricted see terms below			
☒ Inj 500 mg vial – 1% DV Sep-11 to 2014	3.58	1	Mylan
☛ Restricted			
Infectious disease physician or clinical microbiologist			

Antifungals

Imidazoles

KETOCONAZOLE

☒ Tab 200 mg

☛ **Restricted**

Infectious disease physician, clinical microbiologist, dermatologist, endocrinologist or oncologist

Polyene Antimycotics

AMPHOTERICIN B

☒ Inj (liposomal) 50 mg vial – 1% DV Oct-12 to 2015

10

AmBisome

☛ **Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
 - 2.1 Possible invasive fungal infection; and
 - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

☒ Inj 50 mg vial

☛ **Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NYSTATIN			
Tab 500,000 u	17.09	50	Nilstat
Cap 500,000 u	15.47	50	Nilstat

Triazoles

FLUCONAZOLE – **Restricted** see terms below

⚡ Cap 50 mg – 1% DV Jan-12 to 2014	4.77	28	Ozole
⚡ Cap 150 mg – 1% DV Jan-12 to 2014	0.91	1	Ozole
⚡ Cap 200 mg – 1% DV Jan-12 to 2014	13.34	28	Ozole
⚡ Oral liquid 50 mg per 5 ml	34.56	35 ml	Diflucan
⚡ Inj 2 mg per ml, 50 ml vial – 1% DV Oct-13 to 2016	4.95	1	Fluconazole-Claris
⚡ Inj 2 mg per ml, 100 ml vial – 1% DV Oct-13 to 2016	6.47	1	Fluconazole-Claris

➔**Restricted**

Consultant

ITRACONAZOLE – **Restricted** see terms below

⚡ Cap 100 mg – 1% DV Oct-13 to 2016	2.99	15	Itrazole
⚡ Oral liquid 10 mg per ml			

➔**Restricted**

Infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist

POSACONAZOLE – **Restricted** see terms below

⚡ Oral liq 40 mg per ml	761.13	105 ml	Noxafil
-------------------------------	--------	--------	---------

➔**Restricted**

Infectious disease physician or haematologist

Initiation

Re-assessment required after 6 weeks

Both:

- 1 Either:
 - 1.1 Patient has acute myeloid leukaemia; or
 - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy

Continuation

Re-assessment required after 6 weeks

Both:

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
 - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
 - 2.2 Patient is to be treated with high dose consolidation therapy; or
 - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE – **Restricted** see terms on the next page

⚡ Tab 50 mg	730.00	56	Vfend
⚡ Tab 200 mg	2,930.00	56	Vfend
⚡ Oral liq 40 mg per ml	730.00	70 ml	Vfend
⚡ Inj 200 mg vial	185.00	1	Vfend

Price (ex man. excl. GST)		Brand or Generic Manufacturer
\$	Per	

➔Restricted

Infectious disease physician, clinical microbiologist or haematologist

Proven or probable aspergillus infection

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

Possible aspergillus infection

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Resistant candidiasis infections and other moulds

All of the following:

- 1 Patient is immunocompromised, and
- 2 Either:
 - 2.1 Patient has fluconazole resistant candidiasis; or
 - 2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

Other Antifungals

CASPOFUNGIN – **Restricted** see terms below

⚡ Inj 50 mg vial – 1% DV Oct-12 to 2015.....	667.50	1	Cancidas
⚡ Inj 70 mg vial – 1% DV Oct-12 to 2015.....	862.50	1	Cancidas

➔Restricted

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
 - 2.1 Possible invasive fungal infection; and
 - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

FLUCYTOSINE – **Restricted** see terms below

⚡ Cap 500 mg

➔Restricted

Infectious disease physician or clinical microbiologist.

TERBINAFINE

Tab 250 mg – 1% DV Nov-11 to 2014	1.78	14	Dr Reddy's Terbinafine
---	------	----	-------------------------------

Antimycobacterials

Antileprotics

CLOFAZIMINE – **Restricted** see terms below

⚡ Cap 50 mg

➔Restricted

Infectious disease physician, clinical microbiologist or dermatologist

DAPSONE – **Restricted** see terms on the next page

⚡ Tab 25 mg

⚡ Tab 100 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician, clinical microbiologist or dermatologist			
Antituberculotics			
CYCLOSERINE – Restricted see terms below			
⚡ Cap 250 mg			
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below			
⚡ Tab 100 mg	48.01	56	Myambutol
⚡ Tab 400 mg	49.34	56	Myambutol
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
ISONIAZID – Restricted see terms below			
⚡ Tab 100 mg – 1% DV Mar-13 to 2015	20.00	100	PSM
➔Restricted			
Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
ISONIAZID WITH RIFAMPICIN – Restricted see terms below			
⚡ Tab 100 mg with rifampicin 150 mg			
⚡ Tab 150 mg with rifampicin 300 mg			
➔Restricted			
Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
PARA-AMINOSALICYLIC ACID – Restricted see terms below			
⚡ Grans for oral liq 4 g	280.00	30	Paser
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PROTIONAMIDE – Restricted see terms below			
⚡ Tab 250 mg	305.00	100	Peteha
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PYRAZINAMIDE – Restricted see terms below			
⚡ Tab 500 mg			
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
RIFABUTIN – Restricted see terms below			
⚡ Cap 150 mg – 1% DV Sep-13 to 2016	213.19	30	Mycobutin
➔Restricted			
Infectious disease physician, clinical microbiologist, respiratory physician or gastroenterologist			
RIFAMPICIN – Restricted see terms below			
⚡ Tab 600 mg			
⚡ Cap 150 mg			
⚡ Cap 300 mg			
⚡ Oral liq 100 mg per 5 ml			
⚡ Inj 600 mg vial			
➔Restricted			
Internal medicine physician, clinical microbiologist, dermatologist, paediatrician or public health physician			

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Antiparasitics

Anthelmintics

ALBENDAZOLE – **Restricted** see terms below

⚡ Tab 200 mg

⚡ Tab 400 mg

➡ **Restricted**

Infectious disease physician or clinical microbiologist

IVERMECTIN – **Restricted** see terms below

⚡ Tab 3 mg 17.20 4 Stromectol

➡ **Restricted**

Infectious disease physician, clinical microbiologist or dermatologist.

MEBENDAZOLE

Tab 100 mg – 1% DV Nov-11 to 2014 24.19 24 **De-Worm**

Oral liq 100 mg per 5 ml

PRAZIQUANTEL

Tab 600 mg

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE – **Restricted** see terms below

⚡ Tab 20 mg with lumefantrine 120 mg

➡ **Restricted**

Infectious disease physician or clinical microbiologist

ARTESUNATE – **Restricted** see terms below

⚡ Inj 60 mg vial

➡ **Restricted**

Infectious disease physician or clinical microbiologist

ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – **Restricted** see terms below

⚡ Tab 62.5 mg with proguanil hydrochloride 25 mg

⚡ Tab 250 mg with proguanil hydrochloride 100 mg

➡ **Restricted**

Infectious disease physician or clinical microbiologist

CHLOROQUINE PHOSPHATE – **Restricted** see terms below

⚡ Tab 250 mg

➡ **Restricted**

Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist

MEFLOQUINE HYDROCHLORIDE – **Restricted** see terms below

⚡ Tab 250 mg

➡ **Restricted**

Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist

METRONIDAZOLE

Tab 200 mg 10.45 100 Trichozole

Tab 400 mg 18.15 100 Trichozole

Oral liq benzoate 200 mg per 5 ml 25.00 100 ml Flagyl-S

Inj 5 mg per ml, 100 ml bag 2.46 1 Baxter

..... 12.30 5 AFT

Suppos 500 mg 24.48 10 Flagyl

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NITAZOXANIDE – Restricted see terms below			
⚡ Tab 500 mg	1,680.00	30	Alinia
⚡ Oral liq 100 mg per 5 ml			
➔ Restricted Infectious disease physician or clinical microbiologist			
ORNIDAZOLE			
Tab 500 mg	16.50	10	Arrow-Ornidazole
PENTAMIDINE ISETHIONATE – Restricted see terms below			
⚡ Inj 300 mg vial			
➔ Restricted Infectious disease physician or clinical microbiologist			
PRIMAQUINE PHOSPHATE – Restricted see terms below			
⚡ Tab 7.5 mg			
➔ Restricted Infectious disease physician or clinical microbiologist			
PYRIMETHAMINE – Restricted see terms below			
⚡ Tab 25 mg			
➔ Restricted Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
QUININE DIHYDROCHLORIDE – Restricted see terms below			
⚡ Inj 60 mg per ml, 10 ml ampoule			
⚡ Inj 300 mg per ml, 2 ml vial			
➔ Restricted Infectious disease physician or clinical microbiologist			
QUININE SULPHATE			
Tab 300 mg	54.06	500	Q 300
SODIUM STIBOGLUCONATE – Restricted see terms below			
⚡ Inj 100 mg per ml, 1 ml vial			
➔ Restricted Infectious disease physician or clinical microbiologist			
SPIRAMYCIN – Restricted see terms below			
⚡ Tab 500 mg			
➔ Restricted Maternal-foetal medicine specialist			
Antiretrovirals			
HIV Fusion Inhibitors			
ENFUVRTIDE – Restricted see terms on the next page			
⚡ Inj 108 mg vial × 60	2,380.00	1	Fuzeon

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ Restricted

Initiation

Re-assessment required after 12 months

All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Continuation

Patient has had at least a 10-fold reduction in viral load at 12 months

Non-Nucleoside Reverse Transcriptase Inhibitors

➔ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
EFAVIRENZ – Restricted see terms on the preceding page			
⬆ Tab 50 mg	158.33	30	Stocrin
⬆ Tab 200 mg	474.99	90	Stocrin
⬆ Tab 600 mg	474.99	30	Stocrin
⬆ Oral liq 30 mg per ml			
ETRAVIRINE – Restricted see terms on the preceding page			
⬆ Tab 200 mg	770.00	60	Intelence
NEVIRAPINE – Restricted see terms on the preceding page			
⬆ Tab 200 mg – 1% DV Jan-13 to 2015	95.94	60	Nevirapine Alphapharm
⬆ Oral suspension 10 mg per ml	134.55	240 ml	Viramune Suspension

Nucleoside Reverse Transcriptase Inhibitors

➔ **Restricted**

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ABACAVIR SULPHATE – Restricted see terms above

⬆ Tab 300 mg – 1% DV Jul-11 to 2014	229.00	60	Ziagen
⬆ Oral liq 20 mg per ml – 1% DV Jul-11 to 2014	50.00	240 ml	Ziagen

ABACAVIR SULPHATE WITH LAMIVUDINE – Restricted see terms above

⬆ Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa
---	--------	----	--------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DIDANOSINE [DDI] – Restricted see terms on the preceding page			
† Cap 125 mg			
† Cap 200 mg			
† Cap 250 mg			
† Cap 400 mg			
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms on the preceding page			
† Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg	1,313.19	30	Atripla
EMTRICITABINE – Restricted see terms on the preceding page			
† Cap 200 mg	307.20	30	Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms on the preceding page			
† Tab 200 mg with tenofovir disoproxil fumarate 300 mg	838.20	30	Truvada
LAMIVUDINE – Restricted see terms on the preceding page			
† Tab 150 mg			
† Oral liq 10 mg per ml			
STAVUDINE – Restricted see terms on the preceding page			
† Cap 30 mg			
† Cap 40 mg			
† Powder for oral soln 1 mg per ml			
ZIDOVUDINE [AZT] – Restricted see terms on the preceding page			
† Cap 100 mg – 1% DV Oct-13 to 2016	152.25	100	Retrovir
† Oral liq 10 mg per ml – 1% DV Oct-13 to 2016.....	30.45	200 ml	Retrovir
† Inj 10 mg per ml, 20 ml vial			
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Restricted see terms on the preceding page			
† Tab 300 mg with lamivudine 150 mg – 1% DV Dec-12 to 2014.....	63.50	60	Alphapharm

Protease Inhibitors

➡ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Post-exposure prophylaxis following non-occupational exposure to HIV

- Both:
- 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ATAZANAVIR SULPHATE – **Restricted** see terms on the preceding page

⬆ Cap 150 mg	568.34	60	Reyataz
⬆ Cap 200 mg	757.79	60	Reyataz

DARUNAVIR – **Restricted** see terms on the preceding page

⬆ Tab 400 mg	837.50	60	Prezista
⬆ Tab 600 mg	1,190.00	60	Prezista

INDINAVIR – **Restricted** see terms on the preceding page

- ⬆ Cap 200 mg
- ⬆ Cap 400 mg

LOPINAVIR WITH RITONAVIR – **Restricted** see terms on the preceding page

⬆ Tab 100 mg with ritonavir 25 mg	183.75	60	Kaletra
⬆ Tab 200 mg with ritonavir 50 mg	735.00	120	Kaletra
⬆ Oral liq 80 mg with ritonavir 20 mg per ml	735.00	300 ml	Kaletra

RITONAVIR – **Restricted** see terms on the preceding page

⬆ Tab 100 mg – 1% DV Oct-12 to 2015	43.31	30	Norvir
⬆ Oral liq 80 mg per ml			

Strand Transfer Inhibitors

➔ **Restricted**

Confirmed HIV

- Both:
- 1 Confirmed HIV infection; and
 - 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

- Either:
- 1 Prevention of maternal foetal transmission; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

RALTEGRAVIR POTASSIUM – **Restricted** see terms on the preceding page

⬆ Tab 400 mg	1,090.00	60	ISENTRESS
--------------------	----------	----	-----------

Antivirals

Hepatitis B

ADEFOVIR DIPIVOXIL – **Restricted** see terms below

⬆ Tab 10 mg	670.00	30	HEPSERA
-------------------	--------	----	---------

➡ **Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and

Documented resistance to lamivudine, defined as:

- 1 Patient has raised serum ALT ($> 1 \times \text{ULN}$); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 -fold over nadir; and
- 3 Detection of M204I or M204V mutation; and
- 4 Either:

- 4.1 Both:
 - 4.1.1 Patient is cirrhotic; and
 - 4.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or
- 4.2 Both:
 - 4.2.1 Patient is not cirrhotic; and
 - 4.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR – **Restricted** see terms below

⬆ Tab 0.5 mg	400.00	30	BARACLUDE
--------------------	--------	----	-----------

➡ **Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
 - 4.1 ALT greater than upper limit of normal; or
 - 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater or moderate fibrosis) on liver histology; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Patient has $\geq 2,000$ IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued. .

- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

LAMIVUDINE – **Restricted** see terms below

⚡ Tab 100 mg – 1% DV Dec-12 to 2014	32.50	28	Zetlam
⚡ Oral liq 5 mg per ml			

➔**Restricted**

Gastroenterologist, infectious disease specialist, paediatrician or general physician

Initiation

Re-assessment required after 12 months

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or
- 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Continuation - patients who have maintained continuous treatment and response to lamivudine

Re-assessment required after 2 years

All of the following:

- 1 Have maintained continuous treatment with lamivudine; and
- 2 Most recent test result shows continuing biochemical response (normal ALT); and
- 3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or

Continuation - when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine

Re-assessment required after 2 years

All of the following:

- 1 Lamivudine to be used in combination with adefovir dipivoxil; and
- 2 Patient is cirrhotic; and

Documented resistance to lamivudine, defined as:

- 1 Patient has raised serum ALT (> 1 × ULN); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and
- 3 Detection of M204I or M204V mutation; or

Continuation - when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

Re-assessment required after 2 years

All of the following:

- 1 Lamivudine to be used in combination with adefovir dipivoxil; and

Documented resistance to adefovir, defined as:

- 1 Patient has raised serum ALT (> 1 × ULN); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and
- 3 Detection of N236T or A181T/V mutation.

TENOFOVIR DISOPROXIL FUMARATE – **Restricted** see terms on the next page

⚡ Tab 300 mg	531.00	30	Viread
--------------------	--------	----	--------

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ Restricted

Confirmed hepatitis B

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \leq 10-fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has a decompensated cirrhosis with a Mayo score $>$ 20.

Pregnant or Breastfeeding, Active hepatitis B

Limited to twelve months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA $>$ 20,000 IU/mL and ALT $>$ ULN.

Pregnant, prevention of vertical transmission

Limited to six months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA $>$ 20 million IU/mL and ALT normal.

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts $<$ 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts $<$ 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts $>$ 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts $<$ 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Hepatitis C

BOCEPREVIR – **Restricted** see terms below

⚡ Cap 200 mg	5,015.00	336	Victrelis
--------------------	----------	-----	-----------

➔**Restricted**

Chronic hepatitis C - genotype 1, first-line from gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naive; and
- 6 Maximum of 44 weeks therapy.

Chronic hepatitis C - genotype 1, second-line from gastroenterologist, infectious disease physician or general physician.

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any one of:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count <100 x10⁹ /l or Albumin <35 g/l.

Herpesviridae

ACICLOVIR

Tab dispersible 200 mg – 1% DV Sep-13 to 2016	1.78	25	Lovir
Tab dispersible 400 mg – 1% DV Sep-13 to 2016	5.98	56	Lovir
Tab dispersible 800 mg – 1% DV Sep-13 to 2016	6.64	35	Lovir
Inj 250 mg vial – 1% DV Mar-13 to 2015	14.09	5	Zovirax IV

CIDOFOVIR – **Restricted** see terms below

⚡ Inj 75 mg per ml, 5 ml vial

➔**Restricted**

Infectious disease physician, clinical microbiologist, otolaryngologist or oral surgeon

FOSCARNET SODIUM – **Restricted** see terms below

⚡ Inj 24 mg per ml, 250 ml bottle

➔**Restricted**

Infectious disease physician or clinical microbiologist

GANCICLOVIR – **Restricted** see terms below

⚡ Inj 500 mg vial	380.00	5	Cymevene
-------------------------	--------	---	----------

➔**Restricted**

Infectious disease physician or clinical microbiologist

VALACICLOVIR – **Restricted** see terms on the next page

⚡ Tab 500 mg	102.72	30	Valtrex
--------------------	--------	----	---------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Any of the following:

- 1 Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.
- 2 Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.
- 3 Patient has undergone organ transplantation.

Immunocompromised patients

Limited to 7 days treatment

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has herpes zoster.

VALGANCICLOVIR – **Restricted** see terms below

⚡ Tab 450 mg	3,000.00	60	Valcyte
--------------------	----------	----	---------

➔ **Restricted**

Transplant cytomegalovirus prophylaxis

Limited to three months' treatment

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Lung transplant cytomegalovirus prophylaxis

Limited to six months' treatment

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Cytomegalovirus in immunocompromised patients

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Influenza

OSELTAMIVIR – **Restricted** see terms below

⚡ Tab 75 mg

⚡ Powder for oral suspension 6 mg per ml

➔ **Restricted**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

⚡ Powder for inhalation 5 mg	37.36	20 dose	Relenza Rotadisk
------------------------------------	-------	---------	------------------

➔ **Restricted**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Immune Modulators

INTERFERON ALFA-2A

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – Restricted see terms below

⚡ Inj 100 mcg in 0.5 ml vial

➔ **Restricted**

Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – Restricted see terms below

⚡ Inj 135 mcg prefilled syringe			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)			
⚡ Inj 180 mcg prefilled syringe	900.00	4	Pegasys
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)	1,159.84	1	Pegasus RBV Combination Pack
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)	1,290.00	1	Pegasus RBV Combination Pack

➔ **Restricted**

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.
- 2 Maximum of 48 weeks therapy.

Notes:

Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – (Chronic hepatitis C - genotype 1 infection) - gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Initiation (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) - Gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log₁₀ IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Anticholinesterases

EDROPHONIUM CHLORIDE – **Restricted** see terms below

- ⚡ Inj 10 mg per ml, 15 ml vial
- ⚡ Inj 10 mg per ml, 1 ml ampoule

➔**Restricted**

For the diagnosis of myasthenia gravis

NEOSTIGMINE METILSULFATE

Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Sep-11 to 2014 140.00 50 **AstraZeneca**

NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE

Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule
– 1% DV Nov-13 to 2016 27.86 10 **Max Health**

PYRIDOSTIGMINE BROMIDE

Tab 60 mg – 1% DV Sep-11 to 2014 38.90 100 **Mestinon**

Antirheumatoid Agents

AURANOFIN

Tab 3 mg

HYDROXYCHLOROQUINE

Tab 200 mg – 1% DV Nov-12 to 2015 18.00 100 **Plaquenil**

LEFLUNOMIDE

Tab 10 mg 55.00 30 Arava
Tab 20 mg 76.00 30 Arava
Tab 100 mg 54.44 3 Arava

PENICILLAMINE

Tab 125 mg 61.93 100 D-Penaminate
Tab 250 mg 98.98 100 D-Penaminate

SODIUM AUROTHIOMALATE

- Inj 10 mg in 0.5 ml ampoule
- Inj 20 mg in 0.5 ml ampoule
- Inj 50 mg in 0.5 ml ampoule

Drugs Affecting Bone Metabolism

Bisphosphonates

ALENDRONATE SODIUM

⚡ Tab 40 mg 133.00 30 Fosamax

➔**Restricted**

Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

⚡ Tab 70 mg 22.90 4 Fosamax

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Osteoporosis

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≤ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

The patient is continuing systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents)

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – **Restricted** see terms below

⚡ Tab 70 mg with cholecalciferol 5,600 iu	22.90	4	Fosamax Plus
---	-------	---	--------------

➔ **Restricted**

Osteoporosis

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

- Both:
- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

The patient is continuing systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents)

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \geq -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ETIDRONATE DISODIUM

Tab 200 mg – 1% DV Sep-12 to 2015	15.80	100	Arrow-Etidronate
---	-------	-----	-------------------------

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 5 ml vial	18.75	1	Pamisol
Inj 3 mg per ml, 10 ml vial – 1% DV Feb-13 to 2014	16.00	1	Pamidronate BNM
Inj 6 mg per ml, 10 ml vial – 1% DV Feb-13 to 2014	32.00	1	Pamidronate BNM
Inj 9 mg per ml, 10 ml vial – 1% DV Feb-13 to 2014	48.00	1	Pamidronate BNM

ZOLEDRONIC ACID – Restricted see terms on the next page

⚡ Inj 0.05 mg per ml, 100 ml vial	600.00	100 ml	Aclasta
---	--------	--------	---------

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Osteogenesis imperfecta

Patient has been diagnosed with clinical or genetic osteogenesis imperfecta.

Osteoporosis

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \geq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initiation - Paget's disease

Re-assessment required after 12 months

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Continuation - Paget's disease

Re-assessment required after 12 months

Both:

- 1 Any of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
- 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
- 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

RALOXIFENE – **Restricted** see terms below

Tab 60 mg	53.76	28	Evista
-----------------	-------	----	--------

→ **Restricted**

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≥ -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
RISEDRONATE SODIUM			
Tab 35 mg	4.00	4	Risedronate Sandoz
TERIPARATIDE – Restricted see terms below			
⚡ Inj 250 mcg per ml, 2.4 ml cartridge	490.00	1	Forteo

➔**Restricted**

Limited to 18 months' treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- 1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- 2 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialed so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- 3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Dec-11 to 2014	15.90	1,000	Apo-Allopurinol
Tab 300 mg – 1% DV Dec-11 to 2014	16.75	500	Apo-Allopurinol

BENZBROMARONE – Restricted see terms below

⚡ Tab 100 mg	45.00	100	Benzbromaron AL 100
--------------------	-------	-----	---------------------

➔**Restricted**

Both:

- 1 Any of the following:
 - 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid: or
 - 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
 - 1.3 Both:
 - 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 1.4 All of the following:
 - 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 1.4.2 Allopurinol is contraindicated; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

2 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at http://www.rheumatology.org.nz/benzbromarone_prescriber_information.cfm

COLCHICINE

Tab 500 mcg – 1% DV Oct-13 to 2016	10.08	100	Colgout
---	-------	-----	----------------

PROBENECID

Tab 500 mg

RASBURICASE – Restricted see terms below

☑ Inj 1.5 mg vial

➔ **Restricted**

Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE

Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Sep-12 to 2015	6.13	5	Tracrium
Inj 10 mg per ml, 5 ml ampoule – 1% DV Sep-12 to 2015	9.19	5	Tracrium

BACLOFEN

Tab 10 mg – 1% DV Jun-13 to 2016	3.85	100	Pacifen
Oral liq 1 mg per ml			
Inj 0.05 mg per ml, 1 ml ampoule – 1% DV Oct-12 to 2015	11.55	1	Lioresal Intrathecal
Inj 2 mg per ml, 5 ml ampoule – 1% DV Oct-12 to 2015	209.29	1	Lioresal Intrathecal

CLOSTRIDIUM BOTULINUM TYPE A TOXIN

Inj 100 u vial	467.50	1	Botox
Inj 500 u vial	1,295.00	2	Dysport

DANTROLENE

Cap 25 mg	65.00	100	Dantrium
Cap 50 mg	77.00	100	Dantrium
Inj 20 mg vial			<i>e.g. Dantrium IV</i>

MIVACURIUM CHLORIDE

Inj 2 mg per ml, 5 ml ampoule	33.92	5	Mivacron
Inj 2 mg per ml, 10 ml ampoule	67.17	5	Mivacron

ORPHENADRINE CITRATE

Tab 100 mg

PANCURONIUM BROMIDE

Inj 2 mg per ml, 2 ml ampoule – 1% DV Jan-13 to 2015	260.00	50	AstraZeneca
---	--------	----	--------------------

ROCURONIUM BROMIDE

Inj 10 mg per ml, 5 ml vial – 1% DV Sep-12 to 2015	38.25	10	DBL Rocuronium Bromide
---	-------	----	-------------------------------

SUXAMETHONIUM CHLORIDE

Inj 50 mg per ml, 2 ml ampoule	130.00	50	AstraZeneca
--------------------------------------	--------	----	--------------------

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
VECURONIUM BROMIDE			
Inj 4 mg ampoule			
Inj 10 mg vial			

Reversers of Neuromuscular Blockade

SUGAMMADEX – **Restricted** see terms below

⚡ Inj 100 mg per ml, 2 ml vial	1,200.00	10	Bridion
⚡ Inj 100 mg per ml, 5 ml vial	3,000.00	10	Bridion

➡**Restricted**

Any of the following:

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 3 The duration of the patient's surgery is unexpectedly short; or
- 4 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 5 Patient has a partial residual block after conventional reversal.

Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB – **Restricted** see terms below

⚡ Cap 100 mg			
⚡ Cap 200 mg			
⚡ Cap 400 mg			

➡**Restricted**

For preoperative and/or postoperative use for a total of up to 8 days' use.

DICLOFENAC SODIUM

Tab EC 25 mg – 1% DV Mar-13 to 2015	4.00	100	Apo-Diclo
Tab 50 mg dispersible			
Tab EC 50 mg – 1% DV Mar-13 to 2015	16.00	500	Apo-Diclo
Tab long-acting 75 mg – 1% DV Dec-12 to 2015	3.10	30	Diclax SR
	24.52	500	Diclax SR
Tab long-acting 100 mg – 1% DV Dec-12 to 2015	42.25	500	Diclax SR
Inj 25 mg per ml, 3 ml ampoule – 1% DV Sep-11 to 2014	12.00	5	Voltaren
Suppos 12.5 mg – 1% DV Sep-11 to 2014	1.85	10	Voltaren
Suppos 25 mg – 1% DV Sep-11 to 2014	2.22	10	Voltaren
Suppos 50 mg – 1% DV Sep-11 to 2014	3.84	10	Voltaren
Suppos 100 mg – 1% DV Sep-11 to 2014	6.36	10	Voltaren

ETORICOXIB – **Restricted** see terms below

⚡ Tab 30 mg			
⚡ Tab 60 mg			
⚡ Tab 90 mg			
⚡ Tab 120 mg			

➡**Restricted**

For preoperative and/or postoperative use for a total of up to 8 days' use.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
IBUPROFEN			
Tab 200 mg			
➔ Tab 400 mg – Restricted: For continuation only			
➔ Tab 600 mg – Restricted: For continuation only			
Tab long-acting 800 mg – 1% DV Oct-11 to 2014	8.12	30	Brufen SR
Oral liq 20 mg per ml – 1% DV Mar-14 to 2016	1.89	200 ml	Fenpaed
Inj 5 mg per ml, 2 ml ampoule			
INDOMETHACIN			
Cap 25 mg			
Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
KETOPROFEN			
Cap long-acting 100 mg	21.56	100	Oruvail SR
Cap long-acting 200 mg	43.12	100	Oruvail SR
MEFENAMIC ACID – Restricted: For continuation only			
➔ Cap 250 mg			
MELOXICAM – Restricted see terms below			
⚡ Tab 7.5 mg			
➔ Restricted			
Either:			
1 Haemophilic arthropathy, with both of the following:			
1.1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and			
1.2 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or			
2 For preoperative and/or postoperative use for a total of up to 8 days' use.			
NAPROXEN			
Tab 250 mg – 1% DV Jan-13 to 2015	21.25	500	Noflam 250
Tab 500 mg – 1% DV Jan-13 to 2015	22.25	250	Noflam 500
Tab long-acting 750 mg			
Tab long-acting 1 g			
PARECOXIB			
Inj 40 mg vial	100.00	10	Dynastat
SULINDAC – Restricted: For continuation only			
➔ Tab 100 mg			
➔ Tab 200 mg			
TENOXICAM			
Tab 20 mg			
Inj 20 mg vial	9.95	1	AFT
TIAPROFENIC ACID			
Tab 300 mg	19.26	60	Surgam
Topical Products for Joint and Muscular Pain			
CAPSAICIN – Restricted see terms on the next page			
⚡ Crm 0.025%	9.95	45 g	Zostrix

MUSCULOSKELETAL SYSTEM

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Agents for Parkinsonism and Related Disorders

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – **Restricted** see terms below

⚡ Tab 50 mg 400.00 56 Rilutek

➔ **Restricted**

Initiation

Neurologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Continuation

Re-assessment required after 18 months

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limb; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg – 1% DV Sep-13 to 2016 118.00 112 **Motetis**

Anticholinergics

BENZTROPINE MESYLATE

Tab 2 mg 7.99 60 Benztrop

Inj 1 mg per ml, 2 ml ampoule 95.00 5 Cogentin

ORPHENADRINE HYDROCHLORIDE

Tab 50 mg

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

Cap 100 mg – 1% DV Sep-11 to 2014 38.24 60 **Symmetrel**

APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml ampoule

Inj 10 mg per ml, 2 ml ampoule 110.00 5 Apomine

BROMOCRIPTINE

Tab 2.5 mg

Cap 5 mg

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENTACAPONE			
Tab 200 mg – 1% DV Dec-12 to 2015	47.92	100	Entapone
LEVODOPA WITH BENSERAZIDE			
Tab dispersible 50 mg with benserazide 12.5 mg	10.00	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg	8.00	100	Madopar 62.5
Cap 100 mg with benserazide 25 mg	12.50	100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg	17.00	100	Madopar HBS
Cap 200 mg with benserazide 50 mg	25.00	100	Madopar 250
LEVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg	20.00	100	Sinemet <i>e.g. Sindopa</i>
Tab long-acting 200 mg with carbidopa 50 mg	47.50	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg	40.00	100	Sinemet <i>e.g. Sindopa</i>
LISURIDE HYDROGEN MALEATE			
Tab 200 mcg	25.00	30	Dopergin
PERGOLIDE			
Tab 0.25 mg – 1% DV Sep-11 to 2014	48.00	100	Permax
Tab 1 mg – 1% DV Sep-11 to 2014	170.00	100	Permax
PRAMIPEXOLE HYDROCHLORIDE			
Tab 0.125 mg	1.95	30	Dr Reddy's Pramipexole
Tab 0.25 mg	2.40	30	Dr Reddy's Pramipexole
	7.20	100	Ramipex
Tab 0.5 mg	4.20	30	Dr Reddy's Pramipexole
Tab 1 mg	7.20	30	Dr Reddy's Pramipexole
	24.39	100	Ramipex
ROPINIROLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Mar-14 to 2016	2.36	100	Apo-Ropinirole
	6.20	84	Ropin
Tab 1 mg – 1% DV Apr-14 to 2016	5.32	100	Apo-Ropinirole
	15.95	84	Ropin
Tab 2 mg – 1% DV Mar-14 to 2016	7.72	100	Apo-Ropinirole
	24.95	84	Ropin
Tab 5 mg – 1% DV Mar-14 to 2016	14.48	100	Apo-Ropinirole
	38.00	84	Ropin
<i>(Ropin Tab 0.25 mg to be delisted 1 March 2014)</i>			
<i>(Ropin Tab 1 mg to be delisted 1 March 2014)</i>			
<i>(Ropin Tab 2 mg to be delisted 1 March 2014)</i>			
<i>(Ropin Tab 5 mg to be delisted 1 March 2014)</i>			
SELEGILINE HYDROCHLORIDE			
Tab 5 mg			
TOLCAPONE			
Tab 100 mg – 1% DV Sep-11 to 2014	126.20	100	Tasmar

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Anaesthetics

General Anaesthetics

DESFLURANE Soln for inhalation 100%, 240 ml bottle – 1% DV Dec-12 to 2015	1,230.00	6	Suprane
DEXMEDETOMIDINE HYDROCHLORIDE Inj 100 mcg per ml, 2 ml vial			
ETOMIDATE Inj 2 mg per ml, 10 ml ampoule			
ISOFLURANE Soln for inhalation 100%, 250 ml bottle – 1% DV Dec-12 to 2015	1,020.00	6	Aerrane
KETAMINE HYDROCHLORIDE Inj 1 mg per ml, 100 ml bag Inj 4 mg per ml, 50 ml syringe Inj 10 mg per ml, 10 ml syringe Inj 100 mg per ml, 2 ml vial			
METHOHEXITAL SODIUM Inj 10 mg per ml, 50 ml vial			
PROPOFOL Inj 10 mg per ml, 20 ml ampoule	7.60	5	Fresofol 1%
Inj 10 mg per ml, 20 ml vial	7.60	5	Provide MCT-LCT 1%
	42.00		Diprivan
Inj 10 mg per ml, 50 ml syringe	47.00	1	Diprivan
Inj 10 mg per ml, 50 ml vial	4.00	1	Fresofol 1%
			Provide MCT-LCT 1%
	25.00		Diprivan
Inj 10 mg per ml, 100 ml vial	7.60	1	Fresofol 1%
			Provide MCT-LCT 1%
	30.00		Diprivan
SEVOFLURANE Soln for inhalation 100%, 250 ml bottle – 1% DV Dec-12 to 2015	1,230.00	6	Baxter
THIOPENTAL [THIOPENTONE] SODIUM Inj 500 mg ampoule			

Local Anaesthetics

ARTICAINE HYDROCHLORIDE WITH ADRENALINE Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
BENZOCAINE Gel 20%			

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BUPIVACAINE HYDROCHLORIDE			
Inj 5 mg per ml, 4 ml ampoule	50.00	5	Marcaïn Isobaric
Inj 2.5 mg per ml, 20 ml ampoule			
Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 1% DV Oct-12 to 2015	35.00	5	Marcaïn
Inj 5 mg per ml, 10 ml ampoule	35.00	50	Marcaïn
Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Oct-12 to 2015	28.00	5	Marcaïn
Inj 5 mg per ml, 20 ml ampoule			
Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Oct-12 to 2015	28.00	5	Marcaïn
Inj 1.25 mg per ml, 100 ml bag			
Inj 1.25 mg per ml, 200 ml bag			
Inj 2.5 mg per ml, 100 ml bag	150.00	5	Marcaïn
Inj 2.5 mg per ml, 200 ml bag			
Inj 1.25 mg per ml, 500 ml bag			
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Nov-11 to 2014	135.00	5	Marcaïn with Adrenaline
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Nov-11 to 2014	115.00	5	Marcaïn with Adrenaline
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-11 to 2014	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Nov-11 to 2014	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe – 1% DV Nov-11 to 2014	72.00	10	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe – 1% DV Nov-11 to 2014	92.00	10	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE			
Inj 0.5% with glucose 8%, 4 ml ampoule	38.00	5	Marcaïn Heavy
COCAINE HYDROCHLORIDE			
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe	25.46	1	Biomed
COCAINE HYDROCHLORIDE WITH ADRENALINE			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
ETHYL CHLORIDE			
Spray 100%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE			
Gel 2% – 1% DV Oct-12 to 2015	3.40	20 ml	Orion
Soln 4%			
Spray 10% – 1% DV Sep-13 to 2016	75.00	50 ml	Xylocaine
Oral (viscous) soln 2% – 1% DV Sep-11 to 2014	55.00	200 ml	Xylocaine Viscous
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack			
Inj 1%, 5 ml ampoule – 1% DV Jul-13 to 2015	8.75	25	Lidocaine-Claris
Inj 1%, 20 ml ampoule – 1% DV Jul-13 to 2015	2.40	1	Lidocaine-Claris
Inj 2%, 5 ml ampoule – 1% DV Jul-13 to 2015	6.90	25	Lidocaine-Claris
Inj 2%, 20 ml ampoule – 1% DV Jul-13 to 2015	2.40	1	Lidocaine-Claris
Gel 2%, 10 ml urethral syringe	43.26	10	Pfizer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule	27.00	10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial	50.00	5	Xylocaine
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial	60.00	5	Xylocaine
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE			
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe			
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe	43.26	10	Pfizer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE			
Nasal spray 5% with phenylephrine hydrochloride 0.5%			
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE			
Crn 2.5% with prilocaine 2.5%	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg	115.00	20	EMLA
Crn 2.5% with prilocaine 2.5%, 5 g	45.00	5	EMLA
MEPIVACAINE HYDROCHLORIDE			
Inj 3%, 1.8 ml dental cartridge			
Inj 3%, 2.2 ml dental cartridge			
PRILOCAINE HYDROCHLORIDE			
Inj 0.5%, 50 ml vial	100.00	5	Citanest
Inj 2%, 5 ml ampoule	55.00	10	Citanest
PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
ROPIVACAINE HYDROCHLORIDE			
Inj 2 mg per ml, 10 ml ampoule			
Inj 2 mg per ml, 20 ml ampoule	75.00	5	Naropin
Inj 2 mg per ml, 100 ml bag	200.00	5	Naropin
Inj 2 mg per ml, 200 ml bag	265.00	5	Naropin
Inj 7.5 mg per ml, 10 ml ampoule	45.00	5	Naropin
Inj 7.5 mg per ml, 20 ml ampoule	84.00	5	Naropin
Inj 10 mg per ml, 10 ml ampoule	54.00	5	Naropin
Inj 10 mg per ml, 20 ml ampoule			

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ROPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag	198.50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag	270.00	5	Naropin
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Gel 4%			

Analgesics

Non-Opioid Analgesics

ASPIRIN

- Tab EC 300 mg
- Tab dispersible 300 mg

CAPSAICIN – **Restricted** see terms below

⚡ Crm 0.075% 12.50 45 g Zostrix HP

↪ **Restricted**

For post-herpetic neuralgia or diabetic peripheral neuropathy

METHOXYFLURANE – **Restricted** see terms below

⚡ Soln for inhalation 99.9%, 3 ml bottle

↪ **Restricted**

- Both:
- 1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
 - 2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

NEFOPAM HYDROCHLORIDE

Tab 30 mg

PARACETAMOL – **Some items restricted** see terms below

Tab soluble 500 mg
Tab 500 mg

Oral liq 120 mg per 5 ml – **20% DV Dec-11 to 2014** 2.21 500 ml **Ethics Paracetamol**

Oral liq 250 mg per 5 ml – **20% DV Sep-11 to 2014** 6.70 1,000 ml **Paracare Double Strength**

⚡ Inj 10 mg per ml, 50 ml vial – **1% DV Dec-13 to 2014** 22.50 10 **Paracetamol-AFT**

⚡ Inj 10 mg per ml, 100 ml vial – **1% DV Apr-13 to 2014** 22.50 10 **Paracetamol-AFT**

Suppos 25 mg 56.35 20 Biomed

Suppos 50 mg 56.35 20 Biomed

Suppos 125 mg 7.49 20 Panadol

Suppos 250 mg 14.40 20 Panadol

Suppos 500 mg – **1% DV Jan-13 to 2015** 20.70 50 **Paracare**

↪ **Restricted**

Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

SUCROSE

Oral liq 25%

Opioid Analgesics

ALFENTANIL HYDROCHLORIDE

Inj 0.5 mg per ml, 2 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CODEINE PHOSPHATE			
Tab 15 mg – 1% DV Jul-13 to 2016	4.75	100	PSM
Tab 30 mg – 1% DV Jul-13 to 2016	5.80	100	PSM
Tab 60 mg – 1% DV Jul-13 to 2016	12.50	100	PSM
DIHYDROCODEINE TARTRATE			
Tab long-acting 60 mg – 1% DV Sep-13 to 2016	13.64	60	DHC Continus
FENTANYL			
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Sep-12 to 2015	4.50	10	Boucher and Muir
Inj 10 mcg per ml, 50 ml bag – 1% DV Dec-11 to 2014	210.00	10	Biomed
Inj 10 mcg per ml, 50 ml syringe – 1% DV Dec-11 to 2014	165.00	10	Biomed
Inj 50 mcg per ml, 10 ml ampoule – 1% DV Sep-12 to 2015	11.77	10	Boucher and Muir
Inj 10 mcg per ml, 100 ml bag – 1% DV Dec-11 to 2014	210.00	10	Biomed
Inj 20 mcg per ml, 50 ml syringe – 1% DV Dec-11 to 2014	185.00	10	Biomed
Inj 20 mcg per ml, 100 ml bag			
Patch 12.5 mcg per hour	8.90	5	Mylan Fentanyl Patch
Patch 25 mcg per hour	9.15	5	Mylan Fentanyl Patch
Patch 50 mcg per hour	11.50	5	Mylan Fentanyl Patch
Patch 75 mcg per hour	13.60	5	Mylan Fentanyl Patch
Patch 100 mcg per hour	14.50	5	Mylan Fentanyl Patch
METHADONE HYDROCHLORIDE			
Tab 5 mg	1.85	10	Methatabs
Oral liq 2 mg per ml – 1% DV Sep-12 to 2015	5.55	200 ml	Biodone
Oral liq 5 mg per ml – 1% DV Sep-12 to 2015	5.55	200 ml	Biodone Forte
Oral liq 10 mg per ml – 1% DV Sep-12 to 2015	6.55	200 ml	Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial	61.00	10	AFT
MORPHINE HYDROCHLORIDE			
Oral liq 1 mg per ml – 1% DV Oct-12 to 2015	8.84	200 ml	RA-Morph
Oral liq 2 mg per ml – 1% DV Oct-12 to 2015	11.62	200 ml	RA-Morph
Oral liq 5 mg per ml – 1% DV Oct-12 to 2015	14.65	200 ml	RA-Morph
Oral liq 10 mg per ml – 1% DV Oct-12 to 2015	21.55	200 ml	RA-Morph

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MORPHINE SULPHATE			
Tab long-acting 10 mg – 1% DV Sep-13 to 2016	1.95	10	Arrow-Morphine LA
Tab immediate-release 10 mg	2.80	10	Sevredol
Tab immediate-release 20 mg	5.52	10	Sevredol
Tab long-acting 30 mg – 1% DV Sep-13 to 2016	2.98	10	Arrow-Morphine LA
Tab long-acting 60 mg – 1% DV Sep-13 to 2016	5.75	10	Arrow-Morphine LA
Tab long-acting 100 mg – 1% DV Sep-13 to 2016	6.45	10	Arrow-Morphine LA
Cap long-acting 10 mg – 1% DV Feb-14 to 2016	1.70	10	m-Eslon
Cap long-acting 30 mg – 1% DV Feb-14 to 2016	2.50	10	m-Eslon
Cap long-acting 60 mg – 1% DV Feb-14 to 2016	5.40	10	m-Eslon
Cap long-acting 100 mg – 1% DV Feb-14 to 2016	6.38	10	m-Eslon
Inj 1 mg per ml, 100 ml bag – 1% DV Dec-11 to 2014	165.00	10	Biomed
Inj 1 mg per ml, 10 ml syringe – 1% DV Dec-11 to 2014	39.50	10	Biomed
Inj 1 mg per ml, 50 ml syringe – 1% DV Dec-11 to 2014	79.50	10	Biomed
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe – 1% DV Dec-11 to 2014	135.00	10	Biomed
Inj 5 mg per ml, 1 ml ampoule – 1% DV Nov-11 to 2014	5.51	5	DBL Morphine Sulphate
Inj 10 mg per ml, 1 ml ampoule – 1% DV Nov-11 to 2014	4.79	5	DBL Morphine Sulphate
Inj 10 mg per ml, 100 mg cassette			
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule – 1% DV Nov-11 to 2014	5.01	5	DBL Morphine Sulphate
Inj 30 mg per ml, 1 ml ampoule – 1% DV Nov-11 to 2014	5.30	5	DBL Morphine Sulphate
Inj 200 mcg in 0.4 ml syringe			
Inj 300 mcg in 0.3 ml syringe			
MORPHINE TARTRATE			
Inj 80 mg per ml, 1.5 ml ampoule – 1% DV Sep-13 to 2016	35.60	5	Hospira
Inj 80 mg per ml, 5 ml ampoule – 1% DV Sep-13 to 2016	107.67	5	Hospira
OXYCODONE HYDROCHLORIDE			
Tab controlled-release 5 mg	7.51	20	OxyContin
Tab controlled-release 10 mg – 1% DV Oct-13 to 2015	6.75	20	Oxydone BNM
Tab controlled-release 20 mg – 1% DV Oct-13 to 2015	11.50	20	Oxydone BNM
Tab controlled-release 40 mg – 1% DV Oct-13 to 2015	18.50	20	Oxydone BNM
Tab controlled-release 80 mg – 1% DV Oct-13 to 2015	34.00	20	Oxydone BNM
Cap immediate-release 5 mg	2.83	20	OxyNorm
Cap immediate-release 10 mg	5.58	20	OxyNorm
Cap immediate-release 20 mg	9.77	20	OxyNorm
Oral liq 5 mg per 5 ml	11.20	250 ml	OxyNorm
Inj 1 mg per ml, 100 ml bag			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Dec-12 to 2015	10.08	5	Oxycodone Orion
Inj 10 mg per ml, 2 ml ampoule – 1% DV Dec-12 to 2015	19.87	5	Oxycodone Orion
Inj 50 mg per ml, 1 ml ampoule – 1% DV May-13 to 2015	60.00	5	OxyNorm
PARACETAMOL WITH CODEINE			
Tab paracetamol 500 mg with codeine phosphate 8 mg – 1% DV Nov-11 to 2014	2.70	100	Paracetamol + Codeine (Relieve)

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PETHIDINE HYDROCHLORIDE			
Tab 50 mg – 1% DV Mar-13 to 2015	3.95	10	PSM
Tab 100 mg – 1% DV Mar-13 to 2015	5.80	10	PSM
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Nov-11 to 2014	5.51	5	DBL Pethidine Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-11 to 2014	5.83	5	DBL Pethidine Hydrochloride
REMIFENTANIL HYDROCHLORIDE			
Inj 1 mg vial – 1% DV Feb-12 to 2014	27.95	5	Remifentanil-AFT
Inj 2 mg vial – 1% DV Feb-12 to 2014	41.80	5	Remifentanil-AFT
TRAMADOL HYDROCHLORIDE			
Tab sustained-release 100 mg	2.14	20	Tramal SR 100
Tab sustained-release 150 mg	3.21	20	Tramal SR 150
Tab sustained-release 200 mg	4.28	20	Tramal SR 200
Cap 50 mg – 1% DV Sep-11 to 2014	4.95	100	Arrow-Tramadol
Oral drops 100 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule	4.50	5	Tramal 50
Inj 50 mg per ml, 2 ml ampoule	4.50	5	Tramal 100
Antidepressants			
Cyclic and Related Agents			
AMITRIPTYLINE			
Tab 10 mg – 1% DV Jan-13 to 2014	3.32	100	Arrow-Amitriptyline
Tab 25 mg – 1% DV Jun-11 to 2014	1.85	100	Amitrip
Tab 50 mg – 1% DV Jun-11 to 2014	3.60	100	Amitrip
CLOMIPRAMINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Jan-13 to 2015	12.60	100	Apo-Clomipramine
Tab 25 mg – 1% DV Jan-13 to 2015	8.68	100	Apo-Clomipramine
DOTHIEPIN HYDROCHLORIDE			
Tab 75 mg	10.50	100	Dopress
Cap 25 mg	6.17	100	Dopress
DOXEPIN HYDROCHLORIDE			
Cap 10 mg			
Cap 25 mg			
Cap 50 mg			
IMIPRAMINE HYDROCHLORIDE			
Tab 10 mg	5.48	50	Tofranil
	6.58	60	Tofranil
Tab 25 mg	8.80	50	Tofranil
MAPROTYLINE HYDROCHLORIDE			
Tab 25 mg			
Tab 75 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MIANSERIN HYDROCHLORIDE Tab 30 mg			
NORTRIPTYLINE HYDROCHLORIDE Tab 10 mg – 1% DV Jun-13 to 2016	4.00	100	Norpress
Tab 25 mg – 1% DV Jun-13 to 2016	9.00	180	Norpress

Monoamine-Oxidase Inhibitors - Non-Selective

PHENELZINE SULPHATE Tab 15 mg			
TRANYLCYPROMINE SULPHATE Tab 10 mg			

Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE Tab 150 mg – 1% DV Apr-13 to 2015	81.83	500	Apo-Moclobemide
Tab 300 mg – 1% DV Apr-13 to 2015	29.51	100	Apo-Moclobemide

Other Antidepressants

MIRTAZAPINE – Restricted see terms below			
⚡ Tab 30 mg – 1% DV Sep-12 to 2015	8.78	30	Avanza
⚡ Tab 45 mg – 1% DV Sep-12 to 2015	13.95	30	Avanza

➡Restricted

Initiation

Re-assessment required after two years

Both:

- 1 The patient has a severe major depressive episode; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Continuation

Re-assessment required after two years

The patient has a high risk of relapse (prescriber determined)

VENLAFAXINE – Some items restricted see terms on the next page			
Tab modified release 37.5 mg	5.06	28	Arrow-Venlafaxine XR
Tab modified release 75 mg	6.44	28	Arrow-Venlafaxine XR
Tab modified release 150 mg	8.86	28	Arrow-Venlafaxine XR
Tab modified release 225 mg	14.34	28	Arrow-Venlafaxine XR
⚡ Cap modified release 37.5 mg	8.71	28	Efexor XR
⚡ Cap modified release 75 mg	17.42	28	Efexor XR
⚡ Cap modified release 150 mg	21.35	28	Efexor XR

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Initiation

Re-assessment required after two years

- Both:
- 1 The patient has 'treatment-resistant' depression; and
 - 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and,
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Continuation

Re-assessment required after two years

The patient has a high risk of relapse (prescriber determined)

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE			
Tab 20 mg – 1% DV Sep-11 to 2014	2.34	84	Arrow-Citalopram
ESCITALOPRAM			
Tab 10 mg	2.65	28	Loxalate
Tab 20 mg	4.20	28	Loxalate
FLUOXETINE HYDROCHLORIDE			
Tab dispersible 20 mg, scored	2.50	30	Fluox
Cap 20 mg	2.70	84	Fluox
PAROXETINE HYDROCHLORIDE			
Tab 20 mg	4.32	90	Loxamine
SERTRALINE			
Tab 50 mg – 1% DV Sep-13 to 2016	3.64	90	Arrow-Sertraline
Tab 100 mg – 1% DV Sep-13 to 2016	6.28	90	Arrow-Sertraline

Antiepilepsy Drugs

Agents for the Control of Status Epilepticus

CLONAZEPAM			
Inj 1 mg per ml, 1 ml ampoule	19.00	5	Rivotril
DIAZEPAM			
Inj 5 mg per ml, 2 ml ampoule	9.24	5	Mayne
Rectal tubes 5 mg	25.05	5	Stesolid
Rectal tubes 10 mg	30.50	5	Stesolid
LORAZEPAM			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
PARALDEHYDE			
Inj 5 ml ampoule			
PHENYTOIN SODIUM			
Inj 50 mg per ml, 2 ml ampoule			
Inj 50 mg per ml, 5 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Control of Epilepsy			
CARBAMAZEPINE			
Tab 200 mg			
Tab long-acting 200 mg			
Tab 400 mg			
Tab long-acting 400 mg			
Oral liq 20 mg per ml			
CLOBAZAM			
Tab 10 mg			
CLONAZEPAM			
Oral drops 2.5 mg per ml			
ETHOSUXIMIDE			
Cap 250 mg			
Oral liq 50 mg per ml			
GABAPENTIN – Restricted see terms below			
⚡ Tab 600 mg			
⚡ Cap 100 mg	7.16	100	Arrow-Gabapentin Nupentin
⚡ Cap 300 mg	11.00	100	Arrow-Gabapentin Nupentin
⚡ Cap 400 mg	13.75	100	Arrow-Gabapentin Nupentin
	14.75		

➡ **Restricted**

- 1 For preoperative and/or postoperative use for up to a total of 8 days' use; or
- 2 For the pain management of burns patients with monthly review.

Initiation - epilepsy

Re-assessment required after 15 months

- Either:
- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Continuation - epilepsy

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Initiation - neuropathic pain

Re-assessment required after 3 months

Patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Continuation - neuropathic pain

- Either:
- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
 - 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LACOSAMIDE – Restricted see terms below			
⚡ Tab 50 mg	25.04	14	Vimpat
⚡ Tab 100 mg	50.06	14	Vimpat
	200.24	56	Vimpat
⚡ Tab 150 mg	75.10	14	Vimpat
	300.40	56	Vimpat
⚡ Tab 200 mg	400.55	56	Vimpat
⚡ Inj 10 mg per ml, 20 ml vial			
➔ Restricted			
Initiation			
<i>Re-assessment required after 15 months</i>			
Both:			
1 Patient has partial-onset epilepsy; and			
2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).			
Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.			
Continuation			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).			
Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.			
LAMOTRIGINE			
Tab dispersible 2 mg	6.74	30	Lamictal
Tab dispersible 5 mg	9.64	30	Lamictal
	15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg	19.38	56	Logem
	20.40		Arrow-Lamotrigine
	29.09		Mogine
Tab dispersible 50 mg	32.97	56	Lamictal
	34.70		Logem
			Arrow-Lamotrigine
			Mogine
	47.89		Lamictal
Tab dispersible 100 mg	56.91	56	Logem
	59.90		Arrow-Lamotrigine
			Mogine
	79.16		Lamictal
LEVETIRACETAM			
Tab 250 mg	24.03	60	Levetiracetam-Rex
Tab 500 mg	28.71	60	Levetiracetam-Rex
Tab 750 mg	45.23	60	Levetiracetam-Rex
Inj 100 mg per ml, 5 ml vial			
PHENOBARBITONE			
Tab 15 mg – 1% DV Mar-13 to 2015	28.00	500	PSM
Tab 30 mg – 1% DV Mar-13 to 2015	29.00	500	PSM

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PHENYTOIN			
Tab 50 mg			
PHENYTOIN SODIUM			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			
PRIMIDONE			
Tab 250 mg			
SODIUM VALPROATE			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial			
STIRIPENTOL – Restricted see terms below			
☒ Cap 250 mg	509.29	60	Diacomit
☒ Powder for oral liq 250 mg sachet	509.29	60	Diacomit
☛Restricted			
Paediatric neurologist			
Initiation			
<i>Re-assessment required after 6 months</i>			
Both:			
1 Patient has confirmed diagnosis of Dravet syndrome; and			
2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.			
Continuation			
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.			
TOPIRAMATE			
Tab 25 mg	11.07	60	Arrow-Topiramate
	26.04		Topamax
Tab 50 mg	18.81	60	Arrow-Topiramate
	44.26		Topamax
Tab 100 mg	31.99	60	Arrow-Topiramate
	75.25		Topamax
Tab 200 mg	55.19	60	Arrow-Topiramate
	129.85		Topamax
Cap sprinkle 15 mg	20.84	60	Topamax
Cap sprinkle 25 mg	26.04	60	Topamax
VIGABATRIN – Restricted see terms below			
☒ Tab 500 mg			
☛Restricted			
Both:			
1 Either:			
1.1 Patient has infantile spasms; or			
1.2 Both:			
1.2.1 Patient has epilepsy; and			
1.2.2 Either:			
1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes:

"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE

Inj 1 mg per ml, 1 ml ampoule

ERGOTAMINE TARTRATE WITH CAFFEINE

Tab 1 mg with caffeine 100 mg

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL

Tab 5 mg with paracetamol 500 mg

RIZATRIPTAN BENZOATE

Tab orodispersible 10 mg – 1% DV May-12 to 2014 18.00 30 **Rizamelt**

SUMATRIPTAN

Tab 50 mg – 1% DV Sep-13 to 2016 29.80 100 **Arrow-Sumatriptan**

Tab 100 mg – 1% DV Sep-13 to 2016 54.80 100 **Arrow-Sumatriptan**

Inj 12 mg per ml, 0.5 ml cartridge – 1% DV Sep-13 to 2016 13.80 2 **Arrow-Sumatriptan**

Prophylaxis of Migraine

PIZOTIFEN

Tab 500 mcg – 1% DV Mar-13 to 2015 23.21 100 **Sandomigran**

Antinausea and Vertigo Agents

APREPITANT – **Restricted** see terms below

⚡ Cap 2 × 80 mg and 1 × 125 mg 116.00 3 **Emend Tri-Pack**

➔ **Restricted**

Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE

Tab 16 mg 10.00 84 **Vergo 16**

CYCLIZINE HYDROCHLORIDE

Tab 50 mg – 1% DV Sep-12 to 2015 0.59 10 **Nausicalm**

CYCLIZINE LACTATE

Inj 50 mg per ml, 1 ml ampoule 14.95 5 **Nausicalm**

DOMPERIDONE

Tab 10 mg – 1% DV Mar-13 to 2015 3.25 100 **Prokinex**

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DROPERIDOL			
Inj 2.5 mg per ml, 1 ml ampoule			
HYOSCINE HYDROBROMIDE			
Inj 400 mcg per ml, 1 ml ampoule	6.66	5	Mayne
‡ Patch 1.5 mg – 1% DV Dec-13 to 2016	11.95	2	Scopoderm TTS
➔ Restricted			
Any of the following:			
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or			
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or			
3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.			
METOCLOPRAMIDE HYDROCHLORIDE			
Tab 10 mg – 1% DV Jun-11 to 2014	3.95	100	Metamide
Oral liq 5 mg per 5 ml			
Inj 5 mg per ml, 2 ml ampoule – 1% DV Sep-11 to 2014	4.50	10	Pfizer
ONDANSETRON			
Tab 4 mg – 1% DV Jan-14 to 2016	5.51	50	Onrex
Tab dispersible 4 mg	17.18	10	Dr Reddy's Ondansetron Zofran Zydys
Tab 8 mg – 1% DV Jan-14 to 2016	6.19	50	Onrex
Tab dispersible 8 mg	2.00	10	Dr Reddy's Ondansetron
Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016	1.82	5	Ondanaccord
Inj 2 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016	2.18	5	Ondanaccord
PROCHLORPERAZINE			
Tab buccal 3 mg			
Tab 5 mg	16.85	500	Antinaus
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			
PROMETHAZINE THEOCLATE – Restricted: For continuation only			
➔ Tab 25 mg			
TROPISETRON			
Cap 5 mg	77.41	5	Navoban
Inj 1 mg per ml, 2 ml ampoule	19.20	1	Navoban
Inj 1 mg per ml, 5 ml ampoule	38.40	1	Navoban

Antipsychotic Agents

General

AMISULPRIDE			
Tab 100 mg – 1% DV Jul-13 to 2016	6.22	30	Solian
Tab 200 mg – 1% DV Jul-13 to 2016	21.92	60	Solian
Tab 400 mg – 1% DV Jul-13 to 2016	44.52	60	Solian
Oral liq 100 mg per ml – 1% DV Jul-13 to 2016	52.50	60 ml	Solian

‡ Item restricted (see ➔ above); † Item restricted (see ➔ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ARIPIPIRAZOLE – Restricted see terms below			
⚡ Tab 10 mg	123.54	30	Abilify
⚡ Tab 15 mg	175.28	30	Abilify
⚡ Tab 20 mg	213.42	30	Abilify
⚡ Tab 30 mg	260.07	30	Abilify
➔ Restricted			
Both:			
1 Patient is suffering from schizophrenia or related psychoses; and			
2 Either:			
2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or			
2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.			
CHLORPROMAZINE HYDROCHLORIDE			
Tab 10 mg			
Tab 25 mg			
Tab 100 mg			
Oral liq 10 mg per ml			
Inj 25 mg per ml, 2 ml ampoule			
CLOZAPINE			
Tab 25 mg	13.37	50	Clozaril
	26.74	100	Clozaril
	6.69	50	Clopine
	13.37	100	Clopine
Tab 50 mg	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg	17.33	50	Clopine
	34.65	100	Clopine
		50	Clozaril
	69.30	100	Clozaril
Tab 200 mg	34.65	50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml	17.33	100 ml	Clopine
HALOPERIDOL			
Tab 500 mcg – 1% DV Oct-13 to 2016	6.23	100	Serenace
Tab 1.5 mg – 1% DV Oct-13 to 2016	9.43	100	Serenace
Tab 5 mg – 1% DV Oct-13 to 2016	29.72	100	Serenace
Oral liq 2 mg per ml – 1% DV Oct-13 to 2016	23.84	100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-13 to 2016	21.55	10	Serenace
LEVOMEPRMAZINE			
Tab 25 mg			
Tab 100 mg			
Inj 25 mg per ml, 1 ml ampoule			
LITHIUM CARBONATE			
Tab long-acting 400 mg			
Tab 250 mg – 1% DV Sep-12 to 2015	34.30	500	Lithicarb FC
Tab 400 mg – 1% DV Sep-12 to 2015	12.83	100	Lithicarb FC
Cap 250 mg – 1% DV Nov-11 to 2014	9.42	100	Douglas

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OLANZAPINE			
Tab 2.5 mg	2.00	28	Olanzine Zypine
Tab 5 mg	3.85	28	Olanzine Zypine
Tab orodispersible 5 mg	6.36	28	Olanzine-D Zypine ODT
Tab 10 mg	6.35	28	Olanzine Zypine
Tab orodispersible 10 mg	8.76	28	Olanzine-D Zypine ODT
Inj 10 mg vial			
PERICYAZINE			
Tab 2.5 mg			
Tab 10 mg			
QUETIAPINE			
Tab 25 mg	7.00	60	Dr Reddy's Quetiapine Seroquel
	10.50	90	Quetapel
Tab 100 mg	14.00	60	Seroquel
	21.00	90	Dr Reddy's Quetiapine Quetapel
Tab 200 mg	24.00	60	Dr Reddy's Quetiapine Seroquel
	36.00	90	Quetapel
Tab 300 mg	40.00	60	Dr Reddy's Quetiapine Seroquel
	60.00	90	Quetapel

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
RISPERIDONE – Some items restricted see terms below			
Tab 0.5 mg	2.86	20	Risperdal
	3.51	60	Apo-Risperidone Dr Reddy's Risperidone
¶ Tab orodispersible 0.5 mg	21.42	28	Risperdal Quicklet
Tab 1 mg	6.00	60	Apo-Risperidone Dr Reddy's Risperidone
	16.92		Ridal
¶ Tab orodispersible 1 mg	42.84	28	Risperdal
Tab 2 mg	11.00	60	Risperdal Quicklet Apo-Risperidone Dr Reddy's Risperidone
	33.84		Ridal
¶ Tab orodispersible 2 mg	85.71	28	Risperdal
Tab 3 mg	15.00	60	Risperdal Quicklet Apo-Risperidone Dr Reddy's Risperidone
	50.78		Ridal
Tab 4 mg	20.00	60	Risperdal Apo-Risperidone Dr Reddy's Risperidone
	67.68		Ridal
Oral liq 1 mg per ml	18.35	30 ml	Risperdal Apo-Risperidone Risperon
	25.26		Risperdal

↔ Restricted

Acute situations

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Chronic situations

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

TRIFLUOPERAZINE HYDROCHLORIDE

- Tab 1 mg
- Tab 2 mg
- Tab 5 mg

ZIPRASIDONE – Some items restricted see terms on the next page

¶ Cap 20 mg	87.88	60	Zeldox
¶ Cap 40 mg	164.78	60	Zeldox
¶ Cap 60 mg	247.17	60	Zeldox
¶ Cap 80 mg	329.56	60	Zeldox
Inj 20 mg			
Inj 100 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

ZUCLOPENTHIXOL ACETATE

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

ZUCLOPENTHIXOL HYDROCHLORIDE

Tab 10 mg	31.45	100	Clopixol
-----------------	-------	-----	----------

Depot Injections

FLUPENTHIXOL DECANOATE

Inj 20 mg per ml, 1 ml ampoule	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule	20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule	40.87	5	Fluanxol

FLUPHENAZINE DECANOATE

Inj 12.5 mg per 0.5 ml ampoule	17.60	5	Modecate
Inj 25 mg per ml, 1 ml ampoule	27.90	5	Modecate
Inj 100 mg per ml, 1 ml ampoule	154.50	5	Modecate

HALOPERIDOL DECANOATE

Inj 50 mg per ml, 1 ml ampoule	28.39	5	Haldol
Inj 100 mg per ml, 1 ml ampoule	55.90	5	Haldol Concentrate

OLANZAPINE – **Restricted** see terms below

⚡ Inj 210 mg vial	280.00	1	Zyprexa Relprevv
⚡ Inj 300 mg vial	460.00	1	Zyprexa Relprevv
⚡ Inj 405 mg vial	560.00	1	Zyprexa Relprevv

➔ **Restricted**

Initiation

Re-assessment required after 12 months

All of the following:

- 1 The patient has schizophrenia; and
- 2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

Either:

- 1 The patient has had less than 12 months' treatment with olanzapine depot injection and there is no clinical reason to discontinue treatment; or
- 2 The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of olanzapine depot injection.

PIPOTHIAZINE PALMITATE

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
RISPERIDONE – Restricted see terms below			
⚡ Inj 25 mg vial	175.00	1	Risperdal Consta
⚡ Inj 37.5 mg vial	230.00	1	Risperdal Consta
⚡ Inj 50 mg vial	280.00	1	Risperdal Consta

➔ **Restricted**

Initiation

Re-assessment required after 6 months

All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

Either:

- 1 The patient has had less than 12 months' treatment with risperidone depot injection and there is no clinical reason to discontinue treatment; or
- 2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml ampoule	19.80	5	Clopixol
---------------------------------------	-------	---	----------

Anxiolytics

ALPRAZOLAM

Tab 1 mg			
Tab 250 mcg			
Tab 500 mcg			

BUSPIRONE HYDROCHLORIDE

Tab 5 mg	28.00	100	Pacific Buspirone
Tab 10 mg	17.00	100	Pacific Buspirone

CLONAZEPAM

Tab 500 mcg	6.68	100	Paxam
Tab 2 mg	12.75	100	Paxam

DIAZEPAM

Tab 2 mg	11.44	500	Arrow-Diazepam
Tab 5 mg	13.71	500	Arrow-Diazepam

LORAZEPAM

Tab 1 mg	19.82	250	Ativan
Tab 2.5 mg	13.49	100	Ativan

OXAZEPAM

Tab 10 mg			
Tab 15 mg			

Multiple Sclerosis Treatments

GLATIRAMER ACETATE – Restricted see terms below

⚡ Inj 20 mg per ml, 1 ml syringe

➔ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessments Committee

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

INTERFERON BETA-1-ALPHA – **Restricted** see terms below

- ⚡ Inj 6 million iu in 0.5 ml pen
- ⚡ Inj 6 million iu in 0.5 ml syringe
- ⚡ Inj 6 million iu vial

➡ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessments Committee

INTERFERON BETA-1-BETA – **Restricted** see terms below

- ⚡ Inj 8 million iu per ml, 1 ml vial

➡ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessments Committee

Sedatives and Hypnotics

CHLORAL HYDRATE

- Oral liq 100 mg per ml
- Oral liq 200 mg per ml

LORMETAZEPAM – **Restricted**: For continuation only

- ➡ Tab 1 mg

MELATONIN – **Restricted** see terms below

- ⚡ Tab modified-release 2 mg
- ⚡ Tab 1 mg
- ⚡ Tab 2 mg
- ⚡ Tab 3 mg
- ⚡ Cap 2 mg
- ⚡ Cap 3 mg

e.g. Circadin

➡ **Restricted**

For in hospital use only. For the treatment of insomnia where benzodiazepines and zopiclone are contraindicated.

MIDAZOLAM

Tab 7.5 mg	40.00	100	Hypnovel
Oral liq 2 mg per ml			
Inj 1 mg per ml, 5 ml ampoule	10.00	10	Pfizer
	10.75		Hypnovel
Inj 5 mg per ml, 3 ml ampoule	11.90	5	Hypnovel Pfizer

NITRAZEPAM

- Tab 5 mg

PHENOBARBITONE

- Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM

Tab 10 mg – 1% DV Nov-11 to 2014	1.27	25	Normison
--	------	----	-----------------

TRIAZOLAM – **Restricted**: For continuation only

- ➡ Tab 125 mcg
- ➡ Tab 250 mcg

ZOPICLONE

Tab 7.5 mg – 1% DV Jan-12 to 2014	1.90	30	Apo-Zopiclone
---	------	----	----------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Stimulants / ADHD Treatments

ATOMOXETINE – **Restricted** see terms below

⚡ Cap 10 mg	107.03	28	Strattera
⚡ Cap 18 mg	107.03	28	Strattera
⚡ Cap 25 mg	107.03	28	Strattera
⚡ Cap 40 mg	107.03	28	Strattera
⚡ Cap 60 mg	107.03	28	Strattera
⚡ Cap 80 mg	139.11	28	Strattera
⚡ Cap 100 mg	139.11	28	Strattera

➔ **Restricted**

All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

CAFFEINE

Tab 100 mg

DEXAMPHETAMINE SULPHATE – **Restricted** see terms below

⚡ Tab 5 mg – 1% DV Mar-13 to 2015	16.50	100	PSM
---	-------	-----	------------

➔ **Restricted**

ADHD

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

Narcolepsy

Neurologist or respiratory specialist

Patient suffers from narcolepsy

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METHYLPHENIDATE HYDROCHLORIDE – Restricted see terms below			
⚡ Tab extended-release 18 mg	58.96	30	Concerta
⚡ Tab extended-release 27 mg	65.44	30	Concerta
⚡ Tab extended-release 36 mg	71.93	30	Concerta
⚡ Tab extended-release 54 mg	86.24	30	Concerta
⚡ Tab immediate-release 5 mg	3.20	30	Rubifen
⚡ Tab immediate-release 10 mg	3.00	30	Ritalin
			Rubifen
⚡ Tab immediate-release 20 mg	7.85	30	Rubifen
⚡ Tab sustained-release 20 mg	10.95	30	Rubifen SR
	50.00	100	Ritalin SR
⚡ Cap modified-release 10 mg	19.50	30	Ritalin LA
⚡ Cap modified-release 20 mg	25.50	30	Ritalin LA
⚡ Cap modified-release 30 mg	31.90	30	Ritalin LA
⚡ Cap modified-release 40 mg	38.25	30	Ritalin LA

➡ Restricted

ADHD (immediate-release and sustained-release formulations)

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

Patient suffers from narcolepsy

Extended-release and modified-release formulations

Paediatrician or psychiatrist

Both:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Either:
 - 2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

MODAFINIL – Restricted

 see terms below

⚡ Tab 100 mg

➡ Restricted

Neurologist or respiratory specialist

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
 - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
 - 3.2 Methylphenidate and dexamphetamine are contraindicated.

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Treatments for Dementia			
DONEPEZIL HYDROCHLORIDE			
Tab 5 mg	7.71	90	Donepezil-Rex
Tab 10 mg	14.06	90	Donepezil-Rex
Treatments for Substance Dependence			
BUPRENORPHINE WITH NALOXONE – Restricted see terms below			
⚡ Tab 2 mg with naloxone 0.5 mg	57.40	28	Suboxone
⚡ Tab 8 mg with naloxone 2 mg	166.00	28	Suboxone
➔ Restricted			
Detoxification			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and			
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
Maintenance treatment			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient will not be receiving methadone; and			
3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and			
4 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
BUPROPION HYDROCHLORIDE			
Tab modified-release 150 mg – 1% DV Oct-13 to 2016.....	4.97	30	Zyban
DISULFIRAM			
Tab 200 mg	24.30	100	Antabuse
NALTREXONE HYDROCHLORIDE – Restricted see terms below			
⚡ Tab 50 mg – 1% DV Sep-13 to 2016	76.00	30	Naltraccord
➔ Restricted			
Alcohol dependence			
Both:			
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and			
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.			
Constipation			
For the treatment of opioid-induced constipation			
NICOTINE – Some items restricted see terms on the next page			
Gum 2 mg – 5% DV Oct-11 to 2014.....	36.47	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
Gum 4 mg – 5% DV Oct-11 to 2014.....	42.04	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
Patch 7 mg per 24 hours – 5% DV Jul-11 to 2014	18.13	28	Habitrol
Patch 14 mg per 24 hours – 5% DV Jul-11 to 2014	18.81	28	Habitrol
Patch 21 mg per 24 hours – 5% DV Jul-11 to 2014	19.14	28	Habitrol
Lozenge 1 mg – 5% DV Jul-11 to 2014.....	19.94	216	Habitrol
Lozenge 2 mg – 5% DV Jul-11 to 2014.....	24.27	216	Habitrol
⚡ Soln for inhalation 15 mg cartridge			<i>e.g. Nicorette Inhalator</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Any of the following:

- 1 For perioperative use in patients who have a 'nil by mouth' instruction; or
- 2 For use within mental health inpatient units; or
- 3 For acute use in agitated patients who are unable to leave the hospital facilities.

VARENICLINE – **Restricted** see terms below

☞ Tab 0.5 mg × 11 and 1 mg × 14	60.48	25	Champix
☞ Tab 1 mg	67.74	28	Champix
	135.48	56	Champix

➔ **Restricted**

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline in a 12 month period.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Chemotherapeutic Agents			
Alkylating Agents			
BUSULFAN			
Tab 2 mg	59.50	100	Myleran
Inj 6 mg per ml, 10 ml ampoule			
CARMUSTINE			
Inj 100 mg vial			
CHLORAMBUCIL			
Tab 2 mg			
CYCLOPHOSPHAMIDE			
Tab 50 mg	158.00	100	Procytox
Inj 1 g vial – 1% DV Nov-11 to 2014.....	26.70	1	Endoxan
Inj 2 g vial – 1% DV Nov-11 to 2014.....	56.90	1	Endoxan
IFOSFAMIDE			
Inj 1 g vial	96.00	1	Holoxan
Inj 2 g vial	180.00	1	Holoxan
LOMUSTINE			
Cap 10 mg – 1% DV Sep-11 to 2014.....	132.59	20	Ceenu
Cap 40 mg – 1% DV Sep-11 to 2014.....	399.15	20	Ceenu
MELPHALAN			
Tab 2 mg			
Inj 50 mg vial			
THIOTEPA			
Inj 15 mg vial			
Anthracyclines and Other Cytotoxic Antibiotics			
BLEOMYCIN SULPHATE			
Inj 15,000 iu (10 mg) vial			
DACTINOMYCIN [ACTINOMYCIN D]			
Inj 0.5 mg vial			
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial – 1% DV Aug-13 to 2016.....	118.72	1	Pfizer
DOXORUBICIN HYDROCHLORIDE			
Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial – 1% DV Mar-13 to 2015.....	17.00	1	Arrow-Doxorubicin
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial			
Inj 2 mg per ml, 100 ml vial – 1% DV Mar-13 to 2015.....	65.00	1	Arrow-Doxorubicin

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
EPIRUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial – 1% DV Aug-12 to 2015	39.38	1	DBL Epirubicin Hydrochloride
Inj 2 mg per ml, 50 ml vial – 1% DV Aug-12 to 2015	58.20	1	DBL Epirubicin Hydrochloride
Inj 2 mg per ml, 100 ml vial – 1% DV Aug-12 to 2015	94.50	1	DBL Epirubicin Hydrochloride
IDARUBICIN HYDROCHLORIDE			
Cap 5 mg	115.00	1	Zavedos
Cap 10 mg	144.50	1	Zavedos
Inj 5 mg vial – 1% DV Sep-12 to 2015	100.00	1	Zavedos
Inj 10 mg vial – 1% DV Sep-12 to 2015	200.00	1	Zavedos
MITOMYCIN C			
Inj 5 mg vial – 1% DV Oct-13 to 2016	79.75	1	Arrow
MITOZANTRONE			
Inj 2 mg per ml, 5 ml vial	110.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml vial	100.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml vial	407.50	1	Onkotrone
Antimetabolites			
CAPECITABINE			
Tab 150 mg	115.00	60	Xeloda
Tab 500 mg	705.00	120	Xeloda
CLADRIBINE			
Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial	5,249.72	7	Leustatin
CYTARABINE			
Inj 20 mg per ml, 5 ml vial – 1% DV Nov-13 to 2016	55.00	5	Pfizer
Inj 20 mg per ml, 25 ml vial	18.15	1	Pfizer
Inj 100 mg per ml, 10 ml vial – 1% DV Nov-13 to 2016	8.83	1	Pfizer
Inj 100 mg per ml, 20 ml vial – 1% DV Nov-13 to 2016	17.65	1	Pfizer
FLUDARABINE PHOSPHATE			
Tab 10 mg – 1% DV Jun-12 to 2015	433.50	20	Fludara Oral
Inj 50 mg vial – 1% DV Sep-11 to 2014	525.00	5	Fludarabine Ebewe
FLUOROURACIL			
Inj 25 mg per ml, 100 ml vial	13.55	1	Mayne
Inj 50 mg per ml, 10 ml vial	26.25	5	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml vial	7.50	1	Fluorouracil Ebewe
Inj 50 mg per ml, 50 ml vial	18.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial	34.50	1	Fluorouracil Ebewe
GEMCITABINE			
Inj 10 mg per ml, 100 ml vial	62.50	1	Gemcitabine Ebewe
Inj 10 mg per ml, 20 ml vial	12.50	1	Gemcitabine Ebewe
Inj 200 mg vial	12.50	1	Gemcitabine Actavis 200
Inj 1 g vial	62.50	1	DBL Gemcitabine Gemcitabine Actavis 1000

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MERCAPTOPYRINE			
Tab 50 mg – 1% DV Oct-13 to 2016	49.41	25	Puri-nethol
METHOTREXATE			
Tab 2.5 mg	5.22	30	Methoblastin
Tab 10 mg	40.93	50	Methoblastin
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe – 1% DV Jan-14 to 2016.....	17.19	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe – 1% DV Jan-14 to 2016.....	17.25	1	Methotrexate Sandoz
Inj 15 mg prefilled syringe – 1% DV Jan-14 to 2016.....	17.38	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe – 1% DV Jan-14 to 2016.....	17.50	1	Methotrexate Sandoz
Inj 25 mg prefilled syringe – 1% DV Jan-14 to 2016.....	17.63	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe – 1% DV Jan-14 to 2016.....	17.75	1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016	20.20	5	Hospira
Inj 25 mg per ml, 20 ml vial – 1% DV Sep-13 to 2016	27.78	1	Hospira
Inj 100 mg per ml, 10 ml vial – 1% DV Nov-08 to 2014	25.00	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 1% DV Nov-08 to 2014	125.00	1	Methotrexate Ebewe
THIOGUANINE			
Tab 40 mg			

Other Cytotoxic Agents

AMSACRINE

Inj 50 mg per ml, 1.5 ml ampoule

ANAGRELIDE HYDROCHLORIDE

Cap 0.5 mg

ARSENIC TRIOXIDE

Inj 1 mg per ml, 10 ml vial 4,817.00 10 AFT

BORTEZOMIB – Restricted see terms below

¶ Inj 1 mg vial 540.70 1 Velcade

¶ Inj 3.5 mg vial 1,892.50 1 Velcade

↪ Restricted

Initiation - treatment naive multiple myeloma/amyloidosis

Both:

- 1 Either:
 - 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
 - 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initiation - relapsed/refractory multiple myeloma/amyloidosis

All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Continuation - relapsed/refractory multiple myeloma/amyloidosis

Both:

continued...

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and			
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).			
Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:			
1 A known therapeutic chemotherapy regimen and supportive treatments; or			
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.			
Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.			
COLASPASE [L-ASPARAGINASE]			
Inj 10,000 iu vial	102.32	1	Leunase
DACARBAZINE			
Inj 200 mg vial – 1% DV Oct-13 to 2016	51.84	1	Hospira
ETOPOSIDE			
Cap 50 mg	340.73	20	Vepesid
Cap 100 mg	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial	25.00	1	Mayne
ETOPOSIDE (AS PHOSPHATE)			
Inj 100 mg vial – 1% DV Sep-11 to 2014	40.00	1	Etopophos
HYDROXYUREA			
Cap 500 mg	31.76	100	Hydrea
IRINOTECAN HYDROCHLORIDE			
Inj 20 mg per ml, 2 ml vial – 1% DV Nov-12 to 2015	9.34	1	Irinotecan Actavis 40
Inj 20 mg per ml, 5 ml vial – 1% DV Nov-12 to 2015	23.34	1	Irinotecan Actavis 100
PEGASPARGASE – Restricted see terms below			
⚡ Inj 750 iu per ml, 5 ml vial	3,005.00	1	Oncaspar
↪ Restricted			
Newly diagnosed ALL			
<i>Limited to 12 months' treatment</i>			
All of the following:			
1 The patient has newly diagnosed acute lymphoblastic leukaemia; and			
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and			
3 Treatment is with curative intent.			
Relapsed ALL			
<i>Limited to 12 months' treatment</i>			
All of the following:			
1 The patient has relapsed acute lymphoblastic leukaemia; and			
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and			
3 Treatment is with curative intent.			
PENTOSTATIN [DEOXYCOFORMYCIN]			
Inj 10 mg vial			
PROCARBAZINE HYDROCHLORIDE			
Cap 50 mg	225.00	50	Natulan
TEMOZOLOMIDE – Restricted see terms on the next page			
⚡ Cap 5 mg – 1% DV Sep-13 to 2016	8.00	5	Temaccord
⚡ Cap 20 mg – 1% DV Sep-13 to 2016	36.00	5	Temaccord
⚡ Cap 100 mg – 1% DV Sep-13 to 2016	175.00	5	Temaccord
⚡ Cap 250 mg – 1% DV Sep-13 to 2016	410.00	5	Temaccord

↑ Item restricted (see ↪ above); ⚡ Item restricted (see ↪ below)

124 e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE – **Restricted** see terms below

⚡ Cap 50 mg	504.00	28	Thalomid
⚡ Cap 100 mg	1,008.00	28	Thalomid

➔ **Restricted**

Initiation

Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*; or
- 3 The patient has erythema nodosum leprosum.

Continuation

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication

TRETINOIN

Cap 10 mg	435.90	100	Vesanoid
-----------------	--------	-----	----------

Platinum Compounds

CARBOPLATIN

Inj 10 mg per ml, 5 ml vial	20.00	1	Carboplatin Ebewe
Inj 10 mg per ml, 15 ml vial – 1% DV Jan-13 to 2015	19.50	1	Carbaccord
Inj 10 mg per ml, 45 ml vial – 1% DV Jan-13 to 2015	48.50	1	Carbaccord
Inj 10 mg per ml, 100 ml vial	105.00	1	Carboplatin Ebewe

CISPLATIN

Inj 1 mg per ml, 50 ml vial	15.00	1	Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial	21.00	1	Cisplatin Ebewe

OXALIPLATIN

Inj 50 mg vial – 1% DV Aug-12 to 2015	15.32	1	Oxaliplatin Actavis 50
Inj 100 mg vial – 1% DV Aug-12 to 2015	25.01	1	Oxaliplatin Actavis 100

Protein-Tyrosine Kinase Inhibitors

DASATINIB – **Restricted** see terms below

⚡ Tab 20 mg	3,774.06	60	Sprycel
⚡ Tab 50 mg	6,214.20	60	Sprycel
⚡ Tab 70 mg	7,692.58	60	Sprycel
⚡ Tab 100 mg	6,214.20	30	Sprycel

➔ **Restricted**

For use in patients with approval from the CML/GIST Co-ordinator

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ERLOTINIB – Restricted see terms below			
☒ Tab 100 mg	1,133.00	30	Tarceva
☒ Tab 150 mg	1,700.00	30	Tarceva

☛**Restricted**

Initiation

Re-assessment required after 3 months

- Either:
- 1 All of the following:
 - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Either:
 - 1.3.1 Patient is treatment naive; or
 - 1.3.2 Both:
 - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
 - 1.3.2.2 Patient has not received prior treatment with gefitinib; and
 - 1.4 Erlotinib is to be given for a maximum of 3 months, or
 - 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Continuation

Re-assessment required after 6 months

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – Restricted see terms below

☒ Tab 250 mg	1,700.00	30	Iressa
--------------------	----------	----	--------

☛**Restricted**

Initiation

Re-assessment required after 3 months

- Both
- 1 Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 2 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase.

Continuation

Re-assessment required after 6 months

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

LAPATINIB – Restricted see terms below

☒ Tab 250 mg	1,899.00	70	Tykerb
--------------------	----------	----	--------

☛**Restricted**

Initiation

Re-assessment required after 12 months

- Either:
- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
 - 2 All of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
- 2.3 The cancer did not progress whilst on trastuzumab; and
- 2.4 Lapatinib not to be given in combination with trastuzumab; and
- 2.5 Lapatinib to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

PAZOPANIB – **Restricted** see terms below

⚡ Tab 200 mg	1,334.70	30	Votrient
⚡ Tab 400 mg	2,669.40	30	Votrient

⚡ **Restricted**

Initiation

Re-assessment required after 3 months

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of ≤ 70; or
 - 5.6 ≥ 2 sites of organ metastasis.

Continuation

Re-assessment required after 3 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – **Restricted** see terms on the next page

⚡ Cap 12.5 mg	2,315.38	28	Sutent
⚡ Cap 25 mg	4,630.77	28	Sutent
⚡ Cap 50 mg	9,261.54	28	Sutent

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ Restricted

Re-assessment required after 3 months

Initiation - RCC

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Continuation - RCC

Re-assessment required after 3 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Initiation - GIST

Re-assessment required after 3 months

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation - GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of \geq 10% or decrease in tumour density in Hounsfield Units (HU) of \geq 15% on CT and no new lesions and no obvious progression of non-measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued..

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of ≥ 10% and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

IMATINIB MESILATE – **Restricted** see terms below

⚡ Tab 100 mg	2,400.00	60	Glivec
--------------------	----------	----	--------

→**Restricted**

For use in patients with approval from the CML/GIST Co-ordinator

Taxanes

DOCETAXEL

Inj 10 mg per ml, 2 ml vial – 1% DV May-13 to 2014	48.75	1	Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial – 1% DV May-13 to 2014	195.00	1	Docetaxel Sandoz

PACLITAXEL

Inj 6 mg per ml, 5 ml vial – 1% DV Oct-08 to 2014	137.50	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-08 to 2014	91.67	1	Paclitaxel Actavis Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial – 1% DV Oct-08 to 2014	137.50	1	Anzatax Paclitaxel Actavis Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial – 1% DV Oct-08 to 2014	275.00	1	Anzatax Paclitaxel Actavis Paclitaxel Ebewe
Inj 6 mg per ml, 100 ml vial – 1% DV Oct-08 to 2014	550.00	1	Paclitaxel Ebewe

Treatment of Cytotoxic-Induced Side Effects

CALCIUM FOLINATE

Tab 15 mg – 1% DV Nov-11 to 2014	82.45	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule – 1% DV Sep-08 to 2014	24.50	5	Calcium Folate Ebewe
Inj 10 mg per ml, 10 ml vial – 1% DV Sep-08 to 2014	9.75	1	Calcium Folate Ebewe
Inj 10 mg per ml, 30 ml vial – 1% DV Sep-08 to 2014	30.00	1	Calcium Folate Ebewe
Inj 10 mg per ml, 100 ml vial – 1% DV Sep-08 to 2014	90.00	1	Calcium Folate Ebewe

MESNA

Tab 400 mg – 1% DV Oct-13 to 2016	227.50	50	Uromitexan
Tab 600 mg – 1% DV Oct-13 to 2016	339.50	50	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-13 to 2016	148.05	15	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-13 to 2016	339.90	15	Uromitexan

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Vinca Alkaloids			
VINBLASTINE SULPHATE			
Inj 1 mg per ml, 10 ml vial	137.50	5	Mayne
VINCRIStINE SULPHATE			
Inj 1 mg per ml, 1 ml vial – 1% DV Sep-13 to 2016	64.80	5	Hospira
Inj 1 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016	69.60	5	Hospira
VINOReLBINE			
Inj 10 mg per ml, 1 ml vial – 1% DV Sep-12 to 2015	12.85	1	Navelbine
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-12 to 2015	64.25	1	Navelbine

Endocrine Therapy

BICALUTAMIDE – Restricted see terms below

♣ Tab 50 mg – 1% DV Nov-11 to 2014 10.00 28 **Bicalaccord**

➡ **Restricted**

For the treatment of advanced prostate cancer

FLUTAMIDE

Tab 250 mg 55.00 100 Flutamin

MEGESTROL ACETATE

Tab 160 mg – 1% DV Jan-13 to 2015 51.55 30 **Apo-Megestrol**

OCTREOTIDE – Some items restricted see terms below

Inj 50 mcg per ml, 1 ml ampoule – 1% DV May-12 to 2014 19.24 5 **Octreotide MaxRx**

Inj 100 mcg per ml, 1 ml ampoule – 1% DV May-12 to 2014 36.38 5 **Octreotide MaxRx**

Inj 500 mcg per ml, 1 ml ampoule – 1% DV May-12 to 2014 131.25 5 **Octreotide MaxRx**

♣ Inj 10 mg vial 1,772.50 1 Sandostatin LAR

♣ Inj 20 mg vial 2,358.75 1 Sandostatin LAR

♣ Inj 30 mg vial 2,951.25 1 Sandostatin LAR

➡ **Restricted**

Note: restriction applies only to the long-acting formulations of octreotide

Malignant bowel obstruction

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications

Initiation - acromegaly

Re-assessment required after 3 months

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation - acromegaly

Both:

- 1 IGF1 levels have decreased since starting octreotide; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued. . .

2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

Other indications

Any of the following:

- 1 VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

TAMOXIFEN CITRATE

Tab 10 mg	2.63	60	Genox
	17.50	100	Genox
Tab 20 mg – 1% DV Jun-11 to 2014.....	2.63	30	Genox
	8.75	100	Genox

Aromatase Inhibitors

ANASTROZOLE

Tab 1 mg	26.55	30	Aremed DP-Anastrozole
----------------	-------	----	--------------------------

EXEMESTANE

Tab 25 mg – 1% DV Jun-11 to 2014.....	22.57	30	Aromasin
---------------------------------------	-------	----	-----------------

LETROZOLE

Tab 2.5 mg – 1% DV Oct-12 to 2015	4.85	30	Letraccord
---	------	----	-------------------

Immunosuppressants

Calcineurin Inhibitors

CICLOSPORIN

Cap 25 mg	44.63	50	Neoral
Cap 50 mg	88.91	50	Neoral
Cap 100 mg	177.81	50	Neoral
Oral liq 100 mg per ml – 1% DV Oct-12 to 2015.....	198.13	50 ml	Neoral
Inj 50 mg per ml, 5 ml ampoule – 1% DV Oct-12 to 2015	276.30	10	Sandimmun

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TACROLIMUS – Restricted see terms below			
⚡ Cap 0.5 mg	214.00	100	Prograf
⚡ Cap 1 mg	428.00	100	Prograf
⚡ Cap 5 mg	1,070.00	50	Prograf
⚡ Inj 5 mg per ml, 1 ml ampoule			

↪Restricted

For use in organ transplant recipients

Fusion Proteins

ETANERCEPT – Restricted see terms below

⚡ Inj 25 mg vial	949.96	4	Enbrel
⚡ Inj 50 mg autoinjector	1,899.92	4	Enbrel
⚡ Inj 50 mg syringe	1,899.92	4	Enbrel

↪Restricted

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 4 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:
 - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

continued...

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 2 Patient must be reassessed for continuation after 3 doses.

Initiation - plaque psoriasis, treatment-naive

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
- 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Monoclonal Antibodies

ABCIXIMAB – **Restricted** see terms below

⚡ Inj 2 mg per ml, 5 ml vial	579.53	1	ReoPro
------------------------------------	--------	---	--------

↪ **Restricted**

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – **Restricted** see terms on the next page

⚡ Inj 20 mg per 0.4 ml syringe	1,799.92	2	Humira
⚡ Inj 40 mg per 0.8 ml pen	1,799.92	2	HumiraPen
⚡ Inj 40 mg per 0.8 ml syringe	1,799.92	2	Humira

⚡ Item restricted (see ↪ above); ⚡ Item restricted (see ↪ below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 4 months

Either:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.1.2 Either:
 - 1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
- 2 All of the following:
 - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months

All of the following

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Continuation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Crohn's disease

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - Crohn's disease

Gastroenterologist

Re-assessment required after 3 months

Both:

- 1 Either:
 - 1.1 Either:
 - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.1.2 CDAI score is 150 or less; or
 - 1.2 Both:
 - 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
- 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

continued...

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per

continued...

- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

- Both:
- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
 - 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 4 months

- Both:
- 1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 2 Either:
 - 2.1 The patient has experienced intolerable side effects from etanercept; or
 - 2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; and

Initiation - plaque psoriasis, treatment-naive

Dermatologist

Re-assessment required after 4 months

- All of the following:
- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

BASILIXIMAB – Restricted see terms below

⚡ Inj 20 mg vial	3,200.00	1	Simulect
------------------------	----------	---	----------

↪ **Restricted**

For use in solid organ transplants

BEVACIZUMAB – Restricted see terms below

⚡ Inj 25 mg per ml, 16 ml vial

⚡ Inj 25 mg per ml, 4 ml vial

↪ **Restricted**

Either:

- 1 Ocular neovascularisation; or
- 2 Exudative ocular angiopathy.

INFLIXIMAB – Restricted see terms below

⚡ Inj 100 mg	1,227.00	1	Remicade
--------------------	----------	---	----------

↪ **Restricted**

Graft vs host disease

Patient has steroid-refractory acute graft vs. host disease of the gut

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 3-4 months

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and

3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 3 months

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and

2 Either:

2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 3-4 months

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and

2 Either:

2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

1 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation - severe ocular inflammation

Re-assessment required after 3 doses

Both:

- 1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2 Either:
 - 2.1 Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
 - 2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

Initiation - chronic ocular inflammation

Re-assessment required after 3 doses

Both:

- 1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2 Patient has tried at least two other immunomodulatory agents.

Continuation - ocular inflammation

Both:

- 1 Patient had a good clinical response to initial treatment; and
- 2 Either:
 - 2.1 A withdrawal of infliximab has been trialled and patient has relapsed after trial withdrawal; or
 - 2.2 Patient has Behcet's disease.

Pulmonary sarcoidosis

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Continuation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 One of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 One of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - fistulising Crohn's disease

Gastroenterologist

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 Patient must be reassessed for continuation after 4 months of therapy.

Continuation - fistulising Crohn's disease

Gastroenterologist

All of the following:

- 1 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - acute severe fulminant ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful; and
- 3 Patient must be reassessed for continuation after 6 weeks of therapy.

Continuation - severe fulminant ulcerative colitis

Gastroenterologist

All of the following:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - severe ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 The Simple Clinical Colitis Activity Index (SCCAI) is ≥ 4
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - severe ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 SCCAI score has reduced by ≥ 2 points from the SCCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 3 doses

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
- 2 Either:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

continued...

- 2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
- 2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.

Initiation - plaque psoriasis, treatment-naive

Dermatologist

Re-assessment required after 3 doses

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, thotrexate, cyclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

RANIBIZUMAB – **Restricted** see terms on the next page

- ¶ Inj 10 mg per ml, 0.23 ml vial
- ¶ Inj 10 mg per ml, 0.3 ml vial

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔Restricted

Initiation

Re-assessment required after 3 doses

Both:

- 1 Either
 - 1.1 Age-related macular degeneration; or
 - 1.2 Choroidal neovascular membrane; and
- 2 Any of the following:
 - 2.1 The patient has had a severe ophthalmic inflammatory response following bevacizumab; or
 - 2.2 The patient has had a myocardial infarction or stroke within the last three months; or
 - 2.3 The patient has failed to respond to bevacizumab following three intraocular injections; or
 - 2.4 The patient is of child-bearing potential and has not completed a family.

Continuation

Both:

- 1 Documented benefit after three doses must be demonstrated to continue; and
- 2 In the case of but previous non-response to bevacizumab, a retrial of bevacizumab is required to confirm non-response before continuing with ranibizumab.

RITUXIMAB – **Restricted** see terms below

⚡ Inj 10 mg per ml, 10 ml vial	1,075.50	2	Mabthera
⚡ Inj 10 mg per ml, 50 ml vial	2,688.30	1	Mabthera

➔Restricted

Initiation - haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Continuation - haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initiation - post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Continuation - post-transplant

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications

Initiation - indolent, low-grade lymphomas

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
 - 1.3 Both:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.3.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
- 1.3.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Continuation - indolent, low-grade lymphomas

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initiation - aggressive CD20 positive NHL

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Chronic lymphocytic leukaemia

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

TOCILIZUMAB – Restricted see terms below

⚡ Inj 20 mg per ml, 4 ml vial	220.00	1	Actemra
⚡ Inj 20 mg per ml, 10 ml vial	550.00	1	Actemra
⚡ Inj 20 mg per ml, 20 ml vial	1,100.00	1	Actemra

↪ Restricted

Initiation - systemic juvenile idiopathic arthritis

Paediatric rheumatologist

Re-assessment required after 6 months

- Both:
- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
 - 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Continuation - systemic juvenile idiopathic arthritis

Paediatric rheumatologist

Re-assessment required after 6 months

- Either:
- 1 Following up to 6 months initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
 - 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

TRASTUZUMAB – Restricted see terms below

‡ Inj 150 mg vial	1,350.00	1	Herceptin
‡ Inj 440 mg vial	3,875.00	1	Herceptin

➔Restricted

Early breast cancer

Limited to 12 months' treatment

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation - metastatic breast cancer (trastuzumab-naïve patients)

Re-assessment required after 12 months

- Either:
- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
 - 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)

Re-assessment required after 12 months

- All of the following:
- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
 - 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3.1.3 Trastuzumab to be discontinued at disease progression; or
- 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
- 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 12 months

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)			
Inj 50 mg per ml, 5 ml ampoule	2,137.50	5	ATGAM
ANTITHYMOCYTE GLOBULIN (RABBIT)			
Inj 25 mg vial			
AZATHIOPRINE			
Tab 50 mg	18.45	100	Imuprine
Inj 50 mg vial	126.00	1	Imuran
BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below			
⚡ Inj 2-8 × 10 ⁸ CFU vial – 1% DV Sep-13 to 2016	149.37	1	OncoTICE
↪ Restricted			
For use in bladder cancer			
MYCOPHENOLATE MOFETIL – Restricted see terms below			
⚡ Tab 500 mg – 1% DV Nov-13 to 2016	25.00	50	CellCept
⚡ Cap 250 mg – 1% DV Nov-13 to 2016	25.00	100	CellCept
⚡ Powder for oral liq 1 g per 5 ml – 1% DV Nov-13 to 2016	187.25	165 ml	CellCept
⚡ Inj 500 mg vial – 1% DV Nov-13 to 2016	133.33	4	CellCept

↪ Restricted

Either:

- 1 Transplant recipient; or
- 2 Patients with diseases where both:
 - 2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and
 - 2.2 Either:
 - 2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or
 - 2.2.2 Cyclophosphamide treatment is contraindicated.

PICIBANIL

Inj 100 mg vial

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SIROLIMUS – Restricted see terms below			
⚡ Tab 1 mg	813.00	100	Rapamune
⚡ Tab 2 mg	1,626.00	100	Rapamune
⚡ Oral liq 1 mg per ml	487.80	60 ml	Rapamune

➡ **Restricted**

For rescue therapy for an organ transplant recipient

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Antiallergy Preparations

Allergy Desensitisation

BEE VENOM – **Restricted** see terms below

⚡ Inj 120 mcg vial with diluent, 6 vial

⚡ Inj 550 mcg vial with diluent

➔ **Restricted**

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – **Restricted** see terms below

⚡ Inj 550 mcg vial with diluent

➔ **Restricted**

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – **Restricted** see terms below

⚡ Inj 550 mcg vial with diluent

➔ **Restricted**

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE

Nasal spray 50 mcg per dose	4.85	200 dose	Alanase
Nasal spray 100 mcg per dose	5.75	200 dose	Alanase

BUDESONIDE

Nasal spray 50 mcg per dose	4.85	200 dose	Butacort Aqueous
Nasal spray 100 mcg per dose	5.75	200 dose	Butacort Aqueous

FLUTICASONE PROPIONATE

Nasal spray 50 mcg per dose – 1% DV Apr-13 to 2015	2.30	120 dose	Flixonase Hayfever & Allergy
--	------	----------	---

IPRATROPIUM BROMIDE

Nasal spray 0.03%

SODIUM CROMOGLYCATE

Nasal spray 4%

Antihistamines

CETIRIZINE HYDROCHLORIDE

Tab 10 mg – 1% DV Sep-11 to 2014	1.59	100	Zetop
Oral liq 1 mg per ml – 1% DV Nov-11 to 2014	3.52	200 ml	Cetirizine - AFT

CHLORPHENIRAMINE MALEATE

Oral liq 0.4 mg per ml

Inj 10 mg per ml, 1 ml ampoule

CYPROHEPTADINE HYDROCHLORIDE

Tab 4 mg

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
FEXOFENADINE HYDROCHLORIDE			
Tab 60 mg			
Tab 120 mg			
Tab 180 mg			
LORATADINE			
Tab 10 mg – 1% DV Dec-13 to 2016	1.30	100	Lorafix
Oral liq 1 mg per ml	3.10	100 ml	Lorapaed
PROMETHAZINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-12 to 2015	1.99	50	Allersoothe
Tab 25 mg – 1% DV Sep-12 to 2015	2.99	50	Allersoothe
Oral liq 1 mg per ml – 1% DV Feb-13 to 2015	2.79	100 ml	Allersoothe
Inj 25 mg per ml, 2 ml ampoule	11.00	5	Mayne
TRIMEPRAZINE TARTRATE			
Oral liq 6 mg per ml			

Anticholinergic Agents

IPRATROPIUM BROMIDE			
Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule – 1% DV Sep-13 to 2016	3.26	20	Univent
Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016	3.37	20	Univent
TIOTROPIUM BROMIDE – Restricted see terms below			
☒ Powder for inhalation 18 mcg per dose	70.00	30 dose	Spiriva
☛Restricted			
All of the following:			
1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and			
2 In addition to standard treatment, the patient has trialled a short acting bronchodilator of at least 40 mcg ipratropium q.i.d for one month; and			
3 The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is either:			
3.1 Grade 4 (stops for breath after walking about 100 metres or after a few minutes on the level); or			
3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and			
4 Actual FEV ₁ as a % of predicted, must be below 60%.			
5 Either:			
5.1 Patient is not a smoker; or			
5.2 Patient is a smoker and has been offered smoking cessation counselling; and			
6 The patient has been offered annual influenza immunisation.			

Anticholinergic Agents with Beta-Adrenoceptor Agonists

SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose			
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Nov-12 to 2015	3.75	20	Duolin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Beta-Adrenoceptor Agonists

SALBUTAMOL			
Oral liq 400 mcg per ml – 1% DV Jan-14 to 2016.....	2.06	150 ml	Ventolin
Inj 500 mcg per ml, 1 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			
Aerosol inhaler, 100 mcg per dose	4.00	200 dose	Salamol
	6.00		Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Nov-12 to 2015	3.25	20	Asthalin
Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Nov-12 to 2015	3.44	20	Asthalin
TERBUTALINE SULPHATE			
Powder for inhalation 250 mcg per dose			
Inj 0.5 mg per ml, 1 ml ampoule			

Cough Suppressants

PHOLCODINE			
Oral liq 1 mg per ml			

Decongestants

OXYMETAZOLINE HYDROCHLORIDE			
Aqueous nasal spray 0.25 mg per ml			
Aqueous nasal spray 0.5 mg per ml			
PSEUDOEPHEDRINE HYDROCHLORIDE			
Tab 60 mg			
SODIUM CHLORIDE			
Aqueous nasal spray 7.4 mg per ml			
SODIUM CHLORIDE WITH SODIUM BICARBONATE			
Soln for nasal irrigation			
XYLOMETAZOLINE HYDROCHLORIDE			
Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			

Inhaled Corticosteroids

BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler 50 mcg per dose	8.54	200 dose	Beclazone 50
Aerosol inhaler 100 mcg per dose	12.50	200 dose	Beclazone 100
Aerosol inhaler 250 mcg per dose	22.67	200 dose	Beclazone 250
BUDESONIDE			
Nebuliser soln 250 mcg per ml, 2 ml ampoule			
Nebuliser soln 500 mcg per ml, 2 ml ampoule			
Powder for inhalation 100 mcg per dose			
Powder for inhalation 200 mcg per dose			
Powder for inhalation 400 mcg per dose			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
FLUTICASONE			
Aerosol inhaler 50 mcg per dose	7.50	120 dose	Flixotide
Powder for inhalation 50 mcg per dose	8.67	60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose	13.87	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose	13.60	120 dose	Flixotide
Aerosol inhaler 250 mcg per dose	27.20	120 dose	Flixotide
Powder for inhalation 250 mcg per dose	24.51	60 dose	Flixotide Accuhaler

Leukotriene Receptor Antagonists

MONTELUKAST – Restricted see terms below

☞ Tab 4 mg	18.48	28	Singulair
☞ Tab 5 mg	18.48	28	Singulair
☞ Tab 10 mg	18.48	28	Singulair

☞ **Restricted**

Pre-school wheeze

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Exercise-induced asthma

Both:

- 1 Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Aspirin desensitisation

Clinical immunologist or allergist

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Long-Acting Beta-Adrenoceptor Agonists

EFORMOTEROL FUMARATE

- Powder for inhalation 6 mcg per dose
- Powder for inhalation 12 mcg per dose

SALMETEROL

- Aerosol inhaler 25 mcg per dose26.46 120 dose Serevent
- Powder for inhalation 50 mcg per dose26.46 60 dose Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL – Restricted see terms on the next page

- ☞ Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg
- ☞ Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg
- ☞ Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg
- ☞ Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg
- ☞ Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

➔ **Restricted**

Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg	37.48	120 dose	Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg	37.48	60 dose	Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg	49.69	120 dose	Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg	49.69	60 dose	Seretide Accuhaler

Mast Cell Stabilisers

NEDOCROMIL

Aerosol inhaler 2 mg per dose

SODIUM CROMOGLYCAT

Powder for inhalation 20 mg per dose

Aerosol inhaler 5 mg per dose

Methylxanthines

AMINOPHYLLINE

Inj 25 mg per ml, 10 ml ampoule – 1% DV Nov-11 to 2014.....53.75 5 **DBL Aminophylline**

CAFFEINE CITRATE

Oral liq 20 mg per ml (caffeine 10 mg per ml) 14.85 25 ml Biomed

Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule55.75 5 Biomed

THEOPHYLLINE

Tab long-acting 250 mg

Oral liq 80 mg per 15 ml

Mucolytics and Expectorants

DORNASE ALFA – Restricted see terms below

☞ Nebuliser soln 2.5 mg per 2.5 ml ampoule250.00 6 Pulmozyme

➔ **Restricted**

Any of the following:

- 1 Cystic fibrosis and the patient has been approved by the Cystic Fibrosis Panel; and/or
- 2 Significant mucus production and meets the following criteria
- 3 Treatment for up to four weeks for patients meeting the following:
 - 3.1 Patient is an in-patient; and
 - 3.2 The mucus production cannot be cleared by first line chest techniques; or
- 4 Treatment for up to three days for patients diagnosed with empyema.

RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM CHLORIDE			
Nebuliser soln 7%, 90 ml bottle	23.50	90 ml	Biomed

Pulmonary Surfactants

BERACTANT			
Soln 200 mg per 8 ml vial	550.00	1	Survanta
PORACTANT ALFA			
Soln 120 mg per 1.5 ml vial	425.00	1	Curosurf
Soln 240 mg per 3 ml vial	695.00	1	Curosurf

Respiratory Stimulants

DOXAPRAM			
Inj 20 mg per ml, 5 ml vial			

Sclerosing Agents

TALC			
Powder			
Soln (slurry) 100 mg per ml, 50 ml			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
CHLORAMPHENICOL			
Eye oint 1% – 1% DV Jan-13 to 2015	2.76	4 g	Chlorsig
Ear drops 0.5%			
Eye drops 0.5% – 1% DV Sep-12 to 2015	1.20	10 ml	Chlorafast
Eye drops 0.5%, single dose			
CIPROFLOXACIN			
Eye drops 0.3%			
FRAMYCETIN SULPHATE			
Ear/eye drops 0.5%			
FUSIDIC ACID			
Eye drops 1%	4.50	5 g	Fucithalmic
GENTAMICIN SULPHATE			
Eye drops 0.3%	11.40	5 ml	Genoptic
PROPAMIDINE ISETHIONATE			
Eye drops 0.1%			
SULPHACETAMIDE SODIUM			
Eye drops 10%			
TOBRAMYCIN			
Eye oint 0.3% – 1% DV Sep-11 to 2014	10.45	3.5 g	Tobrex
Eye drops 0.3% – 1% DV Sep-11 to 2014	11.48	5 ml	Tobrex
Antifungals			
NATAMYCIN			
Eye drops 5%			
Antivirals			
ACICLOVIR			
Eye oint 3%			
Combination Preparations			
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml			
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g			
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml			
DEXAMETHASONE WITH TOBRAMYCIN			
Eye drops 0.1% with tobramycin 0.3%			
FLUMETASONE PIVALATE WITH CLIOQUINOL			
Ear drops 0.02% with clioquinol 1%			

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HYDROCORTISONE WITH CIPROFLOXACIN Ear drops 1% with ciprofloxacin 0.2%			
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml	Kenacomb

Anti-Inflammatory Preparations

Corticosteroids

DEXAMETHASONE Eye oint 0.1% – 1% DV Sep-11 to 2014	5.86	3.5 g	Maxidex
Eye drops 0.1%	4.50	5 ml	Maxidex
FLUOROMETHOLONE Eye drops 0.1% – 1% DV Dec-12 to 2015	3.80	5 ml	Flucon
PREDNISOLONE ACETATE Eye drops 0.12% Eye drops 1%			
PREDNISOLONE SODIUM PHOSPHATE Eye drops 0.5%, single dose			

Non-Steroidal Anti-Inflammatory Drugs

DICLOFENAC SODIUM Eye drops 0.1% – 1% DV Sep-11 to 2014	13.80	5 ml	Voltaren Ophtha
Eye drops 0.1%, single dose			
KETOROLAC TROMETAMOL Eye drops 0.5%			

Decongestants and Antiallergics

Antiallergic Preparations

LEVOCABASTINE Eye drops 0.05%			
LODOXAMIDE Eye drops 0.1%			
OLOPATADINE Eye drops 0.1%			
SODIUM CROMOGLYCATE Eye drops 2%			

Decongestants

NAPHAZOLINE HYDROCHLORIDE Eye drops 0.1% – 1% DV Sep-11 to 2014	4.15	15 ml	Naphcon Forte
--	------	-------	---------------

Price (ex man. excl. GST)		Brand or Generic
\$	Per	Manufacturer

Diagnostic and Surgical Preparations

Diagnostic Dyes

FLUORESCHEIN SODIUM

Eye drops 2%, single dose

Inj 10%, 5 ml vial 125.00 12 Fluorescite

Ophthalmic strips 1 mg

FLUORESCHEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE

Eye drops 0.25% with lignocaine hydrochloride 4%, single dose

LISSAMINE GREEN

Ophthalmic strips 1.5 mg

ROSE BENGAL SODIUM

Ophthalmic strips 1%

Irrigation Solutions

CALCIUM CHLORIDE WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE, SODIUM CHLORIDE AND SODIUM CITRATE

Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml

e.g. Balanced Salt Solution

Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml

e.g. Balanced Salt Solution

Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml

e.g. Balanced Salt Solution

Ocular Anaesthetics

OXYBUPROCAINE HYDROCHLORIDE

Eye drops 0.4%, single dose

TETRACAINE [AMETHOCAINE] HYDROCHLORIDE

Eye drops 0.5%, single dose

Eye drops 1%, single dose

Viscoelastic Substances

HYPROMELLOSE

Inj 2%, 1 ml syringe

Inj 2%, 2 ml syringe

SODIUM HYALURONATE

Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-12 to 2015..... 50.00

1 **Healon GV**

Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-12 to 2015..... 50.00

1 **Healon GV**

Inj 23 mg per ml, 0.6 ml syringe

Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-12 to 2015..... 30.00

1 **Provisc**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM HYALURONATE WITH CHONDROITIN SULPHATE			
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.4 ml syringe	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.55 ml syringe – 1% DV Sep-11 to 2014	74.00	1	Duovisc
Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe			

Glaucoma Preparations

Beta Blockers

BETAXOLOL			
Eye drops 0.25%			
Eye drops 0.5%			
LEVOBUNOLOL HYDROCHLORIDE			
Eye drops 0.25%	7.00	5 ml	Betagan
Eye drops 0.5%	7.00	5 ml	Betagan
TIMOLOL			
Eye drops 0.25%			
Eye drops 0.25%, gel forming – 1% DV Mar-14 to 2016	3.30	2.5 ml	Timoptol XE
Eye drops 0.5%			
Eye drops 0.5%, gel forming – 1% DV Mar-14 to 2016	3.78	2.5 ml	Timoptol XE

Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE			
Tab 250 mg – 1% DV Nov-11 to 2014	17.03	100	Diamox
Inj 500 mg			
BRINZOLAMIDE			
Eye drops 1%			
DORZOLAMIDE			
Eye drops 2%			
DORZOLAMIDE WITH TIMOLOL			
Eye drops 2% with timolol 0.5%	15.50	5 ml	Cosopt

Miotics

ACETYLCHOLINE CHLORIDE			
Inj 20 mg vial with diluent			
PILOCARPINE HYDROCHLORIDE			
Eye drops 1%			
Eye drops 2%			
Eye drops 2%, single dose			
Eye drops 4%			

Prostaglandin Analogues

BIMATOPROST			
Eye drops 0.03%			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

LATANOPROST
Eye drops 0.005% – **1% DV Sep-12 to 2015** 1.99 2.5 ml **Hysite**

TRAVOPROST
Eye drops 0.004%

Sympathomimetics

APRACLONIDINE
Eye drops 0.5%

BRIMONIDINE TARTRATE
Eye drops 0.2% – **1% DV Jul-12 to 2014** 6.45 5 ml **Arrow-Brimonidine**

BRIMONIDINE TARTRATE WITH TIMOLOL
Eye drops 0.2% with timolol 0.5%

Mydriatics and Cycloplegics

Anticholinergic Agents

ATROPINE SULPHATE
Eye drops 0.5%
Eye drops 1%, single dose
Eye drops 1% 17.36 15 ml Atropt

CYCLOPENTOLATE HYDROCHLORIDE
Eye drops 0.5%, single dose
Eye drops 1%
Eye drops 1%, single dose

TROPICAMIDE
Eye drops 0.5% – **1% DV Sep-11 to 2014** 7.15 15 ml **Mydriacyl**
Eye drops 0.5%, single dose
Eye drops 1% – **1% DV Sep-11 to 2014** 8.66 15 ml **Mydriacyl**
Eye drops 1%, single dose

Sympathomimetics

PHENYLEPHRINE HYDROCHLORIDE
Eye drops 2.5%, single dose
Eye drops 10%, single dose

Ocular Lubricants

CARBOMER
Ophthalmic gel 0.3%, single dose 8.25 30 Poly Gel
Ophthalmic gel 0.2%

CARMELLOSE SODIUM
Eye drops 0.5%
Eye drops 0.5%, single dose
Eye drops 1%
Eye drops 1%, single dose

HYPROMELLOSE
Eye drops 0.5% 3.92 15 ml Methopt

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HYPROMELLOSE WITH DEXTRAN			
Eye drops 0.3% with dextran 0.1%	2.30	15 ml	Poly-Tears
Eye drops 0.3% with dextran 0.1%, single dose			
MACROGOL 400 AND PROPYLENE GLYCOL			
Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose	4.30	24	Systane Unit Dose
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN			
Eye oint 42.5% with soft white paraffin 57.3%			
PARAFFIN LIQUID WITH WOOL FAT			
Eye oint 3% with wool fat 3%			
POLYVINYL ALCOHOL			
Eye drops 1.4%	2.95	15 ml	Vistil
	3.62		Liquifilm Tears
Eye drops 3%	3.80	15 ml	Vistil Forte
	3.88		Liquifilm Forte
POLYVINYL ALCOHOL WITH POVIDONE			
Eye drops 1.4% with povidone 0.6%, single dose			
RETINOL PALMITATE			
Oint 138 mcg per g	3.80	5 g	VitA-POS
SODIUM HYALURONATE			
Eye drops 1 mg per ml	22.00	10 ml	Hylo-Fresh

Other Otological Preparations

ACETIC ACID WITH PROPYLENE GLYCOL	
Ear drops 2.3% with propylene glycol 2.8%	
DOCUSATE SODIUM	
Ear drops 0.5%	

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Agents Used in the Treatment of Poisonings

Antidotes

ACETYLCYSTEINE			
Tab eff 200 mg			
Inj 200 mg per ml, 10 ml ampoule – 1% DV Jul-12 to 2015	178.00	10	Martindale
			Acetylcysteine
Inj 200 mg per ml, 30 ml vial	219.00	4	Acetadote
DIGOXIN IMMUNE FAB			
Inj 38 mg vial			
Inj 40 mg vial			
ETHANOL			
Liq 96%			
ETHANOL WITH GLUCOSE			
Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED			
Inj 100%, 5 ml ampoule			
FLUMAZENIL			
Inj 0.1 mg per ml, 5 ml ampoule	170.10	5	Anexate
HYDROXOCOBALAMIN			
Inj 5 g vial			
Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE			
Inj 400 mcg per ml, 1 ml ampoule	33.00	5	Mayne
PRALIDOXIME IODIDE			
Inj 25 mg per ml, 20 ml ampoule			
SODIUM NITRITE			
Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE			
Inj 500 mg per ml, 20 ml ampoule			
Inj 250 mg per ml, 10 ml vial			
Inj 500 mg per ml, 10 ml vial			
SOYA OIL			
Inj 20%, 500 ml bag			
Inj 20%, 500 ml bottle			

Antitoxins

BOTULISM ANTITOXIN			
Inj 250 ml vial			
DIPHThERIA ANTITOXIN			
Inj 10,000 iu vial			

Antivenoms

RED BACK SPIDER ANTIVENOM			
Inj 500 u vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SNAKE ANTIVENOM Inj 50 ml vial			

Removal and Elimination

CHARCOAL Oral liq 200 mg per ml	43.50	250 ml	Carbasorb-X
DEFERIPRONE Tab 500 mg	533.17	100	Ferriprox
Oral liq 100 mg per ml	266.59	250 ml	Ferriprox
DEFERRIOXAMINE MESILATE Inj 500 mg vial	99.00	10	Hospira
DICOBALT EDETATE Inj 15 mg per ml, 20 ml ampoule			
DIMERCAPROL Inj 50 mg per ml, 2 ml ampoule			
DIMERCAPTOSUCCINIC ACID Cap 100 mg			
DISODIUM EDETATE Inj 150 mg per ml, 20 ml ampoule Inj 150 mg per ml, 20 ml vial Inj 150 mg per ml, 100 ml vial			
SODIUM CALCIUM EDETATE Inj 200 mg per ml, 2.5 ml ampoule Inj 200 mg per ml, 5 ml ampoule			

Antiseptics and Disinfectants

CHLORHEXIDINE Soln 4%	1.86	50 ml	healthE
Soln 5%	15.50	500 ml	healthE
CHLORHEXIDINE WITH CETRIMIDE Crm 0.1% with cetrimide 0.5% Foaming soln 0.5% with cetrimide 0.5%			
CHLORHEXIDINE WITH ETHANOL Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml	2.65	1	healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml	3.54	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml	1.55	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml	2.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 100 ml	3.86	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml	5.45	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml	5.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 500 ml	9.56	1	healthE
IODINE WITH ETHANOL Soln 1% with ethanol 70%, 100 ml	9.30	1	healthE
ISOPROPYL ALCOHOL Soln 70%, 500 ml	5.00	1	PSM
	5.65		healthE

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
POVIDONE-IODINE			
☿ Vaginal tab 200 mg			
➔ Restricted			
Rectal administration pre-prostate biopsy.			
Oint 10%	3.27	25 g	Betadine
Soln 10%	2.95	100 ml	Riodine
	6.20	500 ml	Riodine Betadine
Soln 5%			
Soln 7.5%			
Pad 10%			
Swab set 10%			
POVIDONE-IODINE WITH ETHANOL			
Soln 10% with ethanol 30%	10.00	500 ml	Betadine Skin Prep
Soln 10% with ethanol 70%			
SODIUM HYPOCHLORITE			
Soln			

Contrast Media

Iodinated X-ray Contrast Media

DIATRIZOATE MEGLUMINE WITH DIATRIZOATE SODIUM			
Oral liq 660 mg per ml with diatrizoate sodium 100 mg per ml, 100 ml	21.00	100 ml	Gastrografin
Inj 370 mg with sodium amidotrizoate 100 mg per, 50 ml bottle			
Inj 146 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle	210.00	10	Gastrografin
DIATRIZOATE SODIUM			
Oral liq 370 mg per ml, 10 ml			
IODISED OIL			
Inj 480 mg per ml, 10 ml ampoule			
IODIXANOL			
Inj 270 mg per ml, 20 ml vial			
Inj 270 mg per ml, 50 ml bottle	223.50	10	Visipaque
Inj 270 mg per ml, 100 ml bottle	447.00	10	Visipaque
Inj 320 mg per ml, 20 ml vial			
Inj 320 mg per ml, 50 ml bottle	223.50	10	Visipaque
Inj 320 mg per ml, 100 ml bottle	447.00	10	Visipaque
Inj 320 mg per ml, 150 ml bottle	670.50	10	Visipaque
Inj 320 mg per ml, 200 ml bottle	565.56	6	Visipaque
	894.00	10	Visipaque

VARIOUS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
IOHEXOL			
Inj 240 mg per ml, 50 ml bottle	77.80	10	Omnipaque
Inj 300 mg per ml, 20 ml bottle	24.00	6	Omnipaque
Inj 300 mg per ml, 50 ml bottle	77.80	10	Omnipaque
Inj 300 mg per ml, 100 ml bottle	155.60	10	Omnipaque
Inj 300 mg per ml, 500 ml bottle	468.00	6	Omnipaque
Inj 350 mg per ml, 20 ml bottle	24.00	6	Omnipaque
Inj 350 mg per ml, 50 ml bottle	77.80	10	Omnipaque
Inj 350 mg per ml, 75 ml bottle	116.70	10	Omnipaque
Inj 350 mg per ml, 100 ml bottle	155.60	10	Omnipaque
Inj 350 mg per ml, 200 ml bottle	186.70	6	Omnipaque
	311.16	10	Omnipaque
<i>(Omnipaque Inj 350 mg per ml, 200 ml bottle to be delisted 1 February 2014)</i>			
IOMEPROL			
Inj 150 mg per ml, 50 ml bottle			
Inj 300 mg per ml, 20 ml vial			
Inj 300 mg per ml, 50 ml bottle			
Inj 300 mg per ml, 100 ml bottle			
Inj 350 mg per ml, 20 ml vial			
Inj 350 mg per ml, 50 ml bottle			
Inj 350 mg per ml, 75 ml bottle			
Inj 350 mg per ml, 100 ml bottle			
Inj 400 mg per ml, 50 ml bottle			
IOPROMIDE			
Inj 240 per ml, 50 ml bottle			
Inj 300 per ml, 20 ml vial			
Inj 300 per ml, 50 ml bottle			
Inj 370 per ml, 30 ml vial			
Inj 370 per ml, 50 ml bottle			
Inj 370 per ml, 100 ml bottle			
Inj 370 per ml, 200 ml bottle			
Inj 300 per ml, 100 ml bottle			
IOTROLAN			
Inj 240 mg per ml, 10 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Non-iodinated X-ray Contrast Media

BARIUM SULPHATE

Powder for enema 397 g			
Powder for oral liq 10,000 g			
Powder for oral liq 100 g			
Powder for oral liq 148 g			
Powder for oral liq 22.1 g			
Powder for oral liq 300 g			
Powder for oral liq 340 g			
Eosophogeal cream 30 mg per g			
Eosophogeal cream 600 mg per g			
Liq 1,000 mg per ml			
Oral liq 1 mg per ml			
Oral liq 1,250 mg per ml			
Oral liq 13 mg per ml			
Oral liq 130 mg per ml			
Oral liq 21 mg per ml			
Oral liq 400 mg per ml			
Eosophogeal paste 400 mg per ml			
Oral liq 22 mg per g, 250 ml	175.00	24	CT Plus+
Oral liq 22 mg per g, 450 ml	220.00	24	CT Plus+
Enema 1,250 mg per ml			

CITRIC ACID WITH SODIUM BICARBONATE

Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet			<i>e.g. E-Z-GAS II</i>
--	--	--	------------------------

Paramagnetic Contrast Media

GADOBENIC ACID

Inj 334 mg per ml, 10 ml vial	324.74	10	Multihance
Inj 334 mg per ml, 20 ml vial	636.28	10	Multihance

GADOBUTROL

Inj 1 mmol per ml, 15 ml vial			
Inj 1 mmol per ml, 7.5 ml syringe	253.10	5	Gadovist

GADODIAMIDE

Inj 287 mg per ml, 10 ml syringe	220.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial	180.00	10	Omniscan
Inj 287 mg per ml, 5 ml vial			
Inj 287 mg per ml, 15 ml syringe	330.00	10	Omniscan
Inj 287 mg per ml, 15 ml vial	270.00	10	Omniscan
Inj 287 mg per ml, 20 ml syringe	440.00	10	Omniscan
Inj 287 mg per ml, 20 ml vial			

GADOTERIC ACID

Inj 0.5 mmol per ml, 10 ml syringe			
Inj 0.5 mmol per ml, 20 ml syringe			
Inj 0.5 mmol per ml, 10 ml bottle			
Inj 0.5 mmol per ml, 20 ml bottle			
Inj 0.5 mmol per ml, 5 ml bottle			

VARIOUS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GADOXETATE DISODIUM			
Inj 181 mg per ml, 10 ml syringe			
MEGLUMINE GADOPENTATE			
Inj 469 mg per ml, 10 ml syringe	92.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial	184.00	10	Magnevist
Inj 469 mg per ml, 15 ml vial			
Inj 469 mg per ml, 20 ml vial			

Ultrasound Contrast Media

PLERFUTREN

Inj 1.1 mg per ml, 2 ml

Diagnostic Agents

ARGININE

Inj 50 mg per ml, 500 ml bottle

Inj 100 mg per ml, 300 ml bottle

HISTAMINE ACID PHOSPHATE

Nebuliser soln 0.6%, 10 ml vial

Nebuliser soln 2.5%, 10 ml vial

Nebuliser soln 5%, 10 ml vial

METHACHOLINE CHLORIDE

Powder 100 mg

SECRETIN PENTAHYDROCHLORIDE

Inj 100 u ampoule

SINCALIDE

Inj 5 mcg per vial

TUBERCULIN, PURIFIED PROTEIN DERIVATIVE

Inj 5 TU per 0.1 ml, 1 ml vial

Diagnostic Dyes

BONNEY'S BLUE DYE

Soln

INDIGO CARMINE

Inj 4 mg per ml, 5 ml ampoule

Inj 8 mg per ml, 5 ml ampoule

INDOCYANINE GREEN

Inj 25 mg vial

METHYLTHIONIUM CHLORIDE [METHYLENE BLUE]

Inj 10 mg per ml, 10 ml ampoule

Inj 10 mg per ml, 5 ml ampoule

PATENT BLUE V

Inj 2.5%, 2 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Irrigation Solutions			
CHLORHEXIDINE			
Irrigation soln 0.02%, bottle	2.92	100 ml	Baxter
Irrigation soln 0.05%, bottle	3.02	100 ml	Baxter
	3.63	500 ml	Baxter
Irrigation soln 0.1%, bottle	3.10	100 ml	Baxter
Irrigation soln 0.5%, bottle	4.69	500 ml	Baxter
Irrigation soln 0.02%, 500 ml bottle			
Irrigation soln 0.1%, 30 ml ampoule			
CHLORHEXIDINE WITH CETRIMIDE			
Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule			
Irrigation soln 0.015% with cetrimide 0.15%, bottle	3.21	100 ml	Baxter
	3.47	500 ml	Baxter
	4.17	1,000 ml	Baxter
Irrigation soln 0.05% with cetrimide 0.5%, bottle	4.20	100 ml	Baxter
	3.87	500 ml	Baxter
Irrigation soln 0.1% with cetrimide 1%, bottle	4.38	100 ml	Baxter
	5.81	500 ml	Baxter
GLYCINE			
Irrigation soln 1.5%, bottle	11.38	2,000 ml	Baxter
	14.44	3,000 ml	Baxter
SODIUM CHLORIDE			
Irrigation soln 0.9%, 30 ml ampoule – 1% DV Nov-11 to 2014	19.50	30 ml	Pfizer
Irrigation soln 0.9%, bottle	2.49	100 ml	Baxter
	2.88	500 ml	Baxter
	2.96	1,000 ml	Baxter
	10.00	2,000 ml	Baxter
	12.67	3,000 ml	Baxter
WATER			
Irrigation soln, bottle	2.68	100 ml	Baxter
	2.61	500 ml	Baxter
	2.75	1,000 ml	Baxter
	9.71	2,000 ml	Baxter
	15.80	3,000 ml	Baxter

Surgical Preparations

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN

Paste

DIMETHYL SULFOXIDE

Soln 50%

PHENOL

Inj 6%, 10 ml ampoule

PHENOL WITH IOXAGLIC ACID

Inj 12%, 10 ml ampoule

TROMETAMOL

Inj 36 mg per ml, 500 ml bottle

Price (ex man. excl. GST)		Brand or Generic
\$	Per	Manufacturer

Cardioplegia Solutions

ELECTROLYTES

Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag

*e.g. Cardioplegia
Enriched Paed.
Soln.*

Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag

*e.g. Cardioplegia
Enriched Solution*

Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag

*e.g. Cardioplegia Base
Solution*

Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag

*e.g. Cardioplegia
Solution AHB7832*

Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag

*e.g. Cardioplegia
Electrolyte Solution*

MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

MONOSODIUM L-ASPARTATE

Inj 14 mmol per 10 ml, 10 ml

Cold Storage Solutions

SODIUM WITH POTASSIUM

Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Extemporaneously Compounded Preparations

ACETIC ACID

Liq

ALUM

Powder BP

ARACHIS OIL [PEANUT OIL]

Liq

ASCORBIC ACID

Powder

BENZOIN

Tincture compound BP

BISMUTH SUBGALLATE

Powder

BORIC ACID

Powder

CARBOXYMETHYLCELLULOSE

Soln 1.5%

CETRIMIDE

Soln 40%

CHLORHEXIDINE GLUCONATE

Soln 20 %

CHLOROFORM

Liq BP

CITRIC ACID

Powder BP

CLOVE OIL

Liq

COAL TAR

Soln BP

CODEINE PHOSPHATE

Powder

COLLODION FLEXIBLE

Liq

COMPOUND HYDROXYBENZOATE

Soln

CYSTEAMINE HYDROCHLORIDE

Powder

DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE

Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml
ampoule

DITHRANOL

Powder

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLUCOSE Powder			
GLYCERIN WITH SODIUM SACCHARIN Suspension	35.50	473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE Suspension	35.50	473 ml	Ora-Sweet
GLYCEROL Liq	19.80	2,000 ml	ABM
HYDROCORTISONE Powder – 1% DV Nov-11 to 2014	44.00	25 g	ABM
LACTOSE Powder			
MAGNESIUM HYDROXIDE Paste			
MENTHOL Crystals			
METHADONE HYDROCHLORIDE Powder			
METHYL HYDROXYBENZOATE Powder			
METHYLCELLULOSE Powder			
Suspension	35.50	473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension	35.50	473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension	35.50	473 ml	Ora-Blend
OLIVE OIL Liq			
PARAFFIN Liq			
PHENOBARBITONE SODIUM Powder			
PHENOL Liq			
PILOCARPINE NITRATE Powder			
POLYHEXAMETHYLENE BIGUANIDE Liq			
POVIDONE K30 Powder			
PROPYLENE GLYCOL Liq	12.00	500 ml	ABM

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SALICYLIC ACID Powder			
SILVER NITRATE Crystals			
SODIUM BICARBONATE Powder BP			
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade)	21.75	2,000 ml	Midwest
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

Food Modules

Carbohydrate

➔ **Restricted**

Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

Use as a module

For use as a component in a modular formula

CARBOHYDRATE SUPPLEMENT – **Restricted** see terms above

⬆ Powder 95 g carbohydrate per 100 g, 368 g can

e.g. Moducal

⬆ Powder 96 g carbohydrate per 100 g, 400 g can

e.g. Polycal

(e.g. Moducal Powder 95 g carbohydrate per 100 g, 368 g can to be delisted 1 February 2014)

Fat

➔ **Restricted**

Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

Use as a module

For use as a component in a modular formula

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

⬆ Liquid 50 g fat per 100 ml, 200 ml bottle

e.g. Calogen

⬆ Liquid 50 g fat per 100 ml, 500 ml bottle

e.g. Calogen

MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

⬆ Liquid 50 g fat per 100 ml, 250 ml bottle

e.g. Liquigen

⬆ Liquid 95 g fat per 100 ml, 500 ml bottle

e.g. MCT Oil

WALNUT OIL – **Restricted** see terms above

⬆ Liq

Price (ex man. excl. GST)		Brand or Generic
\$	Per	Manufacturer

Protein

➔ Restricted

Use as an additive

Either:

- 1 Protein losing enteropathy; or
- 2 High protein needs.

Use as a module

For use as a component in a modular formula

PROTEIN SUPPLEMENT – **Restricted** see terms above

<p>⬆ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can</p> <p>⬆ Powder 6 g protein per 7 g, can8.95</p> <p>⬆ Powder 89 g protein, <1.5 g carbohydrate and 2 g fat per 100 g, 225 g can</p>	<p></p> <p>227 g</p> <p></p>	<p><i>e.g. Promod</i></p> <p>Resource Beneprotein</p> <p><i>e.g. Protifar</i></p>
--	------------------------------	---

Other Supplements

BREAST MILK FORTIFIER

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet	<i>e.g. FM 85</i>
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet	<i>e.g. S26 Human Milk Fortifier</i>
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet	<i>e.g. Nutricia Breast Milk Fortifier</i>

CARBOHYDRATE AND FAT SUPPLEMENT – Restricted see terms below

⬇ Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can	<i>e.g. Super Soluble Duocal</i>
--	----------------------------------

➔ Restricted

Both:

- 1 Infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 Cystic fibrosis; or
 - 2.2 Cancer in children; or
 - 2.3 Faltering growth; or
 - 2.4 Bronchopulmonary dysplasia; or
 - 2.5 Premature and post premature infants.

Food/Fluid Thickeners

NOTE:

While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder	<i>e.g. Feed Thickener</i>
	<i>Karicare Aptamil</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GUAR GUM Powder			<i>e.g. Guarcol</i>
MAIZE STARCH Powder			<i>e.g. Resource Thicken Up; Nutilis</i>
MALTODEXTRIN WITH XANTHAN GUM Powder			<i>e.g. Instant Thick</i>
MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID Powder			<i>e.g. Easy Thick</i>

Metabolic Products

➔ Restricted

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – **Restricted** see terms above

- ⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. GA1 Anamix Infant*
- ⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XLYS Low TRY
Maxamaid*

Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms above

- ⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. HCU Anamix Infant*
- ⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XMET Maxamaid*
- ⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XMET Maxamum*
- ⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle *e.g. HCU Anamix Junior
LQ*

Isovaleric Acidemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms above

- ⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. IVA Anamix Infant*
- ⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XLEU Maxamaid*
- ⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XLEU Maxamum*

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted** see terms on the preceding page

- ⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. MSUD Anamix Infant*
- ⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. MSUD Maxamaid*
- ⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. MSUD Maxamum*
- ⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle *e.g. MSUD Anamix Junior LQ*

Phenylketonuria Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – **Restricted** see terms on the preceding page

- ⬆ Tab 8.33 mg *e.g. Phlexy-10*
- ⬆ Powder 29 g protein, 38 g carbohydrate and 13.5 g fibre per 100 g, 29 g sachet *e.g. PKU Anamix Junior*
- ⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. PKU Anamix Infant*
- ⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XP Maxamaid*
- ⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XP Maxamum*
- ⬆ Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet *e.g. Phlexy-10*
- ⬆ Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle *e.g. PKU Lophlex LQ 10*
- ⬆ Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle *e.g. PKU Lophlex LQ 20*
- ⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle 13.10 125 ml PKU Anamix Junior LQ (Berry)
PKU Anamix Junior LQ (Orange)
- ⬆ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle *e.g. PKU Lophlex LQ 20*
- ⬆ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle *e.g. PKU Lophlex LQ 10*
- ⬆ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle *e.g. PKU Lophlex LQ 20*
- ⬆ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle *e.g. PKU Lophlex LQ 10*
- ⬆ Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton *e.g. Easiphen*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – **Restricted** see terms on page 180

- † Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can e.g. MMA/PA Anamix Infant
- † Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can e.g. XMTVI Maxamaid
- † Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can e.g. XMTVI Maxamum

Protein Free Supplements

PROTEIN FREE SUPPLEMENT – **Restricted** see terms on page 180

- † Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can e.g. Energivit

Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms on page 180

- † Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can e.g. TYR Anamix Infant
- † Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can e.g. XPHEN, TYR Maxamaid
- † Powder 29 g protein, 38 g carbohydrate and 13.5 g fat per 100 g, 29 g sachet e.g. TYR Anamix Junior
- † Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle e.g. TYR Anamix Junior LQ

Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – **Restricted** see terms on page 180

- † Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can e.g. Dialamine
- † Powder 79 g protein per 100 g, 200 g can e.g. Essential Amino Acid Mix

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – **Restricted** see terms on page 180

- † Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE – **Restricted** see terms on page 180

- † Liquid, 500 ml bottle

Specialised Formulas

Diabetic Products

➡ **Restricted**

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days;
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued. . .			
5 For use pre- and post-surgery; or			
6 For patients being tube-fed; or			
7 For tube-feeding as a transition from intravenous nutrition.			
LOW-GI ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle	7.50	1,000 ml	Glucerna Select RTH (Vanilla)
⬆ Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Advanced Diason</i>
LOW-GI ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle	1.88	250 ml	Glucerna Select (Vanilla)
⬆ Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle			<i>e.g. Diasip</i>
⬆ Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can	2.10	237	Resource Diabetic (Vanilla)

Elemental and Semi-Elemental Products

➔ Restricted

Any of the following:

- 1 Malabsorption; or
- 2 Short bowel syndrome; or
- 3 Enterocutaneous fistulas; or
- 4 Eosinophilic enteritis (including oesophagitis); or
- 5 Inflammatory bowel disease; or
- 6 Acute pancreatitis where standard feeds are not tolerated; or
- 7 Patients with multiple food allergies requiring enteral feeding.

AMINO ACID ORAL FEED – Restricted see terms above

⬆ Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet 4.50 80.4 g Vivonex TEN

AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted see terms above

⬆ Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton *e.g. Elemental 028 Extra*

PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted see terms above

⬆ Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag *e.g. Nutrison Advanced Peptisorb*

PEPTIDE-BASED ORAL FEED – Restricted see terms above

⬆ Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet 4.40 79 g Vital HN

⬆ Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can *e.g. Peptamen Junior*

⬆ Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can *e.g. MCT Peptide; MCT Peptide 1+*

⬆ Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet 7.50 76 g Alitraq

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
† Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton	4.95	237 ml	Peptamen OS 1.0 (Vanilla)

Fat Modified Products

FAT-MODIFIED FEED – **Restricted** see terms below

‡ Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
--	--	--	---------------------

➔ **Restricted**

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed for adults.

Hepatic Products

➔ **Restricted**

For children (up to 18 years) who require a liver transplant

HEPATIC ORAL FEED – **Restricted** see terms above

† Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can	78.97	400 g	Heparon Junior
--	-------	-------	----------------

High Calorie Products

➔ **Restricted**

Any of the following:

- 1 Patient is fluid volume or rate restricted; or
- 2 Patient requires low electrolyte; or
- 3 Both:
 - 3.1 Any of the following:
 - 3.1.1 Cystic fibrosis; or
 - 3.1.2 Any condition causing malabsorption; or
 - 3.1.3 Faltering growth in an infant/child; or
 - 3.1.4 Increased nutritional requirements; and
 - 3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms above

† Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle	5.50	500 ml	Nutrison Concentrated
† Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle	11.00	1,000 ml	TwoCal HN RTH (Vanilla)

ORAL FEED 2 KCAL/ML – **Restricted** see terms above

† Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle	1.90	200 ml	Two Cal HN
---	------	--------	------------

High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms on the next page

‡ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Protein Plus</i>
--	--	--	-----------------------------------

Price	Brand or
(ex man. excl. GST)	Generic
\$	Manufacturer
Per	

➔Restricted

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms below

⚡ Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

e.g. Nutrison Protein Plus Multi Fibre

➔Restricted

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ORAL FEED 1 KCAL/ML – **Restricted** see terms below

⚡ Liquid 10 g protein, 10.3 g carbohydrate and 2.1 g fat per 100 ml, 200 ml bottle

e.g. Fortimel Regular

➔Restricted

Any of the following:

- 1 Decompensating liver disease without encephalopathy; or
- 2 Protein losing gastro-enteropathy; or
- 3 Patient has increased protein requirements without increased energy requirements.

Infant Formulas

AMINO ACID FORMULA – **Restricted** see terms on the next page

⚡ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can		<i>e.g. Neocate</i>
⚡ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can		<i>e.g. Neocate LCP</i>
⚡ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can53.00	400 g	Neocate Gold (Unflavoured)
⚡ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can		<i>e.g. Neocate Advance</i>
⚡ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can53.00	400 g	Neocate Advance (Vanilla)
⚡ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can53.00	400 g	Elecare LCP (Unflavoured)
⚡ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)
⚡ Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per sachet6.00	48.5 g	Vivonex Paediatric

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Initiation

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – Restricted see terms below

☞ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can

*e.g. Gold Pepti Junior
Karicare Aptamil*

➔ **Restricted**

Initiation - new patients

Any of the following:

- 1 Both:
 - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Initiation - step down from amino acid formula

Both:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

FRUCTOSE-BASED FORMULA

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can

e.g. Galactomin 19

LACTOSE-FREE FORMULA

Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can

*e.g. Karicare Aptamil
Gold De-Lact*

Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can

e.g. S26 Lactose Free

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOW-CALCIUM FORMULA			
Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can			<i>e.g. Locasol</i>
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms below			
☛ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 100 ml bottle			<i>e.g. Infatrini</i>
➔Restricted			
Both:			
1 Either:			
1.1 The patient is fluid restricted; or			
1.2 The patient has increased nutritional requirements due to faltering growth; and			
2 Patient is under 18 months old and weighs less than 8kg.			
PRETERM FORMULA – Restricted see terms below			
☛ Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, can	15.25	400 g	S-26 Gold Premgro
☛ Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle	0.75	100 ml	S26 LBW Gold RTF
☛ Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle			<i>e.g. Pre Nan Gold RTF</i>
☛ Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle			<i>e.g. Karicare Aptamil Gold+Preterm</i>
➔Restricted			
For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.			
THICKENED FORMULA			
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Thickened AR</i>

Ketogenic Diet Products

HIGH FAT FORMULA – Restricted see terms below			
☛ Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, can	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
☛ Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can	35.50	300 g	Ketocal 3:1 (Unflavoured)
➔Restricted			
For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.			

Paediatric Products

➔Restricted			
Both:			
1 Child is aged one to ten years; and			
2 Any of the following:			
2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or			
2.2 Any condition causing malabsorption; or			
2.3 Faltering growth in an infant/child; or			
2.4 Increased nutritional requirements; or			
2.5 The child is being transitioned from TPN or tube feeding to oral feeding.			

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PAEDIATRIC ORAL FEED – Restricted see terms on the preceding page			
☒ Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can	20.00	900 g	Pediasure (Vanilla)
PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag	4.00	500 ml	Nutrini Low Energy Multifibre RTH
PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag	2.68	500 ml	Pediasure RTH
☒ Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini RTH</i>
PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag	6.00	500 ml	Nutrini Energy Multi Fibre
☒ Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini Energy RTH</i>
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
☒ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can	1.34	250 ml	Pediasure (Vanilla)
PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortini</i>
☒ Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortini Multifibre</i>

Renal Products

LOW ELECTROLYTE ENTERAL FEED 2 KCAL/ML – **Restricted** see terms below

☒ Liquid 7 g protein, 20.6 g carbohydrate, 9.6 g fat and 1.56 g fibre per 100 ml, bottle	6.08	500 ml	Nepro RTH
--	------	--------	-----------

☛Restricted

For patients with acute or chronic kidney disease

LOW ELECTROLYTE ORAL FEED – **Restricted** see terms below

☒ Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can			<i>e.g. Kindergen</i>
---	--	--	-----------------------

☛Restricted

For children (up to 18 years) with acute or chronic kidney disease

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below			
⚡ Liquid 7 g protein, 20.6 g carbohydrate, 9.6 g fat and 1.56 g fibre per 100 ml, carton	2.43	200 ml	Nepro (Strawberry) Nepro (Vanilla)
⚡ Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton	3.31	237 ml	Novasource Renal (Vanilla)
⚡ Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle			<i>e.g. Suplena</i>
⚡ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton			<i>e.g. Renilon 7.5</i>

➔ **Restricted**

For patients with acute or chronic kidney disease

Respiratory Products

LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted see terms below

⚡ Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle	1.66	237 ml	Pulmocare (Vanilla)
--	------	--------	---------------------

➔ **Restricted**

For patients with CORD and hypercapnia, defined as a CO₂ value exceeding 55 mmHg

Surgical Products

HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms below

⚡ Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton	4.00	237 ml	Impact Advanced Recovery (Chocolate) Impact Advanced Recovery (Vanilla)
--	------	--------	---

➔ **Restricted**

Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery

Standard Feeds

➔ **Restricted**

Any of the following:

- 1 For patients with malnutrition, defined as any of the following:
 - 1.1 BMI < 18.5; or
 - 1.2 Greater than 10% weight loss in the last 3-6 months; or
 - 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- 2 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 4 For use pre- and post-surgery; or
- 5 For patients being tube-fed; or
- 6 For tube-feeding as a transition from intravenous nutrition; or
- 7 For any other condition that meets the community Special Authority criteria.

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENTERAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
† Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle			e.g. <i>Isosource Standard RTH</i>
† Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag	7.00	1,000 ml	Nutrison Energy
† Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			e.g. <i>Nutrison Energy Multi Fibre</i>
† Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can	1.75	250 ml	Ensure Plus HN
† Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag	7.00	1,000 ml	Ensure Plus HN RTH
† Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag	7.00	1,000 ml	Jevity HiCal RTH
ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
† Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	2.65	500 ml	Osmolite RTH
	5.29	1,000 ml	Osmolite RTH
† Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can	1.24	250 ml	Osmolite
† Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle	2.65	500 ml	Jevity RTH
	5.29	1,000 ml	Jevity RTH
† Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can	1.32	237 ml	Jevity
† Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag			e.g. <i>NutrisonStdRTH; NutrisonLowSodium</i>
† Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag			e.g. <i>Nutrison Multi Fibre</i>
ENTERAL FEED 1.2 KCAL/ML – Restricted see terms on the preceding page			
† Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag			e.g. <i>Jevity Plus RTH</i>
ORAL FEED – Restricted see terms on the preceding page			
† Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can	13.00	900 g	Ensure (Chocolate)
		850 g	Ensure (Vanilla)
		900 g	Ensure (Vanilla)
† Powder 18.7 g protein, 54.5 g carbohydrate and 18.9 g fat per 100 g, can	9.50	900 g	Fortisip (Vanilla)
† Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can	10.22	900 g	Sustagen Hospital Formula (Chocolate)
			Sustagen Hospital Formula (Vanilla)
<i>(Ensure (Vanilla) Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can to be delisted 1 February 2014)</i>			
ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
† Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton			e.g. <i>Resource Fruit Beverage</i>

† Item restricted (see ➡ above); ‡ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ORAL FEED 1.5 KCAL/ML – Restricted see terms on page 189			
⬆ Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can	1.33	237 ml	Ensure Plus (Chocolate) Ensure Plus (Strawberry) Ensure Plus (Vanilla)
⬆ Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton	1.26	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
⬆ Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle			<i>e.g. Fortijuce</i>
⬆ Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortisip</i>
⬆ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortisip Multi Fibre</i>

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms below

¶ Inj 30 IU diphtheria toxoid with 30 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe

➔**Restricted**

For primary vaccination in children

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – **Restricted** see terms below

¶ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial

➔**Restricted**

Either:

- 1 For primary vaccination in children; or
- 2 For revaccination of children following immunosuppression.

Bacterial Vaccines

BACILLUS CALMETTE-GUERIN VACCINE – **Restricted** see terms below

¶ Inj 1.5 mg vial with diluent

➔**Restricted**

For infants at increased risk of tuberculosis

Note: increased risk is defined as:

- 1 Living in a house or family with a person with current or past history of TB; or
- 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or
- 3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

A list of countries with high rates of TB are available at www.moh.govt.nz/immunisation or www.bcgatlas.org/index.php.

DIPHTHERIA AND TETANUS VACCINE – **Restricted** see terms below

¶ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe

➔**Restricted**

Any of the following:

- 1 For vaccination of patients aged between 45 and 65 years old; or
- 2 For vaccination of previously unimmunised patients; or
- 3 For revaccination of children following immunosuppression; or
- 4 For revaccination for patients with tetanus-prone wounds; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – **Restricted** see terms below

¶ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe

➔**Restricted**

Either:

- 1 For primary vaccination in children aged 7-18 years; or
- 2 For pregnant women between gestational weeks 28 and 38 during epidemics.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

HAEMOPHILUS INFLUENZAE TYPE B VACCINE – **Restricted** see terms below

¶ Inj 10 mcg vial with diluent syringe

➔ **Restricted**

Any of the following:

- 1 For primary vaccination in children; or
- 2 For revaccination of children following immunosuppression; or
- 3 For children aged 0-18 years with functional asplenia; or
- 4 For patients pre- and post-splenectomy; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – **Restricted** see terms below

¶ Inj 48 mcg in 0.5 ml vial

➔ **Restricted**

Any of the following:

- 1 For patients pre- and post-splenectomy; or
- 2 For children aged 0-18 years with functional asplenia; or
- 3 For organisation and community based outbreaks; or
- 4 For use in transplant patients; or
- 5 For use following immunosuppression.

MENINGOCOCCAL (A, C, Y AND W-135) POLYSACCHARIDE VACCINE – **Restricted** see terms below

¶ Inj 200 mcg vial with diluent

➔ **Restricted**

Any of the following:

- 1 For patients pre- and post-splenectomy; or
- 2 For children aged 2-18 years with functional asplenia; or
- 3 For organisation and community based outbreaks.

MENINGOCOCCAL C CONJUGATE VACCINE – **Restricted** see terms below

¶ Inj 10 mcg in 0.5 ml syringe

➔ **Restricted**

Any of the following:

- 1 For patients pre- and post-splenectomy; or
- 2 For children aged 0-18 years with functional asplenia; or
- 3 For organisation and community based outbreaks; or
- 4 For use in transplant patients aged under 2 years; or
- 5 For use following immunosuppression in patients aged under 2 years.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – **Restricted** see terms below

¶ Inj 16 mcg in 0.5 ml syringe

➔ **Restricted**

For primary vaccination in children

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – **Restricted** see terms below

¶ Inj 30.8 mcg in 0.5 ml syringe

➔ **Restricted**

Any of the following:

- 1 For high risk children under the age of 5; or
- 2 For patients aged less than 18 years pre- or post-splenectomy or with functional asplenia; or
- 3 For revaccination of children following immunosuppression; or
- 4 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

VACCINES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – **Restricted** see terms below

¶ Inj 575 mcg in 0.5 ml vial

➔ **Restricted**

Any of the following:

- 1 For patients pre- and post-splenectomy; or
- 2 For children aged 2-18 years with functional asplenia; or
- 3 For revaccination of children following immunosuppression; or
- 4 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE – **Restricted** see terms below

¶ Inj 25 mcg in 0.5 ml syringe

➔ **Restricted**

For use during typhoid fever outbreaks

Viral Vaccines

HEPATITIS A VACCINE – **Restricted** see terms below

¶ Inj 720 ELISA units in 0.5 ml syringe

¶ Inj 1440 ELISA units in 1 ml syringe

➔ **Restricted**

Any of the following:

- 1 For use in transplant patients; or
- 2 For use in children with chronic liver disease; or
- 3 For close contacts of known hepatitis A carriers.

HEPATITIS B VACCINE – **Restricted** see terms below

¶ Inj 5 mcg in 0.5 ml vial

¶ Inj 10 mcg in 1 ml vial

➔ **Restricted**

Any of the following:

- 1 Household or sexual contacts of known hepatitis B carriers; or
- 2 Children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 Dialysis patients; or
- 4 HIV-positive patients; or
- 5 Hepatitis C positive patients; or
- 6 For use in transplant patients; or
- 7 For use following immunosuppression; or
- 8 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – **Restricted** see terms below

¶ Inj 120 mcg in 0.5 ml syringe

➔ **Restricted**

Any of the following:

- 1 Women aged between 9 and 19 years old; or
- 2 Male patients aged between 9 and 25 years old with confirmed HIV infection; or
- 3 For use in transplant patients.

INFLUENZA VACCINE – **Restricted** see terms on the next page

¶ Inj 45 mcg in 0.5 ml syringe	90.00	10	Fluarix Influvac
--------------------------------------	-------	----	---------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Any of the following:

- 1 All people 65 years of age and over; or
- 2 People under 65 years of age who:
 - 2.1 Have any of the following cardiovascular diseases:
 - 2.1.1 Ischaemic heart disease; or
 - 2.1.2 Congestive heart disease; or
 - 2.1.3 Rheumatic heart disease; or
 - 2.1.4 Congenital heart disease; or
 - 2.1.5 Cerebro-vascular disease; or
 - 2.2 Have any of the following chronic respiratory diseases:
 - 2.2.1 Asthma, if on a regular preventative therapy; or
 - 2.2.2 Other chronic respiratory disease with impaired lung function; or
 - 2.3 Have diabetes;
 - 2.4 Have chronic renal disease;
 - 2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive;
 - 2.6 Have any of the following other conditions:
 - 2.6.1 Autoimmune disease;
 - 2.6.2 Immune suppression;
 - 2.6.3 HIV;
 - 2.6.4 Transplant recipients;
 - 2.6.5 Neuromuscular and CNS diseases;
 - 2.6.6 Haemoglobinopathies;
 - 2.6.7 Are children on long term aspirin; or
 - 2.7 Are pregnant, or
 - 2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or
- 3 People under 18 years of age living within the boundaries of the Canterbury District Health Board.

Note: The following conditions are excluded from funding:

- asthma not requiring regular preventative therapy; and
- hypertension and/or dyslipidaemia without evidence of end-organ disease.

MEASLES, MUMPS AND RUBELLA VACCINE – **Restricted** see terms below

¶ Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent

➔ **Restricted**

Any of the following:

- 1 For primary vaccination in children; or
- 2 For revaccination following immunosuppression; or
- 3 For any individual susceptible to measles, mumps or rubella.

POLIOMYELITIS VACCINE – **Restricted** see terms below

¶ Inj 80 D-antigen units in 0.5 ml syringe

➔ **Restricted**

Either:

- 1 For previously unvaccinated individuals; or
- 2 For revaccination following immunosuppression.

RABIES VACCINE

Inj 2.5 IU vial with diluent

VARICELLA ZOSTER VACCINE [CHICKEN POX VACCINE] – **Restricted** see terms on the next page

¶ Inj 1350 PFU vial with diluent

¶ Inj 2000 PFU vial with diluent

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Any of the following:

- 1 For non-immune patients:
 - 1.1 with chronic liver disease who may in future be candidates for transplantation; or
 - 1.2 with deteriorating renal function before transplantation; or
 - 1.3 prior to solid organ transplant; or
 - 1.4 prior to any elective immunosuppression; or
 - 1.5 for post exposure prophylaxis who are immune competent inpatients.
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive non-immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has:
 - 5.1 adult household contact - a negative serology result for varicella; or
 - 5.2 child household contact - no clinical history of varicella or negative varicella serology.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Optional Pharmaceuticals			
BLOOD GLUCOSE DIAGNOSTIC TEST METER			
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips	20.00	1	Caresens II Caresens N Caresens N POP
Meter	9.00	1	FreeStyle Lite On Call Advanced Accu-Chek Performa
	19.00		
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP			
Blood glucose test strips	10.56	50 test	CareSens CareSens N FreeStyle Lite
	21.65		Accu-Chek Performa Freestyle Optium
	28.75		On Call Advanced
Blood glucose test strips × 50 and lancets × 5	19.10	50 test	
BLOOD KETONE DIAGNOSTIC TEST METER			
Meter	40.00	1	Freestyle Optium
INSULIN PEN NEEDLES			
29 g × 12.7 mm	10.50	100	B-D Micro-Fine
31 g × 5 mm	11.75	100	B-D Micro-Fine
31 g × 6 mm	10.50	100	ABM
31 g × 8 mm	10.50	100	ABM
			B-D Micro-Fine B-D Micro-Fine
32 g × 4 mm	10.50	100	
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE			
Syringe 0.3 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	ABM B-D Ultra Fine B-D Ultra Fine II
Syringe 1 ml with 31 g × 8 mm needle	13.00	100	
KETONE BLOOD BETA-KETONE ELECTRODES			
Test strips	15.50	10 strip	Freestyle Optium Ketone
MASK FOR SPACER DEVICE			
Size 2	2.99	1	EZ-fit Paediatric Mask
PEAK FLOW METER			
Low Range	11.44	1	Breath-Alert
Normal Range	11.44	1	Breath-Alert
PREGNANCY TEST - HCG URINE			
Cassette	22.80	40 test	Innovacon hCG One Step Pregnancy Test
SODIUM NITROPRUSSIDE			
Test strip	6.00	50 strip	Accu-Chek Ketur-Test

OPTIONAL PHARMACEUTICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SPACER DEVICE			
230 ml (single patient)	4.72	1	Space Chamber Plus
800 ml	8.50	1	Volumatic

- Symbols -		
8-methoxypsoralen	51	
- A -		
A-Scabies	48	
Abacavir sulphate	75	
Abacavir sulphate with lamivudine	75	
Abciximab	136	
Abilify	111	
ABM Hydroxocobalamin	23	
Acarbose	15	
Accarb	15	
Accu-Chek Ketur-Test	197	
Accu-Chek Performa	197	
Accuretic 10	35	
Accuretic 20	35	
Acetadote	167	
Acetazolamide	164	
Acetic acid		
Extemporaneous	175	
Genito-Urinary	53	
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid	53	
Acetic acid with propylene glycol	166	
Acetylcholine chloride	164	
Acetylcysteine	167	
Aciclovir		
Infection	81	
Sensory	161	
Acid Citrate Dextrose A	28	
Acidex	12	
Acipimox	42	
Acitretin	51	
Aclasta	87	
Actemra	151	
Actinomycin D	121	
Adalimumab	136	
Adapalene	48	
Adefin XL	39	
Adefovir dipivoxil	78	
Adenosine	36-37	
Adrenaline	43	
Advantan	50	
Advate	27	
Aerrane	97	
Agents Affecting the Renin-Angiotensin System	35	
Agents for Parkinsonism and Related Disorders	95	
Agents Used in the Treatment of		
Poisonings	167	
Ajmaline	37	
Alanina	155	
Albendazole	72	
Aldara	51	
Alendronate sodium	85-86	
Alendronate sodium with cholecalciferol	86	
Alfacalcidol	23	
Alfentanil hydrochloride	100	
Alinia	73	
Alitraq	183	
Allersoothe	156	
Allopurinol	90	
Alpha tocopheryl acetate	24	
Alpha-Adrenoceptor Blockers	36	
Alphamox	64	
Alprazolam	115	
Alprostadil hydrochloride	44	
Alteplase	31	
Alum	175	
Aluminium hydroxide	12	
Aluminium hydroxide with magnesium hydroxide and simethicone	12	
Amantadine hydrochloride	95	
AmBisome	68	
Ambrisentan	45	
Amethocaine	100, 163	
Nervous	100	
Sensory	163	
Amikacin	62	
Amiloride hydrochloride	41	
Amiloride hydrochloride with furosemide	40	
Amiloride hydrochloride with hydrochlorothiazide	40	
Aminophylline	159	
Amiodarone hydrochloride	37	
Amisulpride	110	
Amitrip	103	
Amitriptyline	103	
Amlodipine	39	
Amorolfine	47	
Amoxycillin	64	
Amoxycillin with clavulanic acid	65	
Amphotericin B		
Alimentary	22	
Infection	68	
Amsacrine	123	
Amyl nitrite	44	
Anabolic Agents	57	
Anaesthetics	97	
Anagrelide hydrochloride	123	
Analgesics	100	
Anastrozole	131	
Andriol Testocaps	57	
Androderm	57	
Androgen Agonists and Antagonists	57	
Anexate	167	
Antabuse	119	
Antacids and Antiflatulents	12	
Anti-Infective Agents	53	
Anti-Infective Preparations		
Dermatological	47	
Sensory	161	
Anti-Inflammatory Preparations	162	
Antiacne Preparations	48	
Antiallergy Preparations	155	
Antianaemics	25	
Antiarrhythmics	36	
Antibacterials	62	
Anticholinergic Agents	156	
Anticholinesterases	85	
Antidepressants	103	
Antidiarrhoeals and Intestinal Anti-Inflammatory Agents	12	
Antiepilepsy Drugs	105	
Antifibrinolytics, Haemostatics and Local Sclerosants	26	
Antifungals	68	
Antihypertensives	37	
Antimigraine Preparations	109	
Antimycobacterials	70	
Antinaus	110	
Antinausea and Vertigo Agents	109	
Antiparasitics	72	
Antipruritic Preparations	48	
Antipsychotic Agents	110	
Antiretrovirals	73	
Antirheumatoid Agents	85	
Antiseptics and Disinfectants	168	
Antispasmodics and Other Agents Altering Gut Motility	14	
Antithrombotics	28	
Antithymocyte globulin (equine)	153	
Antithymocyte globulin		

(rabbit)	153	Arrow-Bendrofluazide	41	hydrochloride	72
Antiulcerants	14	Arrow-Brimonidine	165	Atracurium besylate	91
Antivirals	78	Arrow-Calcium	20	Atripila	76
Anxiolytics	115	Arrow-Citalopram	105	Atropine sulphate	
Anzatax	129	Arrow-Diazepam	115	Cardiovascular	37
Apidra	16	Arrow-Doxorubicin	121	Sensory	165
Apidra Solostar	16	Arrow-Etidronate	87	Atropt	165
Apo-Allopurinol	90	Arrow-Gabapentin	106	Augmentin	65
Apo-Amiloride	41	Arrow-Lamotrigine	107	Auranofin	85
Apo-Amlodipine	39	Arrow-Lisinopril	35	Ava 20 ED	53
Apo-Amoxi	64	Arrow-Losartan &		Ava 30 ED	53
Apo-Azithromycin	63	Hydrochlorothiazide	36	Avanza	104
Apo-Cilazapril/		Arrow-Morphine LA	102	Avelox	66
Hydrochlorothiazide	35	Arrow-Nifedipine XR	39	Avelox IV 400	66
Apo-Clarithromycin	64	Arrow-Norfloxacin	66	Azactam	67
Apo-Clomipramine	103	Arrow-Nornidazole	73	Azathioprine	153
Apo-Diclo	92	Arrow-Quinapril 10	35	Azithromycin	63
Apo-Diltiazem CD	39	Arrow-Quinapril 20	35	Azol	59
Apo-Doxazosin	36	Arrow-Quinapril 5	35	AZT	76
Apo-Gliclazide	16	Arrow-Ranitidine	14	Aztreonam	67
Apo-Megestrol	130	Arrow-Roxithromycin	64		
Apo-Moclobemide	104	Arrow-Sertraline	105	- B -	
Apo-Nadolol	38	Arrow-Simva	42	B-D Micro-Fine	197
Apo-Oxybutynin	56	Arrow-Sumatriptan	109	B-D Ultra Fine	197
Apo-Perindopril	35	Arrow-Tolterodine	56	B-D Ultra Fine II	197
Apo-Pindolol	38	Arrow-Topiramate	108	Bacillus calmette-guerin	
Apo-Prazo	36	Arrow-Tramadol	103	(BCG)	153
Apo-Prednisone	58	Arrow-Venlafaxine XR	104	Bacillus calmette-guerin	
Apo-Prednisone S29	58	Arsenic trioxide	123	vaccine	192
Apo-Propranolol	38	Artemether with lumefantrine	72	Baclofen	91
Apo-Pyridoxine	23	Artesunate	72	Bacterial and Viral Vaccines	192
Apo-Risperidone	113	Articaine hydrochloride with		Bacterial Vaccines	192
Apo-Ropinirole	96	adrenaline	97	Baraclude	78
Apo-Zopiclone	116	Asacol	13	Barium sulphate	171
Apomine	95	Asamax	13	Barrier Creams and	
Apomorphine hydrochloride	95	Ascorbic acid		Emollients	48
Apraclonidine	165	Alimentary	23	Basiliximab	142
Aprepitant	109	Extemporaneous	175	Beclazone 100	157
Apresoline	44	Aspen Adrenaline	43	Beclazone 250	157
Aprotinin	26	Aspen Ceftriaxone	63	Beclazone 50	157
Aqueous cream	49	Aspen Ciprofloxacin	65	Beclomethasone	
Arachis oil [Peanut oil]	175	Aspirin		dipropionate	155, 157
Arava	85	Blood	30	Bee venom	155
Aremed	131	Nervous	100	Bendrofluazide	41
Arginine		Asthalin	157	Bendroflumethazide	
Alimentary	19	Atazanavir sulphate	77	[Bendrofluazide]	41
Various	172	Atenolol	38	BenefIX	27
Argipressin [Vasopressin]	61	Atenolol-AFT	38	Benzathine benzylpenicillin	65
Aripiprazole	111	ATGAM	153	Benzbromaron AL 100	90
Aristocort	50	Ativan	115	Benzbromarone	90
Aromasin	131	Atomoxetine	117	Benzocaine	97
Arrow - Clopid	30	Atorvastatin	41	Benzoin	175
Arrow-Amitriptyline	103	Atovaquone with proguanil		Benzoyl peroxide	48

Benzotropine mesylate	95	strip	197	Calcium carbonate	12, 20
Benzylamine hydrochloride	21	Blood ketone diagnostic test		Calcium Channel Blockers	39
Benzylamine hydrochloride with		meter	197	Calcium chloride	31
cetylpyridinium chloride	21	Boceprevir	81	Calcium chloride with	
Benzylpenicillin sodium [Penicillin		Bonney's blue dye	172	magnesium chloride,	
G]	65	Boric acid	175	potassium chloride, sodium	
Beractant	160	Bortezomib	123	acetate, sodium chloride and	
Beta Scalp	51	Bosentan	45	sodium citrate	163
Beta-Adrenoceptor Agonists	157	Bosvate	38	Calcium folinate	129
Beta-Adrenoceptor Blockers	38	Botox	91	Calcium Folate Ebewe	129
Betadine	169	Botulism antitoxin	167	Calcium gluconate	
Betadine Skin Prep	169	Breath-Alert	197	Blood	31
Betagan	164	Bridion	92	Dermatological	52
Betahistine dihydrochloride	109	Brilinta	30	Calcium Homeostasis	57
Betaine	19	Brimonidine tartrate	165	Calcium polystyrene	
Betamethasone	57	Brimonidine tartrate with		sulphonate	34
Betamethasone dipropionate	49	timolol	165	Calcium Resonium	34
Betamethasone dipropionate		Brinzolamide	164	Calsource	20
with calcipotriol	51	Bromocriptine	95	Cancidas	70
Betamethasone sodium		Brufen SR	93	Candesartan cilexetil	36
phosphate with		Budesonide		Candestar	36
betamethasone acetate	57	Alimentary	12	Capecitabine	122
Betamethasone		Respiratory	155, 157	Capoten	35
valerate	50-51	Budesonide with		Capsaicin	
Betamethasone valerate with		eformoterol	158	Musculoskeletal System	93
clioquinol	50	Bumetanide	40	Nervous	100
Betamethasone valerate with		Bupafen	98	Captopril	35
fusidic acid	50	Bupivacaine hydrochloride	98	Carbaccord	125
Betaxolol	164	Bupivacaine hydrochloride with		Carbamazepine	106
Bevacizumab	142	adrenaline	98	Carbasorb-X	168
Bezafibrate	41	Bupivacaine hydrochloride with		Carbimazole	61
Bezalip	41	fentanyl	98	Carbomer	165
Bezalip Retard	41	Bupivacaine hydrochloride with		Carboplatin	125
Bicalaccord	130	glucose	98	Carboplatin Ebewe	125
Bicalutamide	130	Buprenorphine with		Carboprost trometamol	54
Bicillin LA	65	naloxone	119	Carboxymethylcellulose	
Bile and Liver Therapy	15	Bupropion hydrochloride	119	Alimentary	21
Bimatoprost	164	Burinex	40	Extemporaneous	175
Biodone	101	Buscopan	14	Cardinol LA	38
Biodone Extra Forte	101	Buserelin	60	Cardizem CD	39
Biodone Forte	101	Buspirone hydrochloride	115	CareSens	197
Biotin	19	Busulfan	121	Caresens II	197
Bisacodyl	19	Butacort Aqueous	155	CareSens N	197
Bismuth subgallate	175			Caresens N	197
Bismuth subnitrate and iodoform		- C -		Caresens N POP	197
paraffin	173	Cabergoline	59	Carmellose sodium	165
Bismuth trioxide	15	Caffeine	117	Carmustine	121
Bisoprolol	38	Caffeine citrate	159	Carvedilol	38
Bivalirudin	28	Cal-d-Forte	24	Caspofungin	70
Bleomycin sulphate	121	Calamine	48	Catapres	40
Blood glucose diagnostic test		Calcipotriol	51	Catapres-TTS-1	40
meter	197	Calcitonin	57	Catapres-TTS-2	40
Blood glucose diagnostic test		Calcitriol	24	Catapres-TTS-3	40

Ceenu	121	chlorthalidone	41	Dermatological	47
Cefaclor	63	Cholecalciferol	24	Genito-Urinary	53
Cefalexin	62	Cholestyramine	42	Clove oil	175
Cefalexin Sandoz	62	Choline salicylate with		Clozapine	111
Cefazolin	63	cetalkonium chloride	22	Clozaril	111
Cefepime	63	Cholvastin	42	Co-trimoxazole	68
Cefotaxime	63	Choriogonadotropin alfa	60	Coal tar	175
Cefotaxime Sandoz	63	ciclopirox olamine	47	Coal tar with salicylic acid and	
Cefoxitin	63	Ciclosporin	131	sulphur	51
Ceftriaxone-AFT	63	Cidofovir	81	Coal tar with triethanolamine laryl	
Ceftazadime	63	Cilazapril	35	sulphate and fluorescein	51
Ceftriaxone	63	Cilazapril with		Cocaine hydrochloride	98
Ceftriaxone-AFT	63	hydrochlorothiazide	35	Cocaine hydrochloride with	
Cefuroxime	63	Cilicaine	65	adrenaline	98
Celecoxib	92	Cilicaine VK	65	Codeine phosphate	
Celiprolol	38	Cimetidine	14	Extemporaneous	175
CellCept	153	Cinchocaine hydrochloride with		Nervous	101
Celol	38	hydrocortisone	13	Cogentin	95
Centrally-Acting Agents	40	Cipflox	65	Colaspase [L-asparaginase]	124
Cephalexin ABM	62	Ciprofloxacin		Colchicine	91
Cetirizine - AFT	155	Infection	65	Colestimethate	67
Cetirizine hydrochloride	155	Sensory	161	Colestipol hydrochloride	42
Cetomacrogol	49	Cisplatin	125	Colgot	91
Cetomacrogol with glycerol	49	Cisplatin Ebewe	125	Colifoam	13
Cetrimide	175	Citalopram hydrobromide	105	Colistin sulphomethate	
Champix	120	Citanest	99	[Colestimethate]	67
Charcoal	168	Citric acid	175	Colistin-Link	67
Chemotherapeutic Agents	121	Citric acid with magnesium oxide		Colloidion flexible	175
Chicken pox vaccine	195	and sodium picosulfate	18	Colofac	14
Chlorafast	161	Citric acid with sodium		Colony-Stimulating Factors	31
Chloral hydrate	116	bicarbonate	171	Coloxyl	18
Chlorambucil	121	Cladribine	122	Compound electrolytes	31, 34
Chloramphenicol		Clarithromycin	64	Compound electrolytes with	
Infection	67	Clexane	29	glucose	31, 34
Sensory	161	Clindamycin	67	Compound	
Chlorhexidine		Clindamycin ABM	67	hydroxybenzoate	175
Genito-Urinary	53	Clobazam	106	Compound sodium lactate	
Various	168, 173	Clobetasol propionate	50–51	[Hartmann's solution]	32
Chlorhexidine gluconate		Clobetasone butyrate	50	Compound sodium lactate with	
Alimentary	21	Clofazimine	70	glucose	32
Extemporaneous	175	Clomazol	47, 53	Concerta	118
Genito-Urinary	53	Clomiphene citrate	59	Condylina	52
Chlorhexidine with		Clomipramine hydrochloride	103	Contraceptives	53
cetrimide	168, 173	Clonazepam	105–106, 115	Contrast Media	169
Chlorhexidine with ethanol	168	Clonidine	40	Corangin	43
Chloroform	175	Clonidine BNM	40	Cordarone-X	37
Chloroquine phosphate	72	Clonidine hydrochloride	40	Corticosteroids	
Chlorothiazide	41	Clopidogrel	30	Dermatological	49
Chlorpheniramine maleate	155	Clopine	111	Hormone	57
Chlorpromazine		Clopixol	114, 115	Corticotrorein (ovine)	60
hydrochloride	111	Clostridium botulinum type A		Cosopt	164
Chlorsig	161	toxin	91	Cough Suppressants	157
Chlortalidone [chlorthalidone]	41	Clotrimazole		Crotamiton	48

Crystaderm	47	Hydrochloride	103	Diazepam	105, 115
CT Plus+	171	DBL Rocuronium Bromide	91	Diazoxide	
Curam Duo	65	DBL Tobramycin	62	Alimentary	15
Curosurf	160	DDI	75	Cardiovascular	44
Cvite	23	De-Nol	15	Dichlorobenzyl alcohol with	
Cyclizine hydrochloride	109	De-Worm	72	amylmetacresol	22
Cyclizine lactate	109	Decongestants	157	Diclax SR	92
Cyclopentolate		Decongestants and		Diclofenac sodium	
hydrochloride	165	Antiallergics	162	Musculoskeletal System	92
Cyclophosphamide	121	Decozol	22	Sensory	162
Cycloserine	71	Deferiprone	168	Dicobalt edetate	168
Cyklokapron	27	Defibrotide	28	Didanosine [DDI]	76
Cymevene	81	Demeclocycline		Diflucan	69
Cyproheptadine		hydrochloride	66	Diflucortolone valerate	50
hydrochloride	155	Deoxycoformycin	124	Digestives Including	
Cyproterone acetate	57	Depo-Medrol	58	Enzymes	17
Cyproterone acetate with		Depo-Medrol with Lidocaine	58	Digoxin	37
ethinyloestradiol	53	Depo-Provera	54	Digoxin immune Fab	167
Cysteamine hydrochloride	175	Depo-Testosterone	57	Dihydrocodeine tartrate	101
Cytarabine	122	Deprim	68	Dihydroergotamine	
		Dermol	50, 51	mesylate	109
- D -		Desferrioxamine mesilate	168	Dilatrend	38
D-Penamine	85	Desflurane	97	Diltiazem hydrochloride	39
Dabigatran	28	Desmopressin acetate	61	Dilzem	39
Dacarbazine	124	Desmopressin-PH&T	61	Dimercaprol	168
Dactinomycin [Actinomycin		Dexamethasone		Dimercaptosuccinic acid	168
D]	121	Hormone	57	Dimethicone	48
Daivobet	51	Sensory	162	Dimethyl sulfoxide	173
Daivonex	51	Dexamethasone phosphate	57	Dinoprostone	55
Dalacin C	67	Dexamethasone with framycetin		Diphenamil metilsulfate	52
Dalteparin	28	and gramicidin	161	Diphenoxylate hydrochloride with	
Danaparoid	28	Dexamethasone with neomycin		atropine sulphate	12
Danazol	59	sulphate and polymyxin B		Diphtheria and tetanus	
Danthron with poloxamer	19	sulphate	161	vaccine	192
Dantrium	91	Dexamethasone with		Diphtheria antitoxin	167
Dantrolene	91	tobramycin	161	Diphtheria, tetanus and pertussis	
Dapa-Tabs	41	Dexamphetamine sulphate	117	vaccine	192
Dapsone	70	Dexmedetomidine		Diphtheria, tetanus, pertussis	
Daptomycin	67	hydrochloride	97	and polio vaccine	192
Darunavir	77	Dextrose with sodium citrate and		Diphtheria, tetanus, pertussis,	
Dasatinib	125	citric acid [Acid Citrate		polio, hepatitis B and	
Daunorubicin	121	Dextrose A]	28	haemophilus influenzae type B	
DBL Aminophylline	159	DHC Continus	101	vaccine	192
DBL Cefepime	63	Diabetes	15	Diprivan	97
DBL Cefotaxime	63	Diacomit	108	Dipyridamole	30
DBL Ceftazidime	63	Diagnostic Agents	172	Disodium edetate	168
DBL Epirubicin		Diagnostic and Surgical		Disodium hydrogen phosphate	
Hydrochloride	122	Preparations	163	with sodium dihydrogen	
DBL Ergometrine	55	Diamide Relief	12	phosphate	175
DBL Gemcitabine	122	Diamox	164	Disopyramide phosphate	37
DBL Leucovorin Calcium	129	Diatrizoate meglumine with		Disulfiram	119
DBL Morphine Sulphate	102	diatrizoate sodium	169	Dithranol	175
DBL Pethidine		Diatrizoate sodium	169	Diuretics	40

acid	21	Fluticasone	158	Gemcitabine Actavis 200	122
Ferrous sulphate	21	Fluticasone propionate	155	Gemcitabine Ebewe	122
Ferrous sulphate with ascorbic acid	21	Fluticasone with salmeterol	159	Gemfibrozil	41
Ferrous sulphate with folic acid	21	Foban	47	Genoptic	161
Ferrum H	21	Folic acid	26	Genox	131
Fexofenadine hydrochloride	156	Fondaparinux sodium	29	Gentamicin sulphate Infection	62
Filgrastim	31	Food Modules	178	Sensory	161
Finasteride	55	Food/Fluid Thickeners	179	Gestrinone	59
Flagyl	72	Forteo	90	Glatiramer acetate	115
Flagyl-S	72	Fortisip (Vanilla)	190	Glaucoma Preparations	164
Flamazine	47	Fortum	63	Glucagon Hydrochloride	15
Flecainide acetate	37	Fosamax	85	Glucagon Select (Vanilla)	183
Fleet Phosphate Enema	19	Fosamax Plus	86	Glucerna Select RTH (Vanilla)	183
Flisonase Hayfever & Allergy	155	Foscarnet sodium	81	Glucose	
Flixotide	158	Fosfomycin	67	Alimentary	15
Flixotide Accuhaler	158	Fragmin	28	Blood	32
Florinef	57	Framycetin sulphate	161	Extemporaneous	176
Fluanxol	114	Freeflex	33	Glucose with potassium chloride	32
Fluarix	194	FreeStyle Lite	197	Glucose with potassium chloride and sodium chloride	32
Flucloxacillin	65	Freestyle Optium	197	Glucose with sodium chloride	32
Flucloxin	65	Freestyle Optium Ketone	197	Glucose with sucrose and fructose	15
Flucon	162	Freestyle Optium Ketone	197	Glycerin with sodium saccharin	176
Fluconazole	69	Fresofol 1%	97	Glycerin with sucrose	176
Fluconazole-Claris	69	Frusemide-Claris	40	Glycerol	
Flucytosine	70	Frusemide (frusemide)	40	Alimentary	18
Fludara Oral	122	Fucidin	67	Extemporaneous	176
Fludarabine Ebewe	122	Fucithalamic	161	Glycerol with paraffin	49
Fludarabine phosphate	122	Fungilin	22	Glyceryl trinitrate	
Fludrocortisone acetate	57	Fusidate sodium [Fusidic acid]	47	Alimentary	14
Fluids and Electrolytes	31	Fusidic acid	47	Cardiovascular	43
Flumazenil	167	Dermatological	47	Glycine	173
Flumetasone pivalate with clioquinol	161	Infection	67	Glycopyrronium bromide	14
Fluocortolone caproate with fluocortolone pivalate and cinchocaine	13	Sensory	161	Glypressin	61
Fluorescein sodium	163	Fuzeon	73	Glytrin	43
Fluorescein sodium with lignocaine hydrochloride	163	- G -		Gonadorelin	60
Fluorescite	163	Gabapentin	106	Goserelin	60
Fluorometholone	162	Gadobenic acid	171	- H -	
Fluorouracil	122	Gadobutrol	171	Habitrol	119
Fluorouracil Ebewe	122	Gadodiamide	171	Habitrol (Classic)	119
Fluorouracil sodium	52	Gadoteric acid	171	Habitrol (Fruit)	119
Fluox	105	Gadovist	171	Habitrol (Mint)	119
Fluoxetine hydrochloride	105	Gadoxetate disodium	172	Haem arginate	19
Flupenthixol decanoate	114	Gamma benzene hexachloride	47		
Fluphenazine decanoate	114	Ganciclovir	81		
Flutamide	130	Gastrografin	169		
Flutamin	130	Gastrosoothe	14		
		Gefitinib	126		
		Gelafusal	34		
		Gelatine, succinylated	34		
		Gelofusine	34		
		Gemcitabine	122		
		Gemcitabine Actavis 1000	122		

Itrazole	69	Letraccord	131	Lithium carbonate	111
Ivermectin	72	Letrozole	131	Local Preparations for Anal and Rectal Disorders	13
- J -					
Jadelle	54	Leukotriene Receptor Antagonists	158	Locoid	50, 51
Jevity	190	Leunase	124	Locoid Crelo	50
Jevity HiCal RTH	190	Leuprorelin acetate	60	Locoid Lipocream	50
Jevity RTH	190	Leustatin	122	Lodoxamide	162
- K -					
Kaletra	77	Levetiracetam	107	Logem	107
Kenacomb	162	Levetiracetam-Rex	107	Lomustine	121
Kenacort-A	58	Levobunolol hydrochloride	164	Long-Acting Beta-Adrenoceptor Agonists	158
Kenacort-A40	58	Levocabastine	162	Loniten	44
Ketamine hydrochloride	97	Levocarnitine	20	Loperamide hydrochloride	12
Ketocal 3:1 (Unflavoured)	187	Levodopa with benserazide	96	Lopinavir with ritonavir	77
Ketocal 4:1 (Unflavoured)	187	Levodopa with carbidopa	96	Lopresor	38
Ketocal 4:1 (Vanilla)	187	Levomepromazine	111	Lorafax	156
Ketoconazole		Levonorgestrel	54	Lorapaed	156
Dermatological	47	Levophed	44	Loratadine	156
Infection	68	Levosimendan	43	Lorazepam	105, 115
Ketone blood beta-ketone electrodes	197	Levothyroxine	61	Lormetazepam	116
Ketoprofen	93	Lidocaine [Lignocaine] hydrochloride	99	Losartan potassium	36
Ketorolac trometamol	162	Lidocaine [Lignocaine] hydrochloride with adrenaline	99	Losartan potassium with hydrochlorothiazide	36
Kivexa	75	Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine	99	Lostaar	36
Klacid	64	Lidocaine [Lignocaine] hydrochloride	99	Lovir	81
Klean Prep	18	Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine	99	Loxalate	105
Kogenate FS	27	Lidocaine [Lignocaine] hydrochloride	99	Loxamine	105
Konakion MM	28	Lidocaine [Lignocaine] hydrochloride with chlorhexidine	99	Lucrin Depot PDS	60
Konsyl-D	18	Lidocaine [Lignocaine] hydrochloride with phenylephrine	99	Lycinate	43
- L -					
L-asparaginase	124	Lidocaine [Lignocaine] hydrochloride	99	Lyderm	48
L-ornithine L-aspartate	15	Lidocaine [Lignocaine] hydrochloride with prilocaine	99	- M -	
Labetalol	38	Lidocaine [Lignocaine] hydrochloride with phenylephrine	99	m-Amoxiclav	65
Lacosamide	107	Lidocaine [Lignocaine] hydrochloride	99	m-Captopril	35
Lactose	176	Lidocaine [Lignocaine] with prilocaine	99	m-Cefuroxime	63
Lactulose	18	Lidocaine-Claris	99	m-Eslon	102
Laevolac	18	Lignocaine	98, 99	m-Mometasone	50
Lamictal	107	Lincomycin	67	Mabthera	148
Lamivudine	76, 79	Lindane [Gamma benzene hexachloride]	47	Macrogl 3350 with ascorbic acid, potassium chloride and sodium chloride	18
Lamotrigine	107	Linezolid	67	Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride	19
Lansoprazole	14	Lioresal Intrathecal	91	Macrogl 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate	18
Lantus	16	Liothyronine sodium	61	Macrogl 400 and propylene glycol	166
Lantus SoloStar	16	Lipazil	41	Madopar 125	96
Lapatinib	126	Lipid-Modifying Agents	41	Madopar 250	96
Latanoprost	165	Liquifilm Forte	166	Madopar 62.5	96
Lax-Sachets	19	Liquifilm Tears	166		
Lax-Tabs	19	Lisinopril	35		
Laxatives	18	Lissamine green	163		
Laxofast 120	18	Lisuride hydrogen maleate	96		
Laxofast 50	18	Lithicarb FC	111		
Laxsol	18				
Leflunomide	85				

Madopar HBS	96	Mesalazine	13	Dermatological	47
Madopar Rapid	96	Mesna	129	Infection	72
Mafenide acetate	47	Mestinon	85	Metyrapone	59
Magnesium hydroxide		Metabolic Disorder Agents	19	Mexiletine hydrochloride	37
Alimentary	21	Metabolic Products	180	Mexiletine Hydrochloride	
Extemporaneous	176	Metamide	110	USP	37
Magnesium oxide	21	Metaraminol	44	Miacalcic	57
Magnesium sulphate	21	Metformin	17	Mianserin hydrochloride	104
Magnevist	172	Methacholine chloride	172	Micolette	19
Malathion [Maldison]	48	Methadone hydrochloride		Miconazole	22
Malathion with permethrin and		Extemporaneous	176	Miconazole nitrate	
piperonyl butoxide	48	Nervous	101	Dermatological	47
Maldison	47	Methatabs	101	Genito-Urinary	53
Mannitol	40	Methoblastin	123	Micreme H	51
Maprotiline hydrochloride	103	Methohexital sodium	97	Microgynon 50 ED	53
Marcain	98	Methopt	165	Midazolam	116
Marcain Heavy	98	Methotrexate	123	Midodrine	37
Marcain Isobaric	98	Methotrexate Ebewe	123	Mifepristone	54
Marcain with Adrenaline	98	Methotrexate Sandoz	123	Milrinone	44
Marevan	30	Methoxsalen		Minerals	20
Marine Blue Lotion SPF 30+	52	[8-methoxy psoralen]	51	Minidiab	16
Martindale Acetylcysteine	167	Methoxyflurane	100	Mirinir	61
Mask for spacer device	197	Methyl aminolevulinat		Minocycline	66
Mast Cell Stabilisers	159	hydrochloride	52	Minoxidil	44
Maxidex	162	Methyl hydroxybenzoate	176	Mirtazapine	104
Measles, mumps and rubella		Methylcellulose	176	Misoprostol	14
vaccine	195	Methylcellulose with glycerin and		Mitomycin C	122
Mebendazole	72	sodium saccharin	176	Mitozantrone	122
Mebeverine hydrochloride	14	Methylcellulose with glycerin and		Mitozantrone Ebewe	122
Medrol	58	sucrose	176	Mivacron	91
Medroxyprogesterone	60	Methylidopa	40	Mivacurium chloride	91
Medroxyprogesterone acetate		Methylene blue	172	Moclobemide	104
Genito-Urinary	54	Methylphenidate		Modafinil	118
Hormone	59	hydrochloride	118	Modecate	114
Mefenamic acid	93	Methylprednisolone (as sodium		Mogine	107
Mefloquine hydrochloride	72	succinate)	58	Mometasone furoate	50
Megestrol acetate	130	Methylprednisolone		Monosodium glutamate with	
Meglumine gadopentate	172	aceponate	50	sodium aspartate	174
Melatonin	116	Methylprednisolone acetate	58	Monosodium l-aspartate	174
Meloxicam	93	Methylprednisolone acetate with		Montelukast	158
Melphalan	121	lignocaine	58	Morocotocog alfa [Recombinant	
Meningococcal (A, C, Y and		Methylthioninium chloride		factor VIII)	27
W-135) conjugate		[Methylene blue]	172	Morphine hydrochloride	101
vaccine	193	Methylxanthines	159	Morphine sulphate	102
Meningococcal (A, C, Y and		Metoclopramide		Morphine tartrate	102
W-135) polysaccharide		hydrochloride	110	Motetis	95
vaccine	193	Metoclopramide hydrochloride		Mouth and Throat	21
Meningococcal C conjugate		with paracetamol	109	Moxifloxacin	66
vaccine	193	Metolazone	41	Mucolytics and	
Menthol	176	Metoprolol - AFT CR	38	Expectorants	159
Mepivacaine hydrochloride	99	Metoprolol succinate	38	Multihance	171
Mercaptopurine	123	Metoprolol tartrate	38	Multiple Sclerosis	
Meropenem	62	Metronidazole		Treatments	115

Multivitamins	22–23	Nitrazepam	116	Oestrogens	55
Mupirocin	47	Nitroderm TTS 10	43	Oestrogens (conjugated equine)	58
Muscle Relaxants and Related Agents	91	Nitroderm TTS 5	43	Oestrogens with medroxyprogesterone acetate	59
Myambutol	71	Nitrofurantoin	67	Oil in water emulsion	49
Mycobutin	71	Nitronal	43	Oily phenol [Phenol oily]	14
Mycophenolate mofetil	153	Noflam 250	93	Olanzapine	112, 114
Mydriacyl	165	Noflam 500	93	Olanzine	112
Mydriatics and Cycloplegics	165	Non-Steroidal Anti-Inflammatory Drugs	92	Olanzine-D	112
Mylan Atenolol	38	Nonacog alfa [Recombinant factor IX]	27	Olive oil	176
Mylan Fentanyl Patch	101	Noradrenaline	44	Olopatadine	162
Myleran	121	Norethisterone Genito-Urinary	54	Olisalazine	13
- N -					
Nadolol	38	Hormone	60	Omeprazole	14
Naloxone hydrochloride	167	Norethisterone with mestranol	53	Ormezol Relief	14
Naltracord	119	Norfloracin	66	Omnipaque	170
Naltrexone hydrochloride	119	Normison	116	Omniscan	171
Naphazoline hydrochloride	162	Norpress	104	On Call Advanced	197
Naphcon Forte	162	Nortriptyline hydrochloride	104	Oncaspar	124
Naproxen	93	Norvir	77	OncoTICE	153
Naropin	99, 100	Novasource Renal (Vanilla)	189	Ondanaccord	110
Natamycin	161	Novatrein	51	Ondansetron	110
Natulan	124	NovoMix 30 FlexPen	15	One-Alpha	23
Nauseacalm	109	NovoSeven RT	27	Onkotrone	122
Navelbine	130	Noxafil	69	Onrex	110
Navoban	110	Nupentin	106	Optional Pharmaceuticals	197
Nedocromil	159	Nutrini Energy Multi Fibre	188	Ora-Blend	176
Nefopam hydrochloride	100	Nutrini Low Energy Multifibre RTH	188	Ora-Blend SF	176
Neocate Advance (Vanilla)	185	Nutrison Concentrated	184	Ora-Plus	176
Neocate Gold (Unflavoured)	185	Nutrison Energy	190	Ora-Sweet	176
Neoral	131	Nyefax Retard	39	Ora-Sweet SF	176
NeoRecormon	25	Nystatin Alimentary	22	Oracort	22
Neostigmine metilsulfate	85	Dermatological	47	Oratane	48
Neostigmine metilsulfate with glycopyrronium bromide	85	Genito-Urinary	53	Ornidazole	73
Neosynephrine HCL	44	Infection	69	Orphenadrine citrate	91
Neotigason	51	- O -			
Nepro (Strawberry)	189	Obstetric Preparations	54	Orphenadrine hydrochloride	95
Nepro (Vanilla)	189	Octocog alfa [Recombinant factor VIII]	27	Oruvail SR	93
Nepro RTH	188	Octreotide	130	Osetamivir	82
Neulastim	31	Octreotide MaxRx	130	Osmolite	190
Neupogen	31	Ocular Lubricants	165	Osmolite RTH	190
Nevirapine	75	Oestradiol	58–59	Ospamox	64
Nevirapine Alphapharm	75	Oestradiol valerate	58	Other Cardiac Agents	43
Nicorandil	44	Oestradiol with norethisterone acetate	59	Other Endocrine Agents	59
Nicotine	119	Oestriol Genito-Urinary	55	Other Oestrogen Preparations	59
Nicotinic acid	42	Hormone	59	Other Otological Preparations	166
Nifedipine	39				
Nilstat	22, 69				
Nimodipine	39				
Nitazoxanide	73				
Nitrates	43				

Oxaliplatin Actavis 50	125	Paroxetine hydrochloride	105	Cardiovascular	44
Oxandrolone	57	Paser	71	Sensory	165
Oxazepam	115	Patent blue V	172	Phenytin	108
Oxpentifylline	45	Paxam	115	Phenytoin sodium	105, 108
Oxybuprocaine hydrochloride	163	Pazopanib	127	Pholcodine	157
Oxybutynin	56	Peak flow meter	197	Phosphorus	34
Oxycodone hydrochloride	102	Peanut oil	175	Phytomenadione	28
Oxycodone Orion	102	Pediasure (Chocolate)	188	Picibanil	153
OxyContin	102	Pediasure (Strawberry)	188	Pilocarpine hydrochloride	164
Oxydone BNM	102	Pediasure (Vanilla)	188	Pilocarpine nitrate	176
Oxymetazoline hydrochloride	157	Pediasure RTH	188	Pimafucort	51
OxyNorm	102	Pegaspargase	124	Pindolol	38
Oxytocin	55	Pegasus RBV Combination Pack	83	Pinetarsol	51
Oxytocin BNM	55	Pegasys	83	Pinorax	19
Oxytocin with ergometrine maleate	55	Pegfilgrastim	31	Pinorax Forte	19
Ozole	69	Pegylated interferon alfa-2a	83	Pioglitazone	17
- P -					
Pacifen	91	Penembact	62	Piperacillin with tazobactam	65
Pacific Buspirone	115	Penicillamine	85	Pipothiazine palmitate	114
Paclitaxel	129	Penicillin G	65	Pituitary and Hypothalamic Hormones and Analogues	60
Paclitaxel Actavis	129	Penicillin V	65	Pivmecillinam	68
Paclitaxel Ebewe	129	Pentagastrin	59	Pizaccord	17
Pamidronate BNM	87	Pentamidine isethionate	73	Pizotifen	109
Pamidronate disodium	87	Pentasa	13	PKU Anamix Junior LQ (Berry)	181
Pamisol	87	Pentostatin [Deoxycoformycin]	124	PKU Anamix Junior LQ (Orange)	181
Panadol	100	Pentoxifylline [Oxpentifylline]	45	PKU Anamix Junior LQ (Unflavoured)	181
Pancreatic enzyme	17	Peptamen OS 1.0 (Vanilla)	184	Plaquenil	85
Pancuronium bromide	91	Peptisootho	14	Plendil ER	39
Pantoprazole	15	Pergolide	96	Plerfutren	172
Papaverine hydrochloride	45	Perhexiline maleate	39	pms-Bosentan	45
Paper wasp venom	155	Pericyazine	112	Pneumococcal (PCV10) conjugate vaccine	193
Para-aminosalicylic Acid	71	Perindopril	35	Pneumococcal (PCV13) conjugate vaccine	193
Paracare	100	Permax	96	Pneumococcal (PPV23) polysaccharide vaccine	194
Paracare Double Strength	100	Permethrin	48	Podophyllotoxin	52
Paracetamol	100	Peteha	71	Polidocanol	26
Paracetamol + Codeine (Relieve)	102	Pethidine hydrochloride	103	Poliomyelitis vaccine	195
Paracetamol with codeine	102	Pexsig	39	Poloxamer	18
Paracetamol-AFT	100	Phenelzine sulphate	104	Poly Gel	165
Paraffin Alimentary	18	Phenindione	29	Poly-Tears	166
Dermatological	49	Phenobarbitone	107, 116	Polyhexamethylene biguanide	176
Extemporaneous	176	Phenobarbitone sodium	176	Polyvinyl alcohol	166
Paraffin liquid with soft white paraffin	166	Phenol	176	Polyvinyl alcohol with povidone	166
Paraffin liquid with wool fat	166	Extemporaneous	176	Poractant alfa	160
Paraffin with wool fat	49	Various	173	Posaconazole	69
Paraldehyde	105	Phenol oily	14	Postinor-1	54
Parcoxib	93	Phenol with ioxaglic acid	173		
Paromomycin	62	Phenoxybenzamine hydrochloride	36		
		Phenoxymethylpenicillin [Penicillin V]	65		
		Phentolamine mesylate	36		
		Phenylephrine hydrochloride			

Potassium chloride32, 34	Propofol97	Rectogesic14
Potassium chloride with sodium chloride 33	Propranolol38	Red back spider antivenom167
Potassium citrate56	Propylene glycol176	Redipred58
Potassium dihydrogen phosphate 33	Propylthiouracil61	Relenza Rotadisk82
Potassium iodate	Prostin E255	Remicade142
Alimentary20	Prostin VR44	Remifentanil hydrochloride103
Hormone61	Protamine sulphate29	Remifentanil-AFT103
Potassium iodate with iodine20	Protonamide71	ReoPro136
Potassium perchlorate61	Protirelin61	Resource Beneprotein179
Potassium permanganate51	Provera59, 60	Resource Diabetic (Vanilla)183
Povidone K30176	Provisc163	Respiratory Stimulants160
Povidone-iodine169	Provive MCT-LCT 1%97	Retinol23
Povidone-iodine with	Pseudoephedrine	Retinol Palmitate166
ethanol 169	hydrochloride 157	Retrovir76
Pradaxa28	Psoriasis and Eczema	Revolade26
Pralidoxime iodide167	Preparations 51	Reyataz77
Pramipexole hydrochloride96	PTU61	Ridal113
Prasugrel30	Pulmocare (Vanilla)189	Rifabutin71
Pravastatin42	Pulmonary Surfactants160	Rifampicin71
Praziquantel72	Pulmozyme159	Rilutek95
Prazosin36	Puri-nethol123	Riluzole95
Prednisolone58	Pyrazinamide71	Ringer's solution33
Prednisolone acetate162	Pyridostigmine bromide85	Riodine169
Prednisolone sodium	PyridoxADE23	Risedronate Sandoz90
phosphate 162	Pyridoxal-5-phosphate20	Risedronate sodium90
Prednisone58	Pyridoxine hydrochloride23	Risperdal113
Pregnancy test - hCG urine197	Pyrimethamine73	Risperdal Consta115
Prezista77	Pytazen SR30	Risperdal Quicklet113
Prilocaine hydrochloride99	- Q -	Risperidone113, 115
Prilocaine hydrochloride with	Q 30073	Risperon113
felypressin 99	Quetapel112	Ritalin118
Primaquine phosphate73	Quetiapine112	Ritalin LA118
Primaxin62	Quinapril35	Ritalin SR118
Primidone108	Quinapril with	Ritonavir77
Primolut N60	hydrochlorothiazide 35	Rituximab148
Probenecid91	Quinine dihydrochloride73	Rivaroxaban29
Procaine penicillin65	Quinine sulphate73	Rivotril105
Procarbazine hydrochloride124	- R -	Rizamelt109
Prochlorperazine110	RA-Morph101	Rizatriptan benzoate109
Proctosedyl13	Rabies vaccine195	Rocuronium bromide91
Procyclidine hydrochloride95	Raloxifene89	Ropin96
Procytox121	Raltegravir potassium78	Ropinirrole hydrochloride96
Prodopa40	Ramipex96	Ropivacaine hydrochloride99
Progesterone55	Ranbaxy-Cefaclor63	Ropivacaine hydrochloride with
Proglicem15	Ranibizumab147	fentanyl 100
Prograf132	Ranitidine14	Rose bengal sodium163
Prokinex109	Rapamune154	Roxane12
Promethazine hydrochloride156	Rasburicase91	Roxithromycin64
Promethazine theoclate110	Reandron 100057	Rubifen118
Propafenone hydrochloride37	Recombinant factor IX27	Rubifen SR118
Propamidine isethionate161	Recombinant factor VIIa27	- S -
	Recombinant factor VIII27	S-26 Gold Premgro187
		S26 LBW Gold RTF187

Salamol	157	carbonate	12	Solian	110
Salazopyrin	13	Sodium aurothiomalate	85	Solifenacin succinate	56
Salazopyrin EN	13	Sodium benzoate	20	Solox	14
Salbutamol	157	Sodium bicarbonate		Solu-Cortef	58
Salbutamol with ipratropium		Blood	33–34	Solu-Medrol	58
bromide	156	Extemporaneous	177	Somatropin	60
Salicylic acid	177	Sodium calcium edetate	168	Sotacor	39
Salmeterol	158	Sodium carboxymethylcellulose		Sotalol	39
Salmonella typhi vaccine	194	with pectin and gelatine	22	Soya oil	167
Sandimmun	131	Sodium chloride		Space Chamber Plus	198
Sandomigran	109	Blood	33–34	Spacer device	198
Sandostatin LAR	130	Respiratory	157, 160	Span-K	34
Scalp Preparations	51	Various	173	Specialised Formulas	182
Sclerosing Agents	160	Sodium chloride with sodium		Spiractin	41
Scopoderm TTS	110	bicarbonate	157	Spiramycin	73
Sebizole	47	Sodium citrate		Spiriva	156
Secretin pentahydrochloride	172	Alimentary	12	Spirolactone	41
Sedatives and Hypnotics	116	Extemporaneous	177	Spirotone	41
Selegiline hydrochloride	96	Sodium citrate with sodium		Sprycel	125
Sennosides	19	chloride and potassium		Standard Feeds	189
Serenace	111	chloride	29	Staphlex	65
Seretide	159	Sodium citrate with sodium lauryl		Starch	177
Seretide Accuhaler	159	sulphacetate	19	Stavudine	76
Serevent	158	Sodium citro-tartrate	56	Sterculia with frangula	18
Serevent Accuhaler	158	Sodium cromoglycate		Stesolid	105
Serophene	59	Alimentary	13	Stimulants / ADHD	
Seroquel	112	Respiratory	155, 159	Treatments	117
Sertraline	105	Sensory	162	Stiripentol	108
Sevoflurane	97	Sodium dihydrogen phosphate		Stocrin	75
Sevredol	102	[Sodium acid phosphate]	33	Strattera	117
Silagra	45	Sodium fluoride	20	Streptomycin sulphate	62
Sildenafil	45	Sodium hyaluronate		Stromectol	72
Silver nitrate		Alimentary	22	Suboxone	119
Dermatological	52	Sensory	163, 166	Sucralfate	15
Extemporaneous	177	Sodium hyaluronate with		Sucrose	100
Simethicone	12	chondroitin sulphate	164	Sugammadex	92
Simulect	142	Sodium hypochlorite	169	Sulindac	93
Simvastatin	42	Sodium metabisulfite	177	Sulphacetamide sodium	161
Sincalide	172	Sodium nitrite	167	Sulphadiazine	68
Sinemet	96	Sodium nitroprusside		Sulphadiazine silver	47
Sinemet CR	96	Cardiovascular	45	Sulphasalazine	13
Singulair	158	Optional		Sulphur	177
Sirolimus	154	Pharmaceuticals	197	Sumatriptan	109
Siterone	57	Sodium phenylbutyrate	20	Sunitinib	127
Slow-Lopresor	38	Sodium phosphate with		Sunscreen, proprietary	52
Snake antivenom	168	phosphoric acid	19	Suprane	97
Sodibic	34	Sodium polystyrene		Surgam	93
Sodium acetate	33	sulphonate	34	Surgical Preparations	173
Sodium acid phosphate	33	Sodium stibogluconate	73	Survanta	160
Sodium alginate with magnesium		Sodium tetradecyl sulphate	26	Sustagen Hospital Formula	
alginate	12	Sodium thiosulfate	167	(Chocolate)	190
Sodium alginate with sodium		Sodium valproate	108	Sustagen Hospital Formula	
bicarbonate and calcium		Sodium with potassium	174	(Vanilla)	190

Sutent	127	Thioguanine	123	Alimentary	22
Suxamethonium chloride	91	Thiopental [Thiopentone]		Dermatological	50
Symmetrel	95	sodium	97	Hormone	58
Sympathomimetics	43	Thiopentone	97	Triamcinolone acetonide with	
Synacthen	60	Thiotepa	121	gramicidin, neomycin and	
Synacthen Depot	60	Thrombin	26	nystatin	162
Syntocinon	55	Thymol glycerin	22	Triamcinolone acetonide with	
Syntometrine	55	Thyroid and Antithyroid		neomycin sulphate, gramicidin	
Syrup	177	Preparations	61	and nystatin	51
Systane Unit Dose	166	Thyrotropin alfa	60	Triamcinolone hexacetonide	58
- T -					
Tacrolimus	132	Tiaprofenic acid	93	Triazolam	116
Talc	160	Ticagrelor	30	Trichloroacetic acid	177
Tambocor	37	Ticarcillin with clavulanic acid	65	Trichozole	72
Tambocor CR	37	Ticlopidine	30	Trientine dihydrochloride	20
Tamoxifen citrate	131	Tigecycline	66	Trifluoperazine	
Tamsulosin	56	Timolol	164	hydrochloride	113
Tamsulosin-Rex	56	Timolol maleate	39	Trimeprazine tartrate	156
Tarceva	126	Timoptol XE	164	Trimethoprim	68
Tasmar	96	Tiotropium bromide	156	Trimethoprim with	
Tazocin EF	65	TMP	68	sulphamethoxazole	
Teicoplanin	68	Tobramycin		[Co-trimoxazole]	68
Temaccord	124	Infection	62	Trisodium citrate	29
Temazepam	116	Sensory	161	Trometamol	173
Temozolomide	124	Tobrex	161	Tropicamide	165
Tenecteplase	31	Tocilizumab	151	Tropisetron	110
Tenofovir disoproxil fumarate	79	Tofranil	103	Truvada	76
Tenoxicam	93	Tolcapone	96	Tuberculin, purified protein	
Terazosin	36	Tolterodine tartrate	56	derivative	172
Terbinafine	70	Topamax	108	Two Cal HN	184
Terbutaline	55	Topical Products for Joint and		TwoCal HN RTH (Vanilla)	184
Terbutaline sulphate	157	Muscular Pain	93	Tykerb	126
Teriparatide	90	Topiramate	108	- U -	
Terlipressin	61	Tracleer	45	Ultraproct	13
Testosterone	57	Tracrium	91	Univent	156
Testosterone cypionate	57	Tramadol hydrochloride	103	Ural	56
Testosterone esters	57	Tramal 100	103	Urea	
Testosterone undecanoate	57	Tramal 50	103	Dermatological	49
Tetrabenazine	95	Tramal SR 100	103	Extemporaneous	177
Tetracaine [Amethocaine]		Tramal SR 150	103	Urex Forte	40
hydrochloride		Tramal SR 200	103	Urokinase	31
Nervous	100	Trandolapril	35	Urologicals	55
Sensory	163	Tranexamic acid	27	Uromitexan	129
Tetracosactide		Tranycypromine sulphate	104	Ursodeoxycholic acid	17
[Tetracosactrin]	60	Trastuzumab	152	Ursosan	17
Tetracosactrin	60	Travoprost	165	Utrogestan	55
Tetracyclin Wolff	66	Treatments for Dementia	119	- V -	
Tetracycline	66	Treatments for Substance		Valaciclovir	81
Thalidomide	125	Dependence	119	Valcyte	82
Thalomid	125	Tretinoin		Valganciclovir	82
Theophylline	159	Dermatological	48	Valtrex	81
Thiamine hydrochloride	23	Oncology	125	Vancomycin	68
		Tri-sodium citrate	177	Varenicline	120
		Triamcinolone acetonide			

Varicella zoster vaccine [Chicken pox vaccine]	195	Vivonex TEN	183	Zetlam	79
Vasodilators	44	Volibris	45	Zetop	155
Vasopressin	61	Voltaren	92	Ziagen	75
Vasopressin Agents	61	Voltaren Ophtha	162	Zidovudine [AZT]	76
Vecuronium bromide	92	Volulyte 6%	34	Zidovudine [AZT] with lamivudine	76
Velcade	123	Volumatic	198	Zinc	
Venlafaxine	104	Voluven	34	Alimentary	21
Venofer	21	Voriconazole	69	Dermatological	48
Ventavis	46	Votrient	127	Zinc and castor oil	48
Ventolin	157			Zinc chloride	21
Vepesid	124	- W -		Zinc oxide	177
Veracol	63	Warfarin sodium	30	Zinc sulphate	21
Verapamil hydrochloride	40	Wart Preparations	51	Zinc with wool fat	48
Vergo 16	109	Water		Zincaps	21
Verpamil SR	40	Blood	34	Zinnat	63
Vesanoid	125	Various	173	Ziprasidone	113
Vesicare	56	Wool fat		Zithromax	63
Vfend	69	Dermatological	49	Zofran Zydis	110
Victrelis	81	Extemporaneous	177	Zoladex	60
Vigabatrin	108	- X -		Zoledronic acid	
Vimpat	107	Xanthan	177	Hormone	57
Vinblastine sulphate	130	Xarelto	29	Musculoskeletal System	87
Vincristine sulphate	130	Xeloda	122	Zometa	57
Vinorelbine	130	Xylocaine	99	Zopiclone	116
Viral Vaccines	194	Xylocaine Viscous	99	Zostrix	93
Viramune Suspension	75	Xylometazoline hydrochloride	157	Zostrix HP	100
Viread	79	Xynthia	27	Zovirax IV	81
Visipaque	169	- Y -		Zuclopenthixol acetate	114
Vistil	166	Yellow jacket wasp venom	155	Zuclopenthixol decanoate	115
Vistil Forte	166	- Z -		Zuclopenthixol hydrochloride	114
VitA-POS	166	Zanamivir	82	Zyban	119
Vital HN	183	Zantac	14	Zypine	112
Vitamin A with vitamins D and C	23	Zapril	35	Zypine ODT	112
Vitamin B complex	23	Zarator	41	Zyprexa Relprev	114
Vitamins	22	Zarzio	31		
Vivonex Paediatric	185	Zavedos	122		
		Zeldox	113		











